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ABSTRACT OF THE DISSERTATION
Autologous Stem Cell-Derived

Cells for Diabetes Cell Replacement Therapy
by

Kristina G. Maxwell
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2020
Professor Jeffrey Millman, Chair

Autologous stem cell therapy is a promising treatment for patients with diabetes worldwide.
Previous stem cell-d

d (SC- ) cell protocols were unable to efficiently differentiate multiple

patient induced pluripotent stem cells (iPSCs) into stem cell-derived islets (SC-islets), containing
insulin-secreting SC- c
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differentiation of 14 diabetic and nondiabetic stem cell lines into SC-islets. We used genetic
engineering, specifically CRISPR/Cas9, to correct the diabetes-causing mutation in stem cells from
patients with Wolfram Syndrome. The genetically engineered SC- c
composition similar to nondiabetic SC- c
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r 8 months. Single cell RNA sequencing

identified differences in the diseased and corrected SC- c
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analyze transplanted SC-islets after 6 months in vivo. The transplanted SC-islets had a global
transcriptome profile similar to adult human islets, compared to in vitro SC-islets which are
comparable to juvenile human islets.

xiv

These revelations in transplanted SC-islets led us to study the effect of host mouse sex,
diabetic environment, transplantation site, and dose on maturation of SC-islets in mice. SC-islets
were only able to reverse pre-existing diabetes in mice at the kidney capsule transplantation location
with a dose of 5 million and 2 million SC-islet cells. Alternative intramuscular and subcutaneous, and
lower doses of 0.75 million cells were unable to reverse diabetes. SC-islet maturation was dependent
on mouse host sex and independent of the diabetic environment.
Next, we defined the transcriptome profile and maturation of SC-islets, stem cell-derived
pancreatic progenitors (SC-PPs), and primary cadaveric human islets transplanted under the kidney
capsule in mice. SC-islets achieved similar human C-peptide levels compared to human islets in
mouse serum after 18 weeks in vivo. SC-PPs were able to mature into SC- c

,

serum C-Peptide levels only rose to similar levels of SC-islets upon transplantation. Both SC-islets
and SC-PPs prevented diabetes in mice following STZ induction. SC-PPs yielded a small portion of
SC- a d
a
a

a

d
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,

a

gene signatures specific to original transplanted cells.
Overall, these studies confirm the ability of SC-islets to reverse diabetes in animal models
and define the similarity of transplanted SC-islets to primary human islets. We report differences in
transcriptome and maturation of transplanted cells based on cell type and other parameters. The work
in this dissertation provides evidence that autologous cell therapy could provide a long term therapy
for patients with diabetes.
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Chapter 1
Applications of induced pluripotent stem cell derived
beta cells from patients with diabetes
1.1 Abstract
Improvements in stem cell-derived islet (SC-islet) differentiation protocols have enabled
robust differentiation of

cells from patient induced pluripotent stem cells (iPSCs), moving in

vitro disease modeling forward and increasing the potential for autologous cell therapies. SCislet technology has elucidated key features of human pancreas development and diabetes disease
progression through generation of pancreatic progenitors, endocrine progenitors, and

cells

derived from diabetic and nondiabetic iPSCs. Combining disease modeling with gene editing and
next generation sequencing has revealed the impact of diabetes-causing mutations and diabetic
phenotype on multiple islet cell types. In addition, SC-islets containing

and other islet cell

types are self-renewable and have the potential for personalized medicine, overcoming several
disadvantages posed by donor islets. Therefore, many have tested the therapeutic potential of
iPSC-derived

(iPSC- ) cells in rodent models to determine the effects on

cell maturation and

diabetes treatment. This review will highlight relevant studies involving iPSC- cells and
progenitors, encompassing new conclusions involving diabetic patient cells and therapeutic
potential of iPSC- cells.

1

1.2 Introduction
Diabetes is a worldwide disease diagnosed in more than 451 million patients worldwide
(1). This epidemic is caused by the death and dysfunction of pancreatic, insulin-secreting

cells.

Current treatments for diabetes include exogenous insulin injections and cadaveric donor islet
transplantation (2). Long term exogenous insulin can cause cardiovascular and kidney
complications, as well as hyper- and hypoglycemia when poorly managed (3). Cadaveric islet
transplantation has developed a cell therapy pipeline showcasing the power of cell therapy and
enhanced quality of life for patients with diabetes. However, there is a limited supply of
cadaveric donors and a need for immunosuppression (4, 5). An alternate promising source for
diabetes cell therapy are self-renewable human pluripotent stem cells (hPSCs).
Stem cell-derived
(ESCs) with several key

(SC- ) cells were first generated in 2014 from embryonic stem cells
cell characteristics capable of reversing diabetes in mouse models

several weeks after transplantation (6, 7). Recent advances in differentiation protocols have
allowed for robust generation of SC- cells from patient induced pluripotent stem cells (iPSCs)
(8-10). The refined new protocols generate cell populations commonly termed SC-islets due to
the composition consisting of almost all endocrine (Chromogranin A+) cells, including
glucagon+ alpha (SC-α) and somatostatin+ delta (SC-δ) cells. Patient-derived diabetic iPSCcells allow for disease progression studies at the pancreatic and endocrine progenitor stages
during stages 4 and 5 of differentiation. In addition, disease modeling with patient cells allow for
a better understanding of multiple forms of diabetes, such as Type 1 (T1D), Type 2 (T2D),
Cystic Fibrosis-Related Diabetes (CFRD), and monogenetic diabetes (MD) (11). Genetic
engineering tools can be applied to patient iPSC-islets to generate a nondiabetic (ND) phenotype
and transgenic cell lines. Specifically, our group and colleagues used gene editing to correct
2

monogenetic diabetes variants including Neonatal (NeoD), Maturity Onset Diabetes of the
Young (MODY), and Wolfram Syndrome (WS) (12-15). Results from these studies
demonstrated potential for an autologous diabetes cell therapy. Microfluidic devices also present
an opportunity for improved culture systems and drug screening platforms to study diabetes in
vitro (16). Stem cell technology holds immense potential as a cell therapy to combat diabetes.
This review summarizes current literature on iPSC-islets from patients with diabetes by
interpreting diabetes modeling and cell therapy development to highlight the potential of
personalized therapy.

1.3 Generation efficiency of iPSC-islet differentiation protocols
Differentiation protocols for SC-islets generally target the same developmental stages,
beginning with definitive endoderm and primitive gut tube, then narrowing cell fate to pancreatic
and endocrine progenitors, and ultimately targeting the final differentiated cell to become a

cell

(6-10, 17, 18). Small molecules and growth factors are typically used to regulate the pathways
needed to navigate these differentiation stages that mimic embryonic development, which has
been thoroughly reviewed (19). Sui et al. has also used nuclear transfer embryonic stem (NT-ES)
cells to generate NT-ES- cells (20). Favorable off targets are commonly produced during the
protocol including α and δ cells. Presence of all the main islet endocrine cell types has led the
field to rename SC- cell clusters to SC-islets (15, 21, 22). Enterochromaffin (SC-EC) cells were
recently identified as an off target generated in SC-islet differentiations which persists in vivo,
validated by multiple groups (21, 22). SC-EC cells are an endocrine (CHGA+) cell type and their
effect on SC-islet function and maturation is unknown (21). In addition, adverse off target cell
types, such as neural progenitor cells (NPCs), pancreatic exocrine (mesenchyme, acinar), and
polyhormonal (PH) cells, can also contaminate the final cell cluster. The composition
3

proportions of these off targets can be influenced by differentiation efficiency, genetic
background, and disease state of the PSCs (12, 15, 21).
Prior to recent

cell differentiation protocols, iPSCs were unable to differentiate into SC-

cells as efficiently as ESCs. Protocols were typically optimized for a single ESC line (6, 7, 10).
SC- or SC- -like cells ranged from 17% (23) to 73% C-Peptide+ cells (10), a proxy marker for
insulin at the final stage of differentiation. Protocols with smaller cell yields will employ GFP
reporter cell lines to create higher purity

cell clusters based on

cell markers such as insulin,

NKX6.1, or CD177 (9, 24, 25). Purifying methods enable the study of diabetes-relevant
for disease modeling in vitro and transplanting

cells

cells in vivo.

Innovative refinements to remove off target cells during the endocrine progenitor stage
circumvented these challenges with Latrunculin A, an actin cytoskeleton modulator (8).
Application of Latrunculin A removes off target cells, enriching an endocrine population (8, 15).
This protocol provides an opportunity to perform the SC-islet differentiation in planar for 6
stages, reducing technical expertise and costly equipment for 3D culture. Additionally, removal
of function-inhibiting small molecules and reaggregation in the final differentiation stage have
enhanced the function of SC-islets and showcased rapid reversal of diabetes in rodent models
with patient SC- cells (9, 10). These innovative refinements now require minimal optimization
of multiple patient iPSC lines for successful differentiations. The SC-islets contain almost pure
endocrine cell populations (8). We and our colleagues can now readily investigate SC-islets from
patients with diabetes.

4

1.4 Disease modeling with iPSCs from patients with diabetes
SC-islets from patients with diabetes is critical to gain a better understanding of the
disease and its progression. Thus, iPSCs have been reprogrammed from patients with T1D, T2D,
MODY, CFRD, WS, and NeoD (Figure 1, Table 1 and 2). Typically, the Yamanaka factors
(OCT4, KLF4, SOX2, c-MYC) are used to reprogram the somatic cells through either retrovirus,
Sendai virus, or episomal reprogramming (26, 27). Alternatively, Sui et al. used somatic cell
nuclear transfer (NT) to generate T1D NT-ESCs from skin fibroblasts (20). Studies using patient
iPSCs differentiated into SC- cells and progenitors investigated cell maturation, differentiation
efficiencies, and insulin-secretion function. When found, these differences typically occurred
after pancreatic cell fate was designated. The cells were commonly compared to either
nondiabetic or gene-edited isogenic controls. Genetic engineering is commonly employed to
reverse these effects and correct the known diabetes causing mutations.

5

Figure 1.1 Applications of patient stem cell-derived islets.
Patient tissue biopsies can be reprogrammed into induced pluripotent stem cells (iPSCs) and
differentiated into stem cell-derived islets (SC-islets) that contain (SC- ) cells. These SC-islets
have applications in disease modeling, gene editing, and cell therapy in animal models. They
also provide a source for autologous cell replacement therapy for patients with diabetes. T1D,
Type 1 Diabetes; T2D, Type 2 Diabetes; CFRD, Cystic Fibrosis-Related Diabetes; WS, Wolfram
Syndrome; MODY, Maturity Onset Diabetes of the Young; NeoD, Neonatal Diabetes; DE,
Definitive Endoderm; PGT, Primitive Gut Tube; PP, Pancreatic Progenitor; EP, Endocrine
Progenitor.
Table 1.1 Summary of T1D and T2D patient iPS cell line studies for diabetes-in-a-dish.
T1D, Type 1 Diabetes, T2D, Type 2 Diabetes, iPSCs, induced pluripotent stem cells, SC- /α,
stem cell-derived /α, NT- , nuclear transfer- , PP, pancreatic progenitor.
Study Reference
Leite (2020)

Diabetic
State
T1D

Cell Type
Generated
SC- and SC-α
cells
-like cells

Wang et al. (2019)

T2D

Dwivedi et al.
(2019)
Sui et al. (2018)

T2D

-like cells

T1D

NT- cells

Cosentino et al.
(2018)
Amini et al. (2018)

T2D

-like cells

T1D, T2D

Millman et al.
(2016)
Thatava et al.
(2013)

In vivo
Additional Notes
Transplantation
No
Isogenic co culture with
immune cells
No
Microarray, RNA
sequencing and ChIPseq data from PPs
RNA Sequencing
Yes, prevent
diabetes onset
No

Nuclear transfer patient
stem cells
-

SC- cells

Yes, study in
vivo cells

T1D

SC- cells

T1D

Pancreatic
islet-like cells

Yes, prevent
diabetes onset
-

Chemical screen, RNA
seq of sorted sorted
cells
Microarray data
Microarray data of
iPSCs

Table 1.2 Summary of studies investigating known diabetes variants for T1D, T2D, and
MD. WS, Wolfram Syndrome, SC- , stem cell-derived , MODY, maturity onset diabetes of the
young, T2D, Type 2 Diabetes, iPSC, induced pluripotent stem cell, PP, pancreatic progenitor,
NeoD, neonatal diabetes, T1D, Type 1 Diabetes.
Study
Reference

Diabetic
State

Maxwell et
al. (2020)

WS

Variant
of
Interest
WFS1

Cell Type
Generated

Genetic
Engineering

In vivo
Additional
Transplantation Notes

SC- cells

Yes,
CRISPR/Cas9

Yes, reverse
pre-existing
diabetes

6

Single Cell
RNASequencing

CardenasDiaz et al.
(2019)

MODY3

HNF1A

-like
cells

Wang et al.
(2019)

T2D

PDX1

-like
cells

Prakash
Dwivedi et
al. (2019)

T2D

ZnT8

-like
cells

Balboa et
al. (2018)

NeoD

INS

-like
cells

Kishore et
al. (2020)

Adultonset
diabetes

GATA6

-like
cells

Amini et al.
(2018)

T1D,
T2D,
NeoD

GLIS3

SC- cells

Fabian et
al. (2019)*

MODY3

HNF1A

-like
cells

7

to correct
variant
Yes,
CRISPR/Cas9
to introduce
heterozygous
(HET) and
homozygous
knock out
(KO)
mutations
Yes,
CRISPR/Cas9
to introduce
heterozygous
(HET) and
homozygous
knock out
(KO)
mutations in
iPSC line
Yes,
CRISPR/Cas9
to introduce
protective
alleles into
SLC30A8
locus
Yes,
CRISPR/Cas9
to correct
variant
Yes,
CRISPR/Cas9
to correct
variant
Yes,
CRISPR/Cas9
to introduce
GLIS3
mutations
Yes,
CRISPR/Cas9
to introduce
HNF1A
mutations

No

Microarray of
INSGFP+NKX6.1+
cells

No

Microarray,
RNA
sequencing and
ChIP-seq data
from PPs

Yes, study in
vivo cells

RNA
Sequencing

Yes, study in
vivo cells

Single Cell
RNASequencing

Yes, study in
vivo cells

Chemical
screen, RNA
sequencing of
sorted sorted
cells
Microarray

No

Ma et al.
(2018)

INS

-like
cells

Stepniewski MODY3
et al. (2015)

HNF1A

-like
cells

Shang et al.
(2014)

WS

WFS1

Hua et al.
(2013)

MODY2

GCK

MODY1
MODY1
MODY2
MODY3
MODY5
MODY5
MODY8

HNF4A
HNF4A
GCK
HNF1A
HNF1B
HNF1B
CEL

insulinproducing
cells
iPSCcells
-

Teo et al.
(2013)

NeoD

Yes,
CRISPR/Cas9
correction of
variant
-

Yes, prevent diabetes onset

WT WFS1
Lentivirus to
correct variant
Yes, ZFN to
correct variant
-

Tested ER
chaperone
drugs
Yes, study in vivo
cells
-

Yes, tested iPS
tumor
formation
Yes, prevent
diabetes onset

-

T1D and T2D are the most common forms of diabetes mellitus, constituting about 10 and
90% of patients with diabetes, respectively (11). Understanding the pathophysiology of these
diseases is complex due to risk factors including epigenetics, environment, and lifestyle. Many
rodent models of T1D and T2D exist; however, there are several physiological differences
between rodents and humans, specifically in the islets (28, 29). Therefore, we and others use
stem cell technology to create iPS cells from human patients to model T1D and T2D and gain a
better understanding of disease pathogenesis (Table 1). Early studies use PDX1+/NKX6-1+
pancreatic progenitors (PPs), which give rise to all pancreatic cell fates. T1D iPSC- cells have
differentiation efficiencies and function similar to ND iPSC- cells (30), consistent with previous
reports comparing T1D SC-PPs (31). Under further investigation, in vitro modeling systems
revealed T1D patient-derived endocrine cells respond to stress (30) and react to autologous
immune cells in a cell-type specific manner, providing a better understanding of T1D
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pathogenesis (32). There is no literature investigating SC-islets from patients with T2D;
however, T2D iPSCs are available (26). There are multiple studies using patient iPS cells with
T2D-risk variants in SLC30A8 (33), TRMT10A (23), and PDX1 (34). To further study T2D,
next generation sequencing (NGS) has identified gene expression differences in T2D islets
compared to healthy controls (35, 36). Xin et al. reports differentially expressed genes found in
the main endocrine islet cell types (37). Specifically, in

cells, PAXBP-1, GLS2, FXYD23 are

upregulated and G6PC2, GLRA1, IGFBPL1 are downregulated.
CFRD and MD are rarer forms of diabetes which limits the availability of primary
samples. Thus, patient iPSCs are critical for uncovering disease pathogenesis and therapeutic
development. Pancreatic ductal epithelial cells were derived from iPSCs with a cystic fibrosis
genetic background to create a drug screening platform in vitro (38). MD is caused by a single
gene mutation which occurs in 2% patients diagnosed with diabetes [reviewed by (39)]. Patient
iPSCs from MODY, NeoD, and WS backgrounds have allowed for human monogenic diabetes
modeling. Recent publications have investigated mutations in PDX1, GLIS3, HNF1A, HNF1B,
GCK, INS, GATA6, and WFS1, which are each related to a form of MD (Table 2). Genetic
engineering tools are commonly applied to correct the known mutation, oftentimes leading to a
healthy phenotype, in an isogenic cell line (Table 2) (12-15, 33, 34, 40-42). Diabetic stem cell
derivatives are typically less efficient in generating SC-islets, SC- cells, and SC-PPs. Namely,
this occurred when evaluating mutations in GATA6 (43), WFS1 (15, 42), and PDX1 (34) (Table
2). Transplantation in mice is commonly performed to observe cell maturation in vivo and
examine if cells can either reverse pre-existing or reverse diabetes (Table 2). In summary, human
iPSC differentiation protocols enable the study of diabetic
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cells and progenitors in vitro.

1.5 Next Generation Sequencing
Several iPSC studies employ NGS strategies (12, 15, 34) and microarrays (30, 31, 43, 44)
to study differentially expressed genes between genes and utilize single cell analyses to identify
changes in specific cell types, such as α and

cells. Balboa et al. and Maxwell et al. both observe

increases in beta cell genes for gene-edited SC- -like and SC- cells with single cell RNA
sequencing. Wang et al. identifies downregulated PDX1-bound genes that reduce differentiation
efficiency including MNX1, CES1, and MEG3. Millman et al. identifies TAP1 as the largest
differentially expressed gene in T1D SC- cells compared to healthy patients. Recently,
Augsornworawat et al. evaluated the transcriptome of transplanted SC-islets with single cell
RNA sequencing from both ESCs and iPSCs to show the strong resemblance of in vivo SC-islets
with primary human islets (22). A maturation list for

and α cells was curated from the

sequencing data, providing a resource on what to target for maturation in vitro (22). NGS for
primary human and SC-islets is thoroughly evaluated (45) to highlight key findings for islet cell
types depending on diabetic state. Of note, Muraro et al. and Segerstolpe et al. characterize
human islet samples from ND and T2D patients (35, 46). Krentz et al. and Hrvatin et al. compare
progenitor cell types to human islets (44, 47). Last, Veres et al. profiles the various stages of
differentiation to yield a potential cell sorting mechanism and identify SC-EC cells (21). Xin, et
al. identifies the unfolded protein response in primary

cells from multiple donors (37). These

studies utilize innovative biotechnology to perturb the transcriptome of primary and stem cellderived human islets.
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1.6 Disease-in-a-dish
SC-islets and progenitor derivatives are used to model diabetes-in-a-dish. ER stress
experiments are commonly applied to ND and diabetic SC-islets to represent diabetes in vitro. In
all forms of diabetes, ER stress is found in

cells, causing dysfunction and eventual UPR-

mediated cell death (48). Balboa et al., Shang et al., and Maxwell et al. studied SC- cells and
progenitors from patients with mutations linked to diabetes known to cause ER stress. The
results reveal a combination of increased protein and gene expression of ER stress markers,
dysfunctional insulin processing, and reduced insulin secretion in response to glucose (12, 15,
42). Shang et al. and Maxwell et al. also showed dilated ER with electron microscopy, indicating
ER stress (15, 42). Balboa et al. and Maxwell et al. used NGS to identify increased ER stress
(ATF6, BiP/HSPA5), apoptotic (CHOP, CASP3), and oxidative stress transcripts (TXNiP) (12,
15). SC- cells with greater maturation influences ER stress and study results. As portrayed
when comparing WS studies, SC- cells (15) are more mature than insulin-producing cells (42)
indicated by attainment of

cell markers and functioning insulin secretion in response to

glucose. Specifically, for WS studies C-Peptide+ insulin-producing cells were not reduced with a
WFS1 mutation; however, SC- cell yields were diminished when comparing the unedited and
corrected iPSC differentiations. Greater insulin production, supporting higher functional
capacity, increases ER stress inherently due to increased insulin production and protein folding,
activating the unfolding protein response at a basal level, and likely influencing differentiation
from endocrine progenitors to SC- cell fate. There are few articles available examining ER
stress in human islets (37, 49); therefore, human SC-islets are a critical resource to understand
disease-in-a-dish.
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Transgenic cell lines are generated through editing technologies that insert and express
foreign DNA. For diabetes research, transgenic stem cells are created using biotechnology to
either study diabetes through the insertion of a known diabetes causing variant or monitor
differentiation with a reporter cell line. This technology advancement is critical to study known
variants associated with T1D and T2D. Amin et al. used a GLIS3 mutation associated with T1D,
T2D, and NeoD to generate SC-PP2 and SC-PP2- cells (40). With the mutation, they observed
increased cell death and impaired differentiation compared to isogenic controls, allowing for a
drug screening platform. Shang et al. used lentivirus to transfect WT WFS1 in their patient iPSderived insulin-producing patient to model WS in vitro (42). Dwivedi et al. inserted a ZnT8 LOF
allele expected to protect against T2D using CRISPR/Cas9 in patient iPSCs (33). They found
increased glucose responsiveness, making ZnT8 a promising target to increased insulin secretion
as a T2D treatment. Transgenic stem cell lines are also used to study neurologic, epidermal, and
cardiomyocyte disorders.
Microfluidic devices are used to mimic the in vivo pancreas and islet microenvironment.
Engineered devices perturb islet function by enhancing insulin sensing, islet hormone secretion
in response to glucose, and monitoring pulsatile insulin release. Misun et al. generated a device
to monitor dynamic insulin secretion of a single human islet (50). Lenguito et al. combined
convective fluidic devices and computational modeling of GSIS to develop a competitive
alternative to commercially available perifusion systems with the opportunity to image cells
while in the machine (51). Jun et al. developed a dynamic culture system, as an alternative to
typical static culture, by integrating interstitial flow to better mimic in vivo islet conditions in
vitro (52). Glieberman et al. designed a microfluidic device incorporating the native islet
microenvironment by delivering pulsatile insulin through arteriole and capillary channels on a
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chip (53). This system also continuously monitored insulin release, quantified with fluorescence
anisotropy. Future protocols may benefit from differentiating PSCs in these engineered culture
devices, such as the integrated platform developed by Ishahak et al. that incorporates continuous
perfusion culture with the ability to monitor functional maturation (54). These newly developed
devices are competitive platforms for drug screening and studying dynamic insulin secretion in
vitro.
Sorting SC- cells and progenitors are helpful in studying specific cell types of interest
and removing off target cell types from differentiation protocols. Several studies utilize
NKX6.1GFP/w and INSGFP/w stem cell lines to enhance SC- cell yields (14, 20, 24, 55).
Mahaddalkar et al. identified anterior definitive endoderm (DE) markers CD177 and CD275 to
specify pancreatic and liver fate, respectively (56). Thus, they sort for CD177+CD275- after DE
is defined in the first stage of SC-islet differentiation, which improves the percentage of
INS+NKX6.1+ -like cells at stage 7. Additionally, Veres et al. recently identified CD49a/ITGA1
as a surface marker for

cells in SC-islet clusters, therefore increasing insulin secretion of

individual islets (21). Sorting strategies are beneficial to study

cells for disease-in-a-dish

modeling of diabetes.

1.7 Gene Editing
Gene editing is commonly used in the SC- cell field to determine effects of gain and loss
of function genes on

cell differentiation insulin secretion. The impact of PDX1, MAFA, and

NEUROG3 have been extensively studied in SC- cells [review by (57)]. Gene editing has also
been proposed for cell therapy efforts in both correction of diabetes-causing mutations and
resistance to immune rejection. We and colleagues have used CRISPR/Cas9 and lentiviral
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transduction to correct known diabetes-causing mutations in patient iPS cells. Maxwell et al. and
Ma et al. reveal the ability of gene-correction to reverse and prevent diabetes in mice,
respectively. These results are very promising for the potential of an autologous cell therapy.
Gene corrected cell therapies are currently employed for other diseases. Eichstadt et al. uses
gene-corrected autologous cell therapy in a Phase 1/2a clinical trial for recessive dystrophic
epidermolyis bullosa and has seen no adverse effects (58). R o et al. published results from a
Phase 1/2 clinical trial of gene-corrected hematopoietic gene therapy for patients with Fanconi
Anemia and also saw no immune rejection effects (59). However, there remains concern that
gene editing of autologous cells may cause immune rejection due to the autoimmune reactive
nature of diabetes. Therefore, efforts currently investigating immune rejection resistance in
allogeneic cell therapy may also be needed at a lesser extent for autologous cell therapy. Genome
engineering to address immune intervention has been previously reviewed (60). For SC- cell
therapy, key targets for genome engineering of diabetes cell therapy include HLA modification
to expand SC-islet utility and CTLA-4 and PD-1/PD-L1 adjustment to target T cell immune
rejection upon transplantation (61, 62). Alternate iPSC-derived engineered cell types
(endothelial, smooth muscle, cardiomyocytes) described in Deuse et al. use MHC-mismatched
allogeneic sources to inactivate the MHC class I and II genes and over-express CD47 with
CRISPR/Cas9 to successfully evade immunosuppression in recipients (63). These advances in
SC- and alternate cell genetic engineering aim to address an unmet need in the autologous and
allogeneic stem cell therapy field.

1.8 In vivo cell therapy in animal models
To develop an adequate cell therapy, in vivo testing is needed in animal models for cell
therapy potential validation. Our group and colleagues have established several studies
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confirming the use of SC-islets, SC- cells, and PPs for cell therapy in rodent models. Validation
methods include prevention of diabetes (14, 20, 42, 64, 65) and diabetes reversal (6, 7, 9, 10, 15)
by transplanting cells in the kidney capsule prior to or after diabetes induction, respectively.
Streptozotocin and alloxan are used to induce diabetes in mouse and rat models. Nephrectomies
are also commonly performed to confirm the transplanted cells were the source of euglycemia in
kidney capsule transplants (8, 15, 20, 65-67). Several groups have confirmed maturation of SCislets, SC- cells, and PPs post transplantation by immunostaining. Transplantation sites range
from portal vein, intramuscular, subcutaneous, to kidney capsule (8, 14, 20, 65). The impact on
pregnancy and sex between mouse recipients has also been tested, revealing no difference
between male and female mice (65, 68). In vivo models are also used to test encapsulation
devices with stem cell beta-like cell derivatives (65, 69-72). Transplantation is usually tested in
immune-compromised mice due to immune rejection of SC-islets; however, Yoshihara et al.
successfully transplanted and maintain glucose homeostasis in diabetic immune-competent mice
for 50 days with their human islet-like organoids genetically engineered to overexpress PD-L1
(62). These combined efforts for in vivo testing are encouraging to soon yield a diabetes cell
therapy.

1.9 Personalized cell replacement therapy
The standard of care for diabetes treatment is exogenous insulin. Risks and complications
remain with this treatment including hypoglycemia, swelling and infection at injection sight, and
weight gain. Additionally, long term exposure can increase cardiovascular complications, stroke
risk, and kidney damage (73). Experimental treatment methods currently in practice include
pancreas and cadaveric islet transplantation (74-76). These methods are typically only employed
when a patient is unresponsive to standard treatment or kidney damage is present and patient is
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already undergoing a replacement transplant. Cadaveric islet transplantation requires multiple
donors, and the cells have limited availability and variation between donors. Transplantation of
allogeneic cells and organs require the recipient to be on immunosuppressive drugs, which can
be problematic for patients with type 1 diabetes. SC-islets overcome several of these limitations,
providing an unlimited cell source with robust function for use as a cell therapy. Autologous
diabetes cell therapy is possible with patient iPSC-islets, containing their missing insulinsecreting

cells, and also has the potential to remove the need for immunosuppressive drugs

post-transplant. There is a concern about the cost of autologous cell therapies, for a wide range of
diseases. After cell therapy is established as a safe and viable treatment for disease, cost will be
reduced allowing for mass manufacturing of the cell products. Generation of large cell batches
will be enabled by updated protocols allowing cryopreservation of functional SC- cells (65).
With advances in stem cell technology, diabetes cell therapy can be used in a wider patient
population including insulin-independent patients with T1D and T2D and those undergoing a
pancreatectomy.

1.10 Future Outlook
SC-islets are a promising cell source for diabetes cell therapy due to their unlimited
source and functional maturation with established differentiation protocols (8). While recent
advancements in SC-islet differentiation protocols are encouraging, there is a need for a
universal protocol adaptable to all cell lines for an autologous cell therapy. Several genetic
engineering tools could enable the next advancement in autologous diabetes cell therapy
research. Identification of an iPSC marker that defines iPSC lines suitable for an efficient
differentiation or a marker to overexpress in iPSCs to increase differentiation yield are needed in
the field. Additionally, creating a reporter cell line to improve functional readout or maturation
16

indication after cell fate designation to SC- cells would help both cell therapy development and
drug screening applications. Ideally, SC-islets would be indistinguishable from human islets
upon transplantation. Thus, protocol improvements and enhanced function are needed for SCislets in vitro. Generation of an autologous stem cell therapy would be a highly desirable diabetes
treatment to greatly increase the quality of life for patients worldwide.
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Chapter 2
Transplantation of gene-edited human stem cellderived cells from a diabetic patient rapidly reverses
pre-existing diabetes in mice
Partially adapted from: Maxwell, K.G., Augsornworawat, P., Velazco-Cruz, L., Kim,
M.H., Asada, Ri., Hogrebe, N. J., Morikawa, S., Urano, F., Millman, J. R. (2020).
Transplantation of gene-edited human stem cell-deri ed

cells from a diabetic patient rapidly

reverses pre-existing diabetes in mice. Science Translational Medicine. 12 (540), eaax9106.

2.1 Abstract
Differentiation of insulin-producing

cells from diabetic patient-derived induced

pluripotent stem cells (iPSCs) promises to provide autologous cells for diabetes cell replacement
therapy. However, current approaches produce diabetic patient iPSC-deri ed

(SC- ) cells ith

poor function in vitro and in vivo. Here, we use CRISPR/Cas9 to correct a diabetes-causing
pathogenic variant in the WFS1 gene within iPSCs derived from a Wolfram Syndrome patient.
After differentiation with our recent 6-stage differentiation strategy, corrected WS SC- cells
were capable of performing robust dynamic insulin secretion in response to glucose and rapidly
reverse pre-existing diabetes in mice. Single-cell transcriptomics revealed corrected SC- cells
had increased insulin and decreased expression levels of genes associated with endoplasmic
reticulum stress. The combination of CRISPR/Cas9 correction of a diabetes-inducing gene
variant allows for robust differentiation of autologous SC- cells that can rapidl re erse se ere
diabetes.
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2.2 Introduction
Derivation of iPSCs from patients followed by differentiation into disease-relevant cell
types holds great promise for in vitro disease modeling, drug screening, and autologous cell
replacement therapy for multiple diseases (1, 2). Diabetes mellitus is caused by the death or
dysfunction of insulin-producing

cells ithin the pancreas. While insulin injections are often

used to replace this lost function (3), long-term complications can arise (4). Alternatively,
transplantation of cadaveric allogeneic islets containing

cells has been performed successfull ,

demonstrating the feasibility of a cell therapy approach, but is limited due to low donor number
and the need for immunosuppressant drugs (5-7).
Use of SC- cells differentiated from diabetic patient-derived iPSCs would provide a
source of autologous replacement cells (8), but an unmet need in the field has been the lack of
robust physiological function of these cells (9). Specifically, prior reports with patient iPSCs
have generated pancreatic or endocrine progenitors lacking

cell identity (10-14). Recently we

and others have developed differentiation strategies with human embryonic stem cells (hESCs)
to generate functional non-progenitor SC- cells in vitro as an alternative source of replacement
cells (15-17). While these and similar approaches have been used to generate SC- cells from
Type 1 diabetic (18, 19), Type 2 diabetic (20), and neonatal diabetic (21, 22) patient-derived
iPSCs or nuclear transfer stem cells (NT-SCs) in vitro, these cells have had only modest function
in vitro and in vivo. In particular, unlike ith primar

cells, these diabetic patient-derived SC-

cells required long times after transplantation (12-19 wk) for additional functional maturation to
normalize glucose levels in modestly diabetic mice with high failure rate, were not transplanted
into mice with pre-existing diabetes, formed overgrowths, and/or in vitro dynamic glucosestimulated insulin secretion (GSIS) was not demonstrated. To overcome this limitation in the
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field, we have recently developed a differentiation protocol that leverages a previously unknown
role of the cytoskeleton in pancreatic fate choice that produces highly functional SC- cells
across multiple cell lines (23).
Single pathogenic gene variants causing diabetes can be corrected in iPSCs (21, 22) using
CRISPR/Cas9 gene editing (24). One applicable disease is Wolfram Syndrome (WS), a rare
autosomal recessive disorder caused by pathogenic variants in the WFS1 gene (25, 26), which
causes chronic endoplasmic reticulum (ER) stress that stimulates the unfolded protein response
(UPR) and eventually causes ER stress-mediated cell death in

cells (27-29). WS patients

develop diabetes in childhood along with other ailments, including optic nerve atrophy and
neurodegeneration (26). There is currently no effective treatment for WS or ER stress related
diseases (26). ER stress is a common feature shared with all forms of diabetes and other diseases
(30-35).
Here we demonstrate generation of robustly functional SC- cells deri ed from patients
with WS using CRIPSR/Cas9 gene correction of the WFS1 gene. While both corrected and
unedited WS iPSCs differentiated into SC- cells, corrected WS SC- cells had greatl enhanced
differentiation efficacy and function, demonstrating a dynamic response to glucose with both
first and second phase insulin secretion. Transplantation of corrected but not unedited WS SCcells rapidly restored normoglycemia in mice with severe pre-existing diabetes. Single-cell RNA
sequencing (scRNA-seq) analysis of the transcriptomes of individual SC- cells re ealed similar
expression of

cell-associated transcription factors but reduced insulin and increased UPR,

mitochondrial stress, and apoptotic gene expression in the unedited compared to corrected SCcells. Furthermore, generation of non-pancreatic off-target cell t pes with the unedited iPSCs
were identified with scRNA-seq. Our study successfully demonstrates the application of
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combining a robust newly devised differentiation strategy with CRISPR/Cas9 gene therapy of
diabetic patient-derived iPSCs to generate autologous SC- cells ith robust function capable of
rapidly reversing severe pre-existing diabetes.

2.3 Results
2.3.1 Gene-corrected WS SC- cells display dynamic function and express

cell markers

We started our study with iPSC lines from two WS patients described previously (36)
(WU.WOLF-09 and WU.WOLF-13, designated WS9unedit and WS13unedit, respectively, in this
study) and with generating iPSCs from skin fibroblasts for one additional WS patient described
previously (25) (WU.WOLF-04, designated WS4unedit in this study). We used CRISPR/Cas9 to
correct the pathogenic variants in the WFS1 gene for patient WU.WOLF-04 and WU.WOLF-13,
generating multiple corrected iPSC clones designated WS4corr, WS4corr 2, and WS13corr (Figure
2.1A-C, S2.1A-D). We attempted to adapt the unedited iPSC lines from all three patients to
suspension culture for propagation and differentiation, as we have reported previously to
generate SC- cells (17). However, we were unable to establish these suspension cultures due to
extensive cell death and low cell yields. Due to these challenges, we did not continue to attempt
suspension differentiations for corrected clones and instead used our recent differentiation
protocol based on cytoskeletal modulation (23). WS iPSCs were differentiated in attachment
culture, and the final cell population was aggregated into islet-like clusters for assessment
(Figure 2.1D-E), avoiding the limitations of suspension culture approach. Differentiation of
unedited iPSC lines from all three patients produced cells capable of secreting insulin (Figure
2.1F). However, our three CRISPR/Cas9-corrected cells lines (WS4corr, WS4corr 2, and WS13corr)
were more glucose responsive, capable of responding to glucose by secreting 6.4±1.4x,
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10.6±1.3x, and 7.2±0.6x more insulin at 20 mM glucose compared to their unedited
isogenic/patient-matched controls, respectively (Figure 2.1F). These data indicate that Wolfram
Syndrome-causing pathogenic variants in the WFS1 gene contribute to defects in GSIS that can
be corrected with genetic engineering.
We performed further characterization of the islet-like clusters e pressing , , and cell
hormones with and without CRISPR/Cas9 correction from patient WS4 (Figure S2.2A).
WS4unedit, WS4corr, and WS4corr 2 all produced C-peptide+ cells that co-stained ith

cell

transcription factors (NKX6-1 and PDX1) (Figure 2.2A-C, S2B-D). However, SC- cell
generation, defined by C-peptide+/NKX6-1+ cells, was lower with WS4unedit (22±2%) compared
to WS4corr (47±2%) and WS4corr 2 (59.1±1%) cells (Figure 2.2A-C, S2.2B-D). The fractional
yield of SC- cells from corrected clones was similar to our previously reported non-diabetic
lines (17). The early stages of differentiation generated cells with similar relative gene
expression and fraction of cells expressing key progenitor makers (Figure S2.3). We began to
detect differences in differentiation efficiency at stage 5, when endocrine cell induction
predominantly occurs (Figure S2.3), and these differences amplify during stage 6 (Figure 2.2C).
The mechanistic cause of WS4unedit SC- cell differentiation defects is unknown, but other
reports have shown organelle calcium and oxidative stress to influence differentiation of other
cell types (37, 38). WFS1 gene expression and protein are detectable across all stages of
differentiation. However, the detrimental effects of WFS1 pathogenic variants on differentiation
towards SC- cells appears mostly to occur during later stages of differentiation when WFS1
expression increases (Figure 2.2D, S2.4). We observed lower expression of WFS1 protein in
WS4unedit compared to WS4corr cells (Figure 2.2D). In prior reports, variant WFS1 protein and
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RNA was shown to be unstable and undergo proteasomal degradation, cellular depletion, and
non-sense-mediated decay (39, 40).
The lack of WFS1 can cause

cell d sfunction (27, 29, 32). Indeed, while both WS4unedit

and WS4corr SC- cells ere capable of responding to glucose b secreting insulin in a static
assay (Figure 2.1F), only WS4corr SC- cells were capable of demonstrating robust first and
second phase insulin secretion (Figure 2.2E). WS4corr SC- cells secreted 8.9±2.1x more insulin
in dynamic GSIS assays compared to WS4unedit SC- cells at peak (first phase) insulin secretion
in 20 mM glucose. WS4corr SC- cells ere functionall similar to non-diabetic SC- cells and
human islets as we previously reported (17) (Figure 2.2E). Accounting for the SC- cell
differentiation efficacy differences between WS4unedit and WS4corr iPSC lines, WS4corr SC- cells
continued to have superior static and dynamic GSIS (Figure S2.5). Collectively, these data
demonstrate that the CRISPR/Cas9 correction of the WFS1 pathogenic variant in WS iPSCs
increased SC- cell differentiation efficac and function, including much greater and near isletlike dynamic insulin secretion in response to high glucose.
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Figure 2.1 CRISPR/Cas9 correction of WFS1 permits generation of functional WS SCcells in vitro. (A) Schematic summary of WS patient-derived iPSC generation. (B) Information
of 3 WS patients, including location of autosomal recessive pathogenic variants in WFS1 and
symptom onset age (N=none, M=male, F=female, yo=years old, DM=diabetes mellitus,
OA=optic atrophy, DI=diabetes insipidus). (C) Specific gene variants in WFS1 in WS4unedit and
WS13unedit iPSCs targeted for CRISPR/Cas9 correction. (D) Schematic of differentiation protocol
mimicking embr onic de elopment of pancreatic cells. (E) Bright field images of stage 6
clusters produced with all cell lines in this study. Scale bar, 500 µm. (F) Static GSIS functional
assessment of WS4unedit (n=7), WS9unedit (n=6), and WS13unedit (n=5), WS4corr (n=15) and WS4corr
2 (n=4), and WS13corr (n=4) stage 6 cells in an in vitro static GSIS assay. Data with WS4unedit
and WS13unedit cells are regraphed to help with comparisons. *p<0.05 and ****p<0.0001 by oneway paired t-test.
p<0.001 and
p<0.0001 by two-way unpaired t-test comparing to
unedited high glucose. iPSC, induced pluripotent stem cell; DE, definitive endoderm; PGT,
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primitive gut tube; PP, pancreatic progenitor; EP, endocrine progenitor. Act A, activin A; CHIR,
CHIR99021; KGF, keratinocyte growth factor; RA, retinoic acid; LDN, LDN193189; T3,
triiodothyronine; Alk5i, Alk5 inhibitor type II; ESFM, enriched serum-free medium.

Figure 2.2 In vitro characterization of unedited and corrected WS4 SC- cells. (A)
Representative flow cytometry dot plots and (B) quantified fraction of cells expressing or coe pressing cell or islet markers for WS4unedit (n=4-7) and WS4corr (n=4-8) stage 6 cells.
**p<0.01, ****p<0.0001 by two-way unpaired t-test. (C) Immunostaining of sectioned WS4corr
and WS4unedit stage 6 clusters stained for cell or islet markers. Scale bar, 100 m. (D) Western
blot (left) and quantified intensity (right) of WFS1 protein present in stage 0 and stage 6 WS4corr
(n=3) and WS4unedit (n=3) cells. **p<0.01; ***p<0.001 by two-way unpaired t-test. (E) Dynamic
human insulin secretion of WS4corr (n=5) and WS4unedit (n=4) stage 6 cells and primary human
islets from Velazco-Cruz et al. (17). Clusters were perfused with 2 mM glucose everywhere
except where indicated by high glucose (20 mM). CP, C-peptide; GCG, glucagon; SST,
somatostatin.
2.3.2 Gene-corrected WS SC- cells rapidly correct blood glucose in mice with pre-existing
diabetes
To evaluate the potential of corrected WS SC- cells for cell replacement therap , e
transplanted 5x106 WS4unedit stage 6 cells, WS4corr stage 6 cells, and cadaveric human islet (HI)
30

cells under the kidney capsule of mice previously rendered diabetic by streptozotocin (STZ)
injection to destro endogenous mouse

cells (Figure 2.3A, Figure S2.6). After transplantation

with WS4corr SC- cells, blood glucose dropped <200 mg/dL ithin 1 k (Figure 2.3B), with the
grafts at 2 wk containing cells mostly expressing C-peptide but also containing minority
populations of glucagon+ and somatostatin+ cells (Figure 2.3C, S2.6G). The average blood
glucose level was 81±5 mg/dL from 2-27 wk with WS4corr SC- cell transplantation (Figure
2.3B). Glucose tolerance tests were performed 9 d and 10 wk after transplantation, with WS4corr
SC- cells demonstrating greatly improved glucose tolerance compared to WS4unedit cells and the
sham. (Figure 2.3D-E). Human islets performed similar albeit slower to WS4corr transplanted
mice by returning to normoglycemia at 2 wk, gaining glucose tolerance at 9 days and performing
in vivo GSIS at 2 weeks post transplantation (Figure 2.3B, 2.3D-E). For the 6-month observation
period, mice transplanted with WS4unedit SC- cells and the sham ere unable to achie e
glycemic control while the WS4corr SC- cells maintained blood glucose normali ation (Figure
2.3B). Mouse serum was collected 2 and 10 wk after transplantation, and while all
transplantation groups had detectable human insulin, WS4corr and human islets had much higher
concentrations than WS4unedit (Figure 2.3F). This is consistent with our in vitro observations of
increased insulin secretion and glucose responsiveness of WS4corr compared to WS4unedit SCcells in vitro (Figure 2.1F, 2.2D). Interesting, measured insulin concentration in the serum
doubled from 2 to 10 wk for WS4corr SC- cells, suggesting the SC- cells are maturing in i o
(Figure 2.3F). Mice transplanted with WS4unedit SC- cells also had higher human proinsulin-toinsulin ratio in the serum, suggesting the presence of ER stress and problems with insulin
processing (Figure 2.3G). A nephrectomy was performed on two live mice transplanted with
WS4corr SC- cells 12 k after transplantation, hich demonstrated a return to h pergl cemia
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within 1 wk and indicated prior glycemic control was due to transplanted WS4corr SC- cells
(Figure 2.3H). We observed the kidneys receiving WS4unedit cells contained large overgrowths,
an undesirable feature, that were not present in any kidneys with WS4corr cells (Figure S2.6H).
The ability of WS4corr SC- cell-transplanted mice to rapidly reverse diabetes demonstrates that
CRISPR/Cas9 correction of differentiated diabetic patient iPSCs is a promising cell source of
autologous

cells for diabetes therap .

Figure 2.3 Transplantation of WS4corr SC- cells into mice rapidly reverses pre-existing diabetes. (A)
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Schematic overview of diabetes induction with streptozotocin (STZ), transplantation of stage 6 cells containing WS
SC- cells, and nephrectom of the transplanted mice. (B) Blood glucose measurements before STZ treatment, after
STZ treatment, and after transplantation with SC- cells or human islets. Fi e groups ere studied: Diabetic mice
without a transplant (STZ, No Txp; n=7; black), diabetic mice transplanted with WS4unedit stage 6 cells (STZ,
WS4unedit Txp; 5x106 cells; n=6; blue), diabetic mice transplanted with human islets (STZ, HI Txp; 4000 IEQ; n=4;
green), diabetic mice transplanted with WS4corr stage 6 cells (STZ, WS4corr Txp; 5x106 cells; n=10; red), and nondiabetic mice without a transplant (No STZ, No Txp; n=5; grey). (C) Immunostaining of sectioned kidney explanted
from a mouse that had received WS4corr stage 6 cells 2 wk prior. Scale bar, 100 µm. (D) Glucose tolerance test
(GTT) 9 d and 10 wk after Txp. Five groups were studied: STZ, No Txp (n=7 at 9 d and 10 wk; black); STZ,
WS4unedit Txp (n=6 at 9 d; n=5 at 10 wk; blue); STZ, HI Txp (n=4 at 9 d; green); STZ, WS4corr Txp (n=10 at 9 d;
n=9 at 10 wk; red); and No STZ, No Txp (n=5 at 9 d and 10 wk; grey). (E) Area under the curve (AUC)
quantification for GTT data. **p<0.01 and ****p<0.0001 by two-way unpaired t-test. (F) In vivo GSIS secretion 2
and 10 wk after transplantation for STZ, WS4unedit Txp (n=6 and 5 at 2 and 10 wk; blue), STZ, WS4 corr Txp (n=10
and 9 at 2 and 10 wk; red), and STZ, HI Txp (n=4; green) mice at 0 and 60 min after 2 g/kg glucose injection.
ns=not significant, **p<0.01 by one-way paired t-test. p<0.05 and
p<0.001 by two-way unpaired t-test
compared to WS4unedit 60 min measurements. (G) Molar ratio of serum human proinsulin to insulin for STZ,
WS4unedit Txp (n=5; blue) and STZ, WS4corr Txp (n=9; red) 60 min after 2 g/kg glucose injection 10 wk after
transplantation. ***p<0.001 by two-way unpaired t-test. (H) Blood glucose measurements before and after
nephrectomy of two STZ, WS4corr Txp (orange) mice compared to remaining non-nephrectomized STZ, WS4corr Txp
(n=6; red). CP, C-peptide; GCG, glucagon; SST, somatostatin.

2.3.3 Single-cell RNA sequencing of differentiated WS iPSCs reveals SC- cell, pancreatic
endocrine, and non-pancreatic populations
In order to specifically compare SC- cells generated from WS4corr and WS4unedit iPSCs,
accounting for differences in differentiation efficacy (Figure 2.2A), we performed scRNA-seq
using the 10x Genomics platform. A total of 7,215 and 3,640 stage 6 single cells differentiated
from WS4unedit and WS4corr hiPSCs, respectively, were sequenced, averaging 50,996 reads per
cell. After quality control (Figure S2.7), an average of 2,861 genes were detected per cell. Seurat
guided analyses (41, 42) were used to evaluate scRNA-seq data. Using dimensional reduction
and unsupervised clustering, 8 populations were identified for WS4corr and WS4unedit (Figure
2.4A). The cell populations were identified based on the top upregulated genes in each cluster
and published pancreatic transcriptome data (Figure S2.8) (43).
SC- cell populations ere identified in stage 6 cells differentiated from both WS4corr and
WS4unedit iPSCs (Figure 2.4A). While this population was the largest for WS4corr (42%), it was a
minority population in WS4unedit (11%) (Figure 2.4B). The vast majority (91%) of cells within
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WS4corr stage 6 cells were identified as pancreatic endocrine (SC- , SC- , SC- ) hile
pancreatic endocrine (SC- , pol hormonal) ere a minorit (16.5%) for WS4unedit (Figure 2.4AB). The majority of WS4unedit stage 6 cells were either pancreatic exocrine or non-pancreatic cells
(Figure 2.4A-B), with many cells expressing non- cell markers such as SPINK1 and ID3
(Figure 2.4C, S2.7, S2.9A), suggesting that the WFS1 pathogenic variants carried by these cells
caused misdirection of cell fate choice to off-targets with our differentiation protocol. Gene
expression of the off-target markers is detectable as early as stage 2 with real-time PCR (Figure
S2.9B), and these cells are likely expanding as differentiation progresses to reduce the fraction of
on-target pancreatic cells. The effects of these off-target populations on the function of the SCcell population, particularly in terms of transplantation efficacy, is unknown. Both WS4corr and
WS4unedit pancreatic endocrine populations had cells with multiple detected hormones (insulin,
glucagon, somatostatin) (Figure 2.4C, S2.7C), as has been observed with endocrine stem cell
differentiations and human islets (44-46). Taken together, scRNA-seq enabled identification of
SC- cells from WS4corr and WS4unedit iPSCs differentiated to stage 6 in addition to several
unexpected off-targets from WS4unedit, illustrating the greatly improved SC- cell differentiation
efficacy enabled by CRISPR/Cas9 correction in WS iPSCs.
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Figure 2.4 Single cell transcriptional analysis reveals WS4corr and WS4unedit SC- cell
populations and off-targets. (A) tSNE projection from unsupervised clustering of
transcriptional data from scRNA-seq of WS4unedit and WS4corr stage 6 cells. (B) Calculated
percentages of defined cluster populations for WS4unedit and WS4corr stage 6 cells. (C) Heat map
of gene expression of key population markers (insulin (INS), chromogranin A (CHGA),
SPINK1, ID3) represented at low/none (grey), medium (yellow), and high (red). NP1, neural
progenitor 1; NP2, neural progenitor 2; NP3, neural progenitor 3; PH, polyhormonal; EC,
enterochromaffin.

35

2.3.4 CRISPR/Cas9 gene editing modulated SC- cell gene expression
scRNA-seq enabled investigation of the transcriptome specifically in SC- cells from the
heterogeneous stage 6 cell population in both WS4corr and WS4unedit lines. This eliminated
dilution effects on measurements of the bulk population analysis due to the presence of non-SCcell populations and markers expressed by multiple cell types, such as NKX6-1 expressed by
both pancreatic progenitors and
e pression of

cells, which can confound analysis. We first evaluated

cell markers within the SC- cell population, as our prior work had shown that

inflammatory stress could reduce ke

cell protein (18). INS transcript within SC- cells as

greatly reduced in WS4unedit compared to WS4corr SC- cells (Figure 2.5A, S2.10A). CHGA was
similarly reduced, but surprisingly we found SST and GCG transcripts increased and decreased,
respectively, in WS4unedit compared to WS4corr SC- cells (Figure 2.5A, S2.10A). Also,
surprisingl , transcripts of transcription factors important to

cell identit and GCK, a necessar

cell functional gene, ere similar in WS4unedit compared to WS4corr SC- cells (Figure 2.5A,
S2.10A). Real-time PCR measurements of the total stage 6 populations for WS4unedit, WS4corr,
and WS4corr 2 lines showed similar reductions in INS and CHGA transcripts (Figure 2.5B,
2.10B). While some

cell markers ere lo er in WS4unedit compared to WS4corr and WS4corr 2

stage 6 cells using real-time PCR, such as NKX2-2 (Figure 2.5B), this is likely due to lower
differentiation yields of WS4unedit SC- cells (Figure 2.2A). Immunostaining confirmed that Cpeptide+ cells co-e pressed man

cell markers, including PDX1, CHGA, ISL1, NKX6-1, and

NEUROD1 (Figure 2.5C, S2.10C). These data indicate that SC- cells ith CRISPR/Cas9
correction of WFS1 were mostly similar in terms of

cell marker e pression compared to

unedited patient cells except notably for INS, which had greatly reduced transcript abundance.
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Furthermore, both WS4unedit and WS4corr SC- cells co-e pressed man protein markers of

cell

markers, similar to prior reports on non-diabetic-derived SC- cells (17).

Figure 2.5 CRISPR/Cas9 correction of WFS1 improved WS SC- cell gene expression. (A)
Violin plots detailing log-normalized gene marker expression of the WS4unedit (blue) and WS4corr
(red) SC- cell population defined in Fig. 4 of cell and islet gene transcripts. Log fold change
37

and p-values for violin plots available in Fig. S10A. (B) Real-time PCR analysis of the total
stage 6 population measuring e pression of cell and islet genes for WS4unedit (n=6-13; blue)
and WS4corr (n=7-14; red). *p<0.05, **p<0.01, ****p<0.0001 by two-way unpaired t-test. (C),
Immunostaining of single-cell dispersed WS4corr and WS4unedit stage 6 cells stained for indicated
pancreatic and cell markers. Scale bar, 50 m.

2.3.5 CRISPR/Cas9 gene editing decreased SC- cell stress
Next, we evaluated expression of stress markers within WS4corr and WS4unedit SC- cells
identified by scRNA-seq, as pathogenic variants in WFS1 cause ER stress in

cells (27-29). ER

stress can affect many pathways in cell metabolism, including activation of the UPR,
mitochondrial stress, and apoptosis. We observed increased expression of many of these
markers, such as CHOP, within WS4unedit compared to WS4corr SC- cells (Figure 2.6A, S2.11A).
WFS1 transcript was elevated in WS4corr compared to WS4unedit SC- cells (Figure 2.6A),
consistent with mouse and immortalized cell line studies (28, 29) and transcript and protein
measurements of the entire stage 6 population (Figure 2.2D, S2.4). Discerning definitive trends
with real-time PCR analysis for a wide range of markers in the bulk stage 6 population was
difficult (Figure S2.11B), likely due to the dilution effects of differing SC- cell differentiation
efficacy (Figure 2.2A). These markers are also expressed across most cell types but are typically
more highly expressed in high protein producing and glucose-responsive cells (47), confounding
study in this system.
To investigate the failure of WS4unedit SC- cells to properl function (Figure 2.2E, 2.3),
we used transmission electron microscopy (TEM) to observe the morphology of SC- cell ER
and mitochondria (Figure 2.6B, S2.12A). ER and mitochondria for WS4corr cells appeared
normal and healthy when compared to human islets. WS4unedit cell ER was swollen and expanded
in the cytoplasm, measuring 4.9±1.2x (p<0.05) and 3.0±0.8x (p<0.01) larger than WS4corr cell
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and human islets, respectively, which occurs in response to ER stress (32). The WS4unedit
mitochondria appear fragmented and undergoing fission, measuring 1.9±0.3x (p<0.001) and
2.0±0.3x (p<0.0001) smaller than WS4corr than human islets, respectively, consistent with
mitochondria exhibiting dysfunction in response to chronic ER stress (48-50). Our SC- cells
have a variety of granules in various stages of maturation, as previously reported (15, 16, 51).
Since the ER is critical for proper insulin processing, we measured insulin content and
proinsulin-to-insulin ratio of stage 6 cells, observing WS4unedit cells having lower insulin content
and higher proinsulin-to-insulin ratio than WS4corr (Figure 2.6C, S2.12B). Combined with
increases in UPR markers (Figure 2.6A) and the unhealthy ER morphology in TEM (Figure
2.6B), this data supports that WS4unedit SC- cells ha e defects in insulin processing that persists
for months after transplantation (Figure 2.3G). The mitochondria are critical for proper glucose
sensing, therefore we assessed its function by measuring oxygen consumption rate (OCR) with
injection of interrogating compounds (52). We found that WS4unedit cells had lower OCR after
injection with carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP), a mitochondrial
oxidative phosphorylation uncoupler, compared to WS4corr (p<0.0001; two-way ANOVA),
WS4corr 2, and human islets (p<0.001; two-way ANOVA) (Figure 2.6E, S2.12C). This indicates
WS4unedit cells have reduced maximal mitochondrial respiratory capacity, as seen in other reports
of monogenic diabetes (53) and consistent with stressed and unhealthy mitochondria (Figure
2.6A-B). The difference was not observed with undifferentiated WS4corr and WS4unedit iPSCs
(Figure S2.12C), indicating this phenotype is restricted to certain cell types, such as SC- cells.
Taken together, SC- cells harboring pathogenic ariants in WFS1 displa ed ER and
mitochondrial dysfunction, which is restored with CRISPR/Cas9 gene correction.

39

To further investigate the effects of cellular stress on WS SC- cells, e treated WS4unedit
and WS4corr stage 6 cells with thapsigargin, an inhibitor of sarco/endoplasmic reticulum Ca2+
ATPase (SERCA), to induce ER stress. We performed static GSIS and while insulin secretion
was not affected in WS4unedit cells, likely because these cells already had low secretion and
function, insulin secretion in WS4corr cells was strongly negatively affected by this compound,
decreasing insulin secretion by 3.9±0.7x and losing glucose-responsiveness (Figure 2.6E). We
also observed that both WS4unedit and WS4corr cells respond to multiple stress treatments by
increasing known stress markers using bulk stage 6 population analysis with real-time PCR and
western blot (Figure 2.6F, S2.13, S2.14). These data indicate that the enhanced functional and
reduced ER stress transcriptional benefits of CRISPR/Cas9 gene correction can be reversed with
chemical-induced ER stress.
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Figure 2.6 CRISPR/Cas9 correction of WFS1 reduced WS SC- cell stress. (A) Violin plots
detailing log-normalized gene marker expression of the WS4unedit (blue) and WS4corr (red) SCcell population defined in Fig. 4 of stress genes. Log fold change and adjusted p-values for violin
plots available in Fig. S11A. (B) Representative transmission electron microscopy images of ER
(top) and mitochondria (bottom) for WS4unedit, WS4corr SC- cells, and human islets. White
dotted lines outline the ER and mitochondria in the cell cytoplasm. Scale bar, 500 nm. (C)
Human insulin content (left) and proinsulin/insulin content ratio (right) of WS4unedit (n=7; blue)
and WS4corr (n=9; red) stage 6 cells. **p<0.01 and ****p<0.0001 by two-way unpaired t-test.
(D) Mitochondrial respiration of WS4unedit stage 6 (n=11; blue), WS4corr stage 6 (n=9; red), and
human islets (n=6; green) represented as percentage of baseline oxygen consumption rate
measurements. Respiration was interrogated by measuring changes in relative OCR after
injection with oligomycin (OM), FCCP, and antimycin A (AA)/rotenone (R). (E) Static GSIS
functional assessment of stage 6 cells treated with DMSO or thapsigargin (Tg). n=3. ns and
***p<0.001 by two-way unpaired t-test. (F) Real-time PCR analysis of bulk stage 6 population
measuring expression of stress genes with treatment of cytokine mixture (CM), high glucose
(Glu), or Tg. n=4. **p<0.01 and ***p<0.001 by two-way unpaired t-test compared to ctrl.
ctrl=control.
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2.4 Discussion
Here we apply a technological strategy of combining WS patient iPSC derivation,
CRISPR/Cas9 correction of the disease-causing pathological gene variant, and a recent robust
differentiation protocol to generate SC- cells, a disease-relevant cell type, that are able to
successfully and rapidly rescue mice with severe pre-existing diabetes. Correction of WFS1
drastically improved SC- cell differentiation efficac and function from this patient, ith the
cells displaying robust first and second phase insulin secretion. scRNA-seq and direct assessment
of the ER and mitochondria revealed reduction of stress in these organelles and reduction in
apoptotic markers with CRISPR/Cas9 correction.
Prior work with WS patient-derived iPSCs in the context of diabetes did not utilize gene
therapy nor generate SC- cells. Instead, this work focused on earlier stages of development by
generating and studying pancreatic progenitors and polyhormonal endocrine cells that lack bone
fide

cell features, such as high insulin per cell, dynamic function, or diabetes reversal in mice

upon transplantation (12). More recent work with patient-derived iPSCs or NT-SCs having other
forms of diabetes has instead generated SC- cells, but these cells are still missing important
features of mature

cells, most note orth being continued inferior function (18-22). Of note,

there is limited data regarding differentiation of NT-SCs (19) compared to iPSCs (15-18, 21, 22)
to SC- cells, so more stud comparing these two potential autologous cell sources is needed,
particularly as the immunogenicity of these cells is unclear (8). In terms of cell therapy, only
prevention, not reversal, of diabetes in mice using diabetic patient-derived SC- cells has been
reported. This required long maturation times in vivo (12-19 wk) and has only been successful
with limited mouse numbers, often with high failure rates (18, 19, 22). Overgrowths and other
abnormal structures have also been observed in some of these reports (19, 22). In contrast, we
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show rapid reversal of severe pre-existing diabetes in all mice with corrected WS SC- cell
transplantation with no observed teratoma or cystic structure formation by use of our
differentiation strategy. We do observe overgrowths in the WS4unedit SC- cell transplants, likely
resulting from the detected proliferating off-target mesenchyme and progenitors.
Our study demonstrates that CRISPR/Cas9 correction of a diabetes-inducing gene variant
allows for robust differentiation of autologous SC- cells capable of rapidl re ersing se ere preexisting diabetes. Application of our strategy for treating diabetes in mice enables development
of autologous cell replacement therapy in diabetic patients. By using patient-derived cells that
have been gene corrected to fix diabetic variants and produce robustly functional cells, the need
for the patient to take immunosuppressant drugs could be avoided for many forms of diabetes
(8). Alternative strategies for encapsulating cells for immune protection are currently being
explored with allogeneic products but still require improvements for efficacy and safety (54, 55).
Instead, autogeneic SC- cell therap is possible and ould benefit from combination ith
transplantation using macroporous scaffolds to better enable retrievability (56, 57) or other cells
or materials to promote engraftment, survival, and function (58-62). A concern in iPSC culture
(63) and in CRISPR/Cas9 (64) is the induction of off-target mutations, which likely necessitates
careful karyotyping and genomic sequencing before use of specific cell lines for therapy.
Another major feature of our corrected WS SC- cells is their ability to display robust
dynamic function in vitro, with first- and second-phase insulin secretion. This feature is weak,
absent, or not demonstrated in other diabetic patient-derived SC- cell strategies (18, 20-22),
indicating that our observation of robust improvements in function with CRISPR/Cas9 would
have been difficult with alternate approaches. Demonstrating dynamic function in patient SC-
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cells is important for the study of diabetes, as dynamic function is commonly lost early on in the
disease (65-68).
While human WS patient-deri ed
rarit of the disease and death of

cells are not normall a ailable for stud due to the

cells during disease progression (69), our ability to

differentiate these cells from patient iPSCs facilitates in-depth modeling of this disease. Current
common models of WS, including Wfs1 knockout mice and insulinoma lines, are of limited value
in the study of WS due to species differences (21, 27-29, 31, 32). Of importance, Wfs1 knockout
mice have only mild diabetes, in contrast with WS patients having insulin-dependent diabetes
(31, 70). Understanding of human WS progression is lacking, making development of effective
therapies difficult, and while the scope of this report is focused on one WS patient, we hope it
enables more in-depth mechanistic study. Our human model of WS validated elevated ER stress,
activation of the UPR, and defects in insulin processing (39, 40). The proportion of endocrine
subtype markers was affected in our model, with relatively lower expression of glucagon and Cpeptide/insulin and higher somatostatin with the WFS1 pathogenic variant. Focused study of the
influence of WFS1 and ER stress on differentiation could provide new insights. A major
limitation of this study is the depth that we were capable of investigating molecular control and
signaling of cellular stress, predominantly because of the purity differences of the SC- cell
population based on WFS1 pathogenic state and compared to human islets. The use of single-cell
RNA sequencing enabled examination of gene expression differences but sorting SC- cells
would be an ideal option for more robust study. Patient-derived SC- cells can ser e as a human
patient-specific model of WS for further stud of molecular e ents in
screening, and a source of autologous cells for therapy (8).
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cell failure, drug

Single-cell sequencing and in vitro assays demonstrated that WS4unedit SC- cells displa
ER stress. ER stress is found in other types of diabetes, including Type 1 and 2, neonatal
diabetes, maturity onset diabetes of the young (MODY), and many other disorders (30-35).
Future studies investigating WS and other forms of diabetes are now more rigorously possible
via our platform for the discovery of new biology, therapeutic compounds, and replacement
cells. WS, neonatal diabetes, MODY are all monogenic forms of diabetes, and through gene
therapy using CRISPR/Cas9, the pathogenic variant in specific genes causing diabetes in these
patients can be corrected. Our approach, leveraging CRISPR/Cas9 and a robust differentiation
protocol, allows for rigorous study of these forms of diabetes for disease modeling and drug
screening. In the future, we suspect our advanced strategy combining patient iPSCs, gene
editing, and differentiation to high functioning SC- cells and other cell types will produce a
viable, personalized cell source for cell therapy in diabetic patients and other degenerative
disorders (71).

2.5 Materials and Methods
2.5.1 Study design
The objective of this study was to analyze and transplant insulin-producing

cells into

mice with pre-existing diabetes to determine the translational potential of differentiated diabetic
patient iPSCs following CRISPR/Cas9 correction of the pathogenic diabetes-causing variant.
Three WS patient iPSC lines were used and CRISPR/Cas9 correction was performed to generate
three corrected iPSC lines, all of which were differentiated to SC- cells. WS4corr SC- cells,
WS4unedit SC- cells, and HI were transplanted into nine, six, and four STZ-treated diabetic mice,
respectively. STZ-treated diabetic and nondiabetic mice without transplants served as
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transplantation controls. Mouse groups were assigned randomly, and the study was not blinded.
Transplanted mice were monitored through blood glucose measurements and blood serum
collection, then sacrificed for ex vivo analysis. A nephrectomy surgery was performed on WS4corr
transplanted mice to confirm transplanted SC- cells were the source of glucose tolerance and
nondiabetic blood glucose levels. For all in vitro analyses, at least 3 differentiations were used.
Sample size was not determined with a power calculation, and specific sample cells are defined
for each dataset. Data collection was stopped at pre-determined, arbitrary times. No data was
excluded.

2.5.2 hiPSC line generation
This work as performed in accordance with the ESCRO Committee at Washington
University in St. Louis. WS9unedit and WS13unedit iPSC lines were previously published as Wolf2010-9 and Wolf-2010-13, respectively (36). WS4unedit iPSC line was generated from a
previously described WS patient (WU.WOLF-04) (25) as we previously described (36) by the
Genetic Engineering and iPSC Center (GEiC) at Washington University in St. Louis from skin
fibroblast with Sendai viral reprogramming (Life Technologies).

2.5.3 hiPSC line culture
Undifferentiated hiPSCs were cultured with mTeSR1 (StemCell Technologies; 05850) in
an incubator with 5% CO2 at 37 C. Cells ere passaged e er 3-4 days by single cell dispersion
using TrypLE (Life Technologies; 12-604-039). Viable cells were counted with a Vi-Cell XR
(Beckman Coulter) and seeded onto DMEM-diluted (Gibco, 11965-084) Matrigel-coated
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(Fisher, 356230) culture flasks at 1.1x105 cells/cm2 in mTESR1 with 10 µM Y27532 (Abcam;
ab120129).

2.5.4 CRISPR/Cas9 gene correction
CRISPR/Cas9 gene correction of the WFS1 pathogenic variants in the WS4 and WS13
iPSC lines was performed at GEiC at Washington University in St. Louis. Guide RNAs were
generated to target the WFS1 variants and validated using next generation deep sequencing
analysis (NGS) (72). YH421.WFS1.sp14 and YS422.WFS1.sp11 was selected for homology
directed repair using a single stranded DNA oligo (ssODN) as a template to target the point
mutation in WFS1 on allele 2 for WS4 iPSCs and allele 1 for WS13 iPSCs, respectively. The
designated allele to correct was determined based on the highest CRISPR/Cas9 gRNA
specificity. Cells with successful CRISPR/Cas9 correction of WFS1 were termed WS4corr, and
cells in which WFS1 retained the point mutation were termed WS4unedit, as confirmed by targeted
NGS (72), which was preferred due to the single insertion or nucleotide correction. The top 5
off-target sequences were also confirmed with NGS. Used sequences are listed in Table 2.1.

2.5.5 Immunostaining
Flow cytometry staining and analysis was performed by dispersing and fixing single cells
in 4% paraformaldehyde (PFA) (Electron Microscopy Science; 15714) 30 min at RT, blocking,
and staining with primary antibodies diluted in immunostaining solution (Table 2.4) overnight at
4 C, staining ith second antibodies for 2 hr at 4 C, and anal ed on the LSRII and BD LSR
Fortessa X-20 (BD Biosciences). FlowJo generated dot plots and percentages. Processing and
staining sections was performed by fixing clusters or transplanted kidneys in 4% PFA overnight
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at 4 C, placed in Histogel (Thermo Scientific; hg-4000-012), and processed by the Division of
Comparative Medicine (DCM) Research Animal Diagnostic Laboratory Core at Washington
University. Paraffin was removed with histoclear (Thermo Scientific; C78-2-G), samples
rehydrated, antigens were retrieved with 0.05 M EDTA (Ambion; AM9261) in a pressure cooker
(Proteogenix; 2100 Retriever), immunostaining performed as above, and samples mounted with
DAPI Fluoromount-G (SouthernBiotech; 0100-20). Processing and staining plated cells on black
tissue culture 96 well plates (Corning; 3904) was performed by fixing with 4% PFA 30 min at
RT, immunostaining as above, and staining for DAPI. Immunostained cells were imaged with a
Leica DMI4000 fluorescence or Nikon A1Rsi confocal microscope. Antibody details can be
found in Table 2.5.

2.5.6 Stem cell-derived

cell differentiation

Undifferentiated cells were seeded at 5.2-7.3x105 cells/cm2 and differentiated performed
as outlined in Tables S2-4 to generate SC- cells (23). Cells were aggregated 7-9 d into stage 6
on an OrbiShaker (Benchmark) at 100 RPM for assessment. Islets were purchased from Prodo
Labs and cultured in islet media (Table 2.4) for comparison 24 hr after shipment arrival. Bright
field images were captured with a Leica DMi1.

2.5.7 Western Blot
Detection of phosphor lated and total eIF2 as performed b l sing cells in 1% Triton
buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 1% Triton X-100, 10% glycerol (Sigma; 56-815), 1 mM EDTA, 10 mM tetrasodium p rophosphate (Sigma; 13472-36-1), 17.5 mM glycerophosphate (Sigma; 154804-51-0), PhosSTOP (Roche; 4906845001), and cOmplete
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protease inhibitor cocktail (Roche; 4693159001)). Detection of all other proteins was done by
lysing cells in M-PER

Mammalian Protein E traction Reagent (Thermo Scientific; 78505)

supplemented ith cOmplete

protease inhibitor cocktail. After 30 min incubation on ice,

samples were centrifuged, supernatants collected, and protein-equivalent samples were loaded
onto 4 20% Mini-PROTEAN

TGX

Precast Protein Gels (Bio-Rad; 4561096) and

transferred to an Immobilon-P PVDF Membrane (Millipore; IPVH00010). The membrane was
treated with 5% skimmed milk for 1 hr at RT and probed with the primary antibodies. The
antibodies were detected using HRP-linked secondary antibodies. The density of each band was
quantified using Image Lab software (Bio-Rad). Antibodies used are listed in Table 2.5.

2.5.8 Glucose-Stimulated Insulin Secretion
For static, approximately 30 stage 6 clusters were placed in transwells (Corning; 431752),
equilibrated for 1 hr in 2 mM glucose KRB (Table 2.4), and challenged with sequential 1-hr 2
and 20 mM KRB treatments. For dynamic, clusters were loaded into a cell chamber, perifused
with buffer at 100 µL/min, and equilibrated in 2 mM glucose KRB for 90 min. The samples were
then challenged for 12 min at 2 mM, 24 min at 20 mM, and 12 min at 2 mM glucose KRB,
collecting effluent every 2-4 min. For Human insulin was quantified with ELISA and data
normalized to cell counts from Vi-Cell XR or DNA quantification using Quant-iT Picogreen
dsDNA assay kit (Invitrogen; P7589).

2.5.9 Mouse Transplants
Animal studies were performed in accordance with Washington University IACUC. Mice
were randomly designated for streptozotocin (STZ) treatment and transplantation groups. Mouse
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number per group was selected to allow for statistical significance based on our prior studies (15,
17, 18). Surgical procedures and follow up studies were performed by unblinded individuals.
Male 7 wk old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (stock no. 005557) were purchased
from Jackson Laboratories, rendered diabetic with injection of 45 mg/kg STZ (R&D; 1621500)
for 5 d, with diabetes confirmed after 8 d. Anaesthetized mice were injected with 5x106 WS4unedit
stage 6, 5x106 WS4corr stage 6, 5x106 (4000 IEQ) islet cells, or saline under the kidney capsule.
Islet transplantation was performed in a separate cohort. Animals were monitored up to 6
months. Blood glucose was measured with a Contour Blood Glucose Monitoring System (Bayer;
9545C). Glucose tolerance and in vivo GSIS assays were performed by fasting mice for 4 hr and
injecting with 2 g/kg glucose. Serum hormones were quantified using Human Ultrasensitive
Insulin ELISA kit (ALPCO Diagnostics; 80-ENSHUU-E01.1), Mouse C-peptide ELISA
(ALPCO Diagnostics; 80-CPTMS-E01), and human proinsulin ELISA (Mercodia; 10-1118-01).
12-wk after transplantation, live nephrectomy was performed on 2 anaesthetized transplanted
mice.

2.5.10 Single-cell RNA sequencing
Library preparation and sequencing was performed at the Washington University in St.
Louis Genome Technolog Access Center using the Chromium Single Cell 3 Librar and Gel
Bead Kit v2 (10x Genomics; 120237) and the HiSeq2500 System (Illumina) at 26x98bp. Cells
containing high mitochondrial percentages were filtered out, and only cells containing 50-7500
genes were used for analysis. Seurat v2.0 analyses was used to perform unsupervised clustering
(42).
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We used global-scaling normalization and removed unwanted variation calculated by
scaled z-score dispersion. We inputted the variable genes into principle component analysis
(PCA) to perform linear dimensional reduction and identify statistically significant principal
components (PCs). JackStraw recalculated the PCA with a null distribution of gene scores to
reduce noise. The new PCs were selected based on genes with strong enrichment of low pvalues. Cells with similar gene expression patterns are located near each other based on PCA
using the FindClusters function. We used a resolution of 0.4 and 10 dimensions for WS4unedit and
WS4corr cells to present clusters on tSNE plots with single points representing individual cells.
The differential gene expression pattern, that distinguished each cluster from all other cells, was
found with the FindAllMarkers function. The top 50 genes for each cluster was used to define
the cluster cell type. The genes were compared to current single cell pancreas transcriptomes to
define cell types (43, 73). Feature plots using a tSNE plot were used to visualize gene expression
across different populations.
Differential expression between WS4unedit and WS4corr cells: Seurat v2.0 was used to
combined the two objects (WS4unedit and WS4corr SC- cells) and perform canonical correlation
analyses (CCA) (Function: RunCCA) to remove any sources of variation between the two objects
(42). Next, the CCA subspaces were aligned (Function: AlignSubspace) with 50 dimensions to
create dimensional reduction in order to perform clustering. A single integrated analysis was then
performed on the combined object. Clusters were defined using FindClusters (resolution=0.6, 10
dimensions) and a tSNE plot was generated using RunTSNE. The gene markers that were
upregulated in each cluster, regardless of WS4unedit or WS4corr SC- cells, ere defined based on
p-values using the function, FindConservedMarkers. The top 50 genes for each cluster were used
to define the cluster cell type. The genes were compared to current single cell pancreas
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transcriptomes to define the cell types (43, 73). We were able to visualize differences in gene
expression with violin plots (VlnPlot) between, specificall the
WS4corr objects for

cells, in the WS4unedit and

cell markers, pancreatic markers, and ER stress genes. As the

cell

population did not contain off target markers, we used violin plots to compare the off-target
marker gene expression between entire WS4unedit and WS4corr objects. We performed statistics of
the iolin plots e aluating ER stress, , and islet cell markers using the FindAllMarkers function
(logfc.threshold=0) which provided unadjusted and adjusted p values based on percentage of
cells where gene was detected (pct.1 for WS4corr; pct.2 for WS4unedit). In addition, the log foldchange of average expression between WS4corr and WS4unedit (avg_logFC) was calculated. The
positive and negative values indicate the gene is more highly expressed in WS4corr or WS4unedit,
respectively.

2.5.11 Real Time PCR
RNA was extracted with the RNeasy Mini Kit (Qiagen; 74016) with DNase treatment
(Qiagen; 79254), cDNA was synthesized with the High Capacity cDNA Reverse Transcriptase
Kit (Applied Biosystems; 4368814) using a thermocycler (Applied Biosystems; A37028), realtime PCR reactions were generated with PowerUp SYBR Green Master Mix (Applied
Bios stems; A25741) using a StepOnePlus (Applied Bios stems), and data anal ed using

Ct

methodology. TBP and GUSB were used as normalization genes. Primer sequences used can be
found in Table 2.6.
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2.5.12 Electron Microscopy
Cells were fixed for 2 hr at RT with 2.5% glutaraldehyde, 1.25% PFA, and 0.03% picric
acid in 0.1M sodium cacodylate buffer at pH 7.4 and shipped to Harvard Medical School
Electron Microscopy Core Facility for processing and sectioning. The sectioned samples were
imaged on the JEM-1400+ Transmission Electron Microscope (JEOL), running at 120 kV. Size
of endoplasmic reticulum and mitochondria organelles were quantified with ImageJ. Some of the
images show overlapping views.

2.5.13 Insulin and Proinsulin Content
Clusters were immersed in 1.5% HCl and 70% ethanol for 72 hr at -20⁰C, with periodic
vortex, centrifuged for 15 min at 2100 RCF, supernatant collected, pH neutralized with equal
volume of 1 M TRIS (pH 7.5), and hormones quantified with ELISA, with cell count
normalization (Vi-Cell XR).

2.5.14 Mitochondrial respiration studies
Cells were seeded on Seahorse microplates (Agilent; 100850-001) overnight, media
replaced with RPMI 1640 (Sigma; R6504) at 7.4 pH in each well, and the cells placed in a
Seahorse XFe24 extracellular flux analyzer (Agilent). After 4 baseline measurements, cells were
treated with sequential injections of 3 µM oligomycin (Calbiochem; 1404-19-9), 0.25 µM
carbonyl cyande-4-(trifluoromethoxy) phenylhydrazone (FCCP) (Sigma; 270-86-5) and 1 µM
rotenone (Calbiochem; 83-79-4) and 2 µM antimycin A (Sigma; 1397-94-0).

53

2.5.15 ER stress studies
Cells were incubated for 48 hr with 10µM Thapsigargin (EMD Chemicals; 586005), 30
mM glucose, or a c tokine mi including 500 ng/mL IFN (R&D S stems; 285-IF-100), 500
ng/mL TNF (R&D S stems; 210-TA-010), and 100 ng/mL IL-1 (R&D S stems; 201-LB005).

2.5.16 Statistical Analysis
Statistical analysis was calculated with GraphPad Prism using one- and two-sided
unpaired and paired t-tests, one- and two-way ANOVA ith multiple comparisons Sidak s,
Tukey, or Dunnet tests. Specific test is specified in individual figure legends. p<0.05 was
considered statistically significant. Data is shown as mean±s.e.m unless otherwise noted. The
sample size, n, indicates the total number of biological replicates.
Table 2.1 CRISPR sequences
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Table 2.2 Differentiation protocol
Stage 0

Day
1

Media
Factor
mTeSR1 Y27632

Stage 1

Day
2

Media
BE1

Stage 1
Stage 1
Stage 1

3
4
5

Stage 2

Final
Concentration
10 M

BE1
BE1
BE1

Factor
Activin A
CHIR99021
Activin A
Activin A
Activin A

Final
Concentration
100 ng/mL
3 M
100 ng/mL
100 ng/mL
100 ng/mL

Day
6
7

Media
BE2
BE2

Factor
KGF
KGF

Final
Concentration
50 ng/mL
50 ng/mL

Stage 3

Day
8

Media
BE3

Stage 3

9

BE3

Factor
LDN193189
KGF
SANT1
RA
TPPB
LDN193189
KGF
SANT1
RA
TPPB

Final
Concentration
200 nM
50 ng/mL
0.25 M
2 M
200 nM
200 nM
50 ng/mL
0.25 M
2 M
200 nM

Stage 4

Day
10

Media
BE3

11

BE3

Final
Factor
Concentration
KGF
50 ng/mL
SANT1
0.25 M
RA
0.1 M
TPPB
200 nM
LDN193189 200 nM
KGF
50 ng/mL
SANT1
0.25 M
RA
0.1 M
TPPB
200 nM
LDN193189 200 nM
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Stage 5

12

BE3

13

BE3

Day
14

Media
S5

15

S5

16

S5

17

S5

18

S5

KGF
SANT1
RA
TPPB
LDN193189
KGF
SANT1
RA
TPPB
LDN193189

Factor
SANT1
RA
XXI
Alk5i
T3
Latrunculin
A
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin

50 ng/mL
0.25 M
0.1 M
200 nM
200 nM
50 ng/mL
0.25 M
0.1 M
200 nM
200 nM
Final
Concentration
0.25 M
0.1 M
1 M
10 M
1 M
1 M
20 ng/mL
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
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Stage 6

19

S5

20

S5

SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin

0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL

Feed S6 every other day
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Table 2.3 Differentiation factor list
Compound
Activin A
CHIR99021
KGF
LDN193189
Retinoic Acid
SANT1
Y27632
Latrunculin A
Alk5 inhibitor type II
Betacellulin
T3
XXI
TPPB

Company
R&D Systems
Stemgent
Peprotech
Reprocell
MilliporeSigma
MilliporeSigma
Abcam
Cayman Chemical
Enzo Life Sciences
R&D Systems
Biosciences
MilliporeSigma
Tocris

Part #
338-AC
04-0004-10
AF-100-19
40074
R2625
S4572
ab120129
10010630
ALX-270-445-M005
261-CE-050
64245
595790
53431

Table 2.4 Media and buffer formulations
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Reagent

BE1

BE2

BE3

S5

S6

Company

MCDB131

500 mL

500 mL

500 mL

500 mL

500 mL

Cellgro

Glucose
NaHCO3
FAF-BSA
ITS-X
Glutamax
Vitamin C
Heparin
Pen/Strep

0.8 g
0.587 g
0.5 g
N/A
5 mL
N/A
N/A
N/A

0.4 g
0.587 g
0.5 g
N/A
5 mL
22 mg
N/A
N/A

0.22 g
0.877 g
10 g
2.5 mL
5 mL
22 mg
N/A
N/A

1.8 g
0.877 g
10 g
2.5 mL
5 mL
22 mg
5 mg
5 mL

0.23 g
N/A
10.5 g
N/A
5.2 mL
N/A
10 µg/mL
5.2 mL

MilliporeSigma
MilliporeSigma
Proliant
Invitrogen
Invitrogen
MilliporeSigma
MilliporeSigma
Cellgro

NonEssential
Amino
Acids
ZnSO4

N/A

N/A

N/A

N/A

5.2 mL

Corning

N/A

N/A

N/A

N/A

1 µM

MilliporeSigma

10883

Trace
N/A
Elements A
Trace
N/A
Elements B

N/A

N/A

N/A

523 µL

Corning

N/A

N/A

N/A

523 µL

Corning

25-021CI
25-022CI
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Catalog
#
15-100CV
G7528
S3817
68700
51500056
35050079
A4544
H3149
30-002CI
25-025CI

Table 2.5 Antibody list
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Table 2.6 Primers used for real-time PCR
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2.7 Supplemental Figures

Figure S2.1 Additional patient and cell line information. This figure is associated with Figure
2.1. (A). Patient number (Pt #) and code previously used to describe 3 WS patients (25) with
coordinates of pathogenic variants on WFS1 gene mapped to hg19 and repeated allele
information from Fig. 1. (B) Normal 46XX (WS4, WS13) and 46XY (WS9) karyotype of
derived iPS cell line (WS4unedit, WS9unedit, WS13unedit) and corrected iPS cell line (WS4corr,
WS4corr 2, WS13corr). (C) Representative flow cytometry dot plots of dispersed WS4unedit,
WS9unedit, WS13unedit, WS4corr, WS4corr 2, and WS13corr iPSCs stained for OCT3/4 and Nanog.
(D) NGS off-target analysis of top 5 off-target sites targeted by WS4 gRNA for CRISPR
correction of WFS1 pathogenic variant on Allele 2.
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Figure S2.2 Additional WS4 stage 6 and human islet analysis. This figure is associated with
Figure 2.2. (A) Representative flow cytometry dot plots of dispersed WS4unedit, WS4corr, and
WS4corr 2 stage 6 cells for C-peptide, glucagon (GCG), and somatostatin (SST). (B)
Representative flow cytometry dot plot of dispersed WS4corr 2 stage 6 cells for C-peptide and
NKX6-1, representing percentage of SC- cells deri ed from the si -stage differentiation
protocol. (C) Quantified fraction of cells expressing or co-e pressing cell or islet markers for
WS4unedit (n=4-7) and WS4corr 2 (n=4) stage 6 cells. WS4unedit data points are replotted form Fig.
2 to compare with additional WS4corr clone. *p<0.05, **p<0.01, ****p<0.0001 by two-way
unpaired t-test. CP, C-peptide. (D) Immunostaining of sectioned WS4corr 2 stage 6 and human
islet clusters stained for cell or islet markers. Scale bar, 100 m.
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Figure S2.3 Analysis of differentiation progression and efficiency for WS4corr and WS4unedit
lines. This figure is associated with Figure 2.2. (A) Quantified fraction of cells expressing or coexpressing cell markers for WS4corr (n=4) and WS4unedit (n=4) stages 0, 1, 3, 4, and 5 of
differentiation. (B) Relative gene expression of key cell markers for WS4corr (n=4) and WS4unedit
(n=4) expressed during stages 3, 4, and 5 of differentiation measured with real-time PCR. St,
stage; INS, insulin; CHGA, chromogranin A; SST, somatostatin; GCG, glucagon; ISL1, islet1;
GCK, glucokinase.
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Figure S2.4 Analysis of WFS1 throughout SC- cell differentiation for WS4corr and
WS4unedit lines. This figure is associated with Figure 2.2. (A) Relative gene expression of WFS1
for WS4corr (n=4) and WS4unedit (n=4) at various stages of differentiation, normalized to WS4corr
stage 0 cells. (B) Immunostaining of single cell dispersed and sectioned clusters of WS4corr and
WS4unedit iPSC (stage 0) and stage 6 cells, respectively. Stage 0 stem cells co-stained with stem
cell marker, Nanog (green), and stage 6 cells co-stained with SC- cell marker, c-peptide (CP,
green). Scale bar, 50 m.
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Figure S2.5 Glucose-stimulated insulin secretion normalized to cell population. This figure
is associated with Figure 2.2. (A-B) Static and dynamic GSIS assay of WS4unedit (n=7) and
WS4corr (n=15) stage 6 cells normalized to fraction of C-Peptide+/NKX6.1+ cells.
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Figure S2.6 Additional analysis of WS4corr and WS4unedit SC- cell transplantations in
diabetic mice. This figure is associated with Figure 2.3. (A) Serum mouse c-peptide 3 wk after
transplantation of WS4unedit (STZ, WS4unedit Txp; n=6, blue) or WS4corr (STZ, WS4corr Txp; n=10;
red) stage 6 cells, diabetic mice without a transplant (STZ, No Txp; n=7; white), and nondiabetic
mice without a transplant (No STZ, No Txp; n=5; gre ) demonstrating loss of mouse cell
function after STZ injection. n.s. not significant, **** p<0.0001 by one-way ANOVA Tukey
multiple comparisons test comparing all groups. (B) Glucose tolerance test (4g/kg) of mice with
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STZ treatment to induce diabetes (STZ; n=25; open square) and without STZ treatment (No
STZ; n=5; closed circle) before transplantation demonstrating robust induction of pre-existing
diabetes. **p<0.01, ****p<0.0001 by two- a ANOVA Sidak s multiple comparisons test. (C)
Serum human insulin detected in mice 3 wk after transplantation of WS4unedit (STZ, WS4unedit
Txp; n=6; blue) or WS4corr (STZ, WS4corr Txp; n=10; red) stage 6 cells, diabetic mice without a
transplant (STZ, No Txp; n=7; white), and nondiabetic mice without a transplant (No STZ, No
Txp; n=5; grey) with random bleeds demonstrating the absence of human insulin in mice without
a graft. (D) Body weight of mice 12 wk after transplantation with either WS4unedit (STZ,
WS4unedit Txp; n=5; blue) or WS4corr (STZ, WS4corr Txp; n=7; red) stage 6 cells, diabetic mice
without a transplant (STZ, No Txp; n=7; white), and nondiabetic mice without a transplant (No
STZ, No Txp; n=5; grey). *p<0.05, n.s., not significant (if not defined) by one-way ANOVA
Tukey multiple comparisons test. (E) Body weight of mice after STZ treatment to induce
diabetes, before transplantation with WS stage 6 cells. The mice were grouped based on
transplantation method as WS4unedit (STZ, WS4unedit Txp; n=6; blue) or WS4corr (STZ, WS4corr
Txp; n=10; red) stage 6 cells, diabetic mice without a transplant (STZ, No Txp; n=7; white), and
nondiabetic mice without a transplant (No STZ, No Txp; n=5; grey). n.s., not significant by oneway ANOVA Tukey multiple comparisons test. (F) Weekly body weight measurement before
STZ treatment, after STZ treatment to induce diabetes, and after TXP of WS4unedit (STZ,
WS4unedit Txp; n=4-6) and WS4corr (STZ, WS4corr Txp; n=6-10) stage 6 cells in diabetic mice,
diabetic mice without a transplant (STZ, No Txp; n=5-8), and nondiabetic (ND) mice without a
transplant (No STZ, No Txp; n=5). (G) Immunostaining of sectioned kidneys explanted from
STZ, WS4corr TXP mice 2 weeks after transplantation stained for C-peptide (CP), somatostatin
(SST), glucagon (GCG), or nuclear marker DAPI. White dashed line borders the graft in the
mouse kidney capsule. This is a lower magnification image of what is shown in Fig. 2. Blood
cells are noted to autofluoresce. Scale bar=100µm. (H) Images of explanted kidneys from TXP
of WS4unedit (STZ, WS4unedit Txp) and WS4corr (STZ, WS4corr Txp) stage 6 cells into diabetic
mice. We sacrificed one WS4unedit and one WS4corr mouse at 2 wk, and one WS4unedit and two
WS4corr SC- cell mice at 10-12 wk, and the rest at the end of the experiment. Three sham mice
spontaneously died, two at 14 wk and one at 25 wk, presumably due to their diabetes.
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Figure S2.7 Additional analysis of WS4corr and WS4unedit SC- cell scRNA-seq. This figure is
associated with Figure 2.4. (A) Mitochondrial count per cell distribution represented as violin
plot for both WS4corr and WS4unedit stage 6 cells. Cells above the red line threshold were filtered
out for analysis. (B) Gene count per cell distribution represented as violin plot for both WS4corr
and WS4unedit stage 6 cells. Cells above the red line threshold are considered apoptotic and were
filtered out for analysis. (C) Gene expression of defined population-specific markers presented as
low (grey), medium (yellow), and high (red) levels in the cell population clusters for WS4unedit
and WS4corr stage 6 cells. (D) tSNE projection from unsupervised clustering of WS4unedit and
WS4corr stage 6 cells combined with canonical correlation analysis. Clusters defined based on
genes differentially expressed between clustered population.
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Figure S2.8. Additional analysis of WS4corr and WS4unedit SC- cell scRNA-seq and
population upregulated genes. This figure is associated with Figure 2.4. (A) Percentage of
sequenced cells present in each population shown in Fig. 3. (B) Top 5 enriched genes for each
population for WS4unedit and WS4corr stage 6 cells separately. (C) Top 5 enriched genes for
WS4unedit and WS4corr stage 6 cells combined.
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Figure S2.9. Additional analysis of WS4corr and WS4unedit SC- cell scRNA-seq for offtargets. This figure is associated with Figure 2.4. (A) Violin plots detailing log-normalized gene
marker expression of genes defining off-target populations comparing all sequenced cells from
WS4unedit (blue) and WS4corr (red) stage 6 cells. (B) (top) Real-time PCR measuring population
level gene expression of off-target genes WS4unedit (n=3-4; blue) and WS4corr (n=3-4; red) stage 6
cells. (bottom) Real-time PCR measuring population level gene expression of off-target genes in
WS4unedit (n=4; blue) and WS4corr (n=4; red) in definitive endoderm cells (stage 1). *p<0.05,
**p<0.01, ****p<0.0001 by two-way unpaired t-test.
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Figure S2.10. Additional analysis of differences in SC- cell beta and islet markers for
WS4corr clones and WS4unedit lines. This figure is associated with Figure 2.5. (A) Log fold
change values between WS4corr and WS4unedit SC- cells, detailing which cell type has greater
expression according to avg_logFC. Nonadjusted (p_val) and adjusted (p_val_adj) p-values, and
percentage of cells positive for measured gene in WS4corr (pct.1) and WS4unedit (pct.2) SC- cells
calculated for violin plots in Fig. 5A. (B) Real-time PCR analysis of the total stage 6 population
measuring e pression of cell and islet genes for WS4unedit (n=7-113; blue) and WS4corr 2 (n=4;
striped red). WS4unedit values are replotted from Fig. 5B. **p<0.01, ****p<0.0001 by two-way
unpaired t-test. (C) Immunostaining of single-cell dispersed WS4corr 2 stained for indicated
pancreatic and cell markers. Scale bar, 50 m.
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Figure S2.11. Additional analysis of ER stress gene expression. This figure is associated with
Figure 2.6. (A) Log fold change values between WS4corr and WS4unedit SC- cells, detailing
which cell type has greater expression according to avg_logFC. nonadjusted (p_val) and adjusted
(p_val_adj) p-values, and percentage of cells positive for measured gene in WS4corr (pct.1) and
WS4unedit (pct.2) SC- cells calculated for iolin plots in Fig. 6A. (B) Real-time PCR analysis of
the total stage 6 population measuring expression of stress markers. n=3-13. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001 by two-way unpaired t-test.
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Figure S2.12. Additional analysis of TEM and mitochondrial respiration. This figure is
associated with Figure 2.6. (A) Representative TEM images for WS4corr and WS4unedit stage 6
cells and human islets without dashed line marking key organelles to improve visibility. Scale
bar, 500 nm. (B) Human insulin content (left) and proinsulin/insulin content ratio (right) of
WS4corr 2 (n=4). (C) Mitochondrial respiration of WS4corr (n=6) and WS4unedit (n=5) iPSC
represented as percentage of baseline oxygen consumption rate measurements using the Seahorse
XFe24.
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Figure S2.13. Treatment of SC- cells with chemical stressors. This figure is associated with
Figure 2.6. (A) Real-time PCR analysis of bulk stage 6 population treated with cytokine mixture
(CM), high glucose (Glu), or thapsigargin (Tg) measuring stress markers. n=3. *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001 by two-way unpaired t-test. (B) Western blot analysis of
bulk stage 6 population treated with Tg measuring stress or insulin processing markers.
Quantitation is normali ed b -tubulin. n=3. PDI, protein disulfide isomerase.
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Figure S2.14. Stress marker measurements of WS4corr 2 and human islets. This figure is
associated with Figure 2.6. Real-time PCR analysis of cells treated with high glucose (Glu) or
thapsigargin (Tg) measuring stress markers. n=3. *p<0.05, **p<0.01, ***p<0.001, by two-way
unpaired t-test.
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Chapter 3
Single-Cell Transcriptome Profiling Reveals Cell
Maturation in Stem Cell-Derived Islets after
Transplantation
Partially adapted from: *Augsornworawat, P., *Maxwell, K.G., Velazco-Cruz, L.,
Millman, J. R. (2020). Single-Cell Transcriptome Profiling Reveals

Cell Maturation in Stem

Cell-Derived Islets after Transplantation. Cell Reports. 32 (8), 108067. *Co-first Authors

3.1 Abstract
Human pluripotent stem cells differentiated to insulin-secreting

cells (SC- cells) in islet

organoids could provide an unlimited cell source for diabetes cell replacement therapy. However,
current SC- cells generated in vitro are transcriptionally and functionally immature compared to
native adult

cells. Here we use single-cell transcriptomic profiling to catalogue changes that

occur in transplanted SC- cells. We find that transplanted SC- cells e hibit drastic
transcriptional changes and mature to more closely resemble adult

cells. Insulin and IAPP

protein secretions increase upon transplantation along with expression of maturation genes
lacking with differentiation in vitro, including INS, MAFA, CHGB, and G6PC2. Other
differentiated cell types, such as SC- and SC-enterochromaffin (SC-EC) cells, also exhibit large
transcriptional changes. This study provides a comprehensive resource for understanding human
islet cell maturation and provides important insights into maturation of SC- cells and other SCislet cell types to enable future differentiation strategy improvements.
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3.2 Introduction
Diabetes is a global disease caused by death or dysfunction of pancreatic insulinproducing

cells. Current conventional therapeutic strategies, such as e ogenous insulin

treatment, are insufficient in recapitulating the role of health endogenous

cells for man

patients (1). Transplantation of replacement human islets is a promising alternative (2-4).
However, this therapy faces the challenge of limited availability from cadaveric donors. This is
compounded by the need of multiple donors to treat one diabetic patient in most cases. Human
pluripotent stem cells (hPSCs) differentiated into functional islets (SC-islets) containing

cells

(SC- cells) ould provide a rene able cell source for cell replacement therap (5). Recently,
differentiation strategies have been developed to successfully specify fate selection of
differentiating hPSCs into SC-islets (6, 7). Further refinements to these protocols have improved
function and gene expression (8-13). Nonetheless, SC-islets generated in vitro remain unequal to
cadaveric islets both functionally and transcriptionally.
Single-cell RNA sequencing (scRNA-seq) and other assays of global transcription have
been used to rigorously study and uncover pancreatic identities (14), including assessment of SCcell populations in diabetic models (15, 16), analysis of SC-islets from in vitro differentiation
(6, 17), and studying islets or islet development (12, 18-26). When compared to

cells from

cadaveric islets, these technologies revealed that in vitro-derived SC- cells lack or have lo
expression of many important maturation genes, such as MAFA and G6PC2 (6, 12, 17).
However, after transplantation, the function and amount of insulin secreted by SC- cells
increases (6, 7, 9, 11, 12, 15, 27). The cause of this increase is unknown and may be due to
differentiation of accompanying progenitors, remodeling of the graft, and the maturation state of
cells not being set by the in vitro conditions under which they were derived. However, further
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assessment of these transplanted cells has been limited to immunostaining and functional
assessment of ex vivo grafts (11, 15, 28-30).
Here, we utilize scRNA-seq to elucidate the cellular identity, maturation, and changes in
gene expression of transplanted (Grafted) SC-islets compared to in vitro-generated (Stage 6) SCislets and primar cadaveric islets. We demonstrate that

and

cells differentiated from both

human embryonic stem cell (hESC) and human induced pluripotent stem cell (hiPSC) lines
undergo functional and drastic transcriptional changes after transplantation to closel resemble
and

cells from cadaveric islets. Specifically, for SC- cells, e find that transplantation

increases e pression of man missing or lo l e pressed

cell maturation and identity genes,

including MAFA, G6PC2, MNX1, and INS, while decreasing GCG and SST. In addition, we chart
the transcriptional changes of stem cell-derived enterochromaffin cells (SC-ECs) that were
recently described to be generated during SC-islet differentiation (17). This is a critical resource
for understanding and advancing current directed differentiation technologies to develop novel
cell therapies for diabetes.

3.3 Results
3.3.1 Retrieval and identification of SC-islet cell populations after transplantation
We differentiated a hESC and hiPSC line with our six-stage differentiation protocol into
SC-islets (12) (Figures S3.1A, S3.1B). Differentiated SC-islets were then transplanted into the
kidney capsule of streptozotocin-induced diabetic mice (Figure 3.1A). Glucose tolerance test
(GTT) was performed in transplanted diabetic mice, showing improvements in blood glucose
regulation after 4 weeks and further reversal of diabetes at 6 months (Figure 3.1B). Moreover,
we detected increasing glucose stimulated human C-peptide secretion in serum of transplanted
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mice (Figure 3.1C). After 6 months, we harvested the kidneys from mice to extract transplanted
SC-islets. These grafts display endocrine cell protein markers including Chromogranin A
(CHGA), Homeobox protein Nkx-6.1 (NKX6.1), C-Peptide (CP), and Glucagon (GCG) (Figure
3.1D). The extracted SC-islet grafts were processed for ex vivo analysis by single-cell dispersing
the excised kidney with collagenase D and enriching grafted cells with a magnetic bead mouse
cell depletion kit. After library preparation with the 10x Genomics Chromium platform, we
sequenced 45,674 cells from isogenic matched Stage 6 (in vitro) and Grafted (in vivo) cells with
the NovaSeq 6000 (Figure 3.1E, 3.1F). Filtering was performed to remove cells with high
mitochondrial content or high gene number, indicative of apoptotic cells and doublets,
respectively. To remove residual mouse kidney cells, we performed unsupervised clustering of
the Grafted samples to generate tSNE plots (Figure S3.1C). We identified a cluster of cells in
each sample containing low human mapped gene counts which marked predominantly mouse
cells (Figure S3.1D). TTC36, a kidney gene marker that aligns to both the mouse and human
genome, is represented in each cluster with low gene counts in all graft samples. To verify, we
generated violin plots to show upregulated expression of TTC36 in the identified low gene count
population (Figure S3.1E and Table S3.1) (31). For all grafted samples, we removed all cells
enriched with TTC36 as a method to distinguish mouse cells and remove them from subsequent
analysis.
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Figure 3.1 Single-cell transcriptional characterization of Stage 6 and Grafted hPSC-islets
identify endocrine and non-endocrine cell populations. A) Schematic summary of single cell
analysis of Stage 6 SC-islets and Grafted SC-islets following 6 months of in vivo maturation in
diabetic mice. (B) Glucose tolerance test (GTT) at 4 week and 6 months after transplantation of
SC-islets (n=5). (C) In vivo glucose stimulated c-peptide secretion at 0 min, before, and 60 min
after glucose injection at 3 and 26 weeks post transplantation (n=5). *p<0.05, ***p<0.001 by
two-way unpaired t-test. (D) Immunostaining of kidney graft explanted form SC-islet
transplanted mice at 6 months. Scale bar, 100 µm. (E-H) Individual tSNE projection (E, G) and
cell population fractions (F, H) from unsupervised cluster of Stage 6 and Grafted hESC- and
hiPSC-islets. CP, C-peptide; CHGA, Chromogranin A; GCG, glucagon; EC,
enterochromaffin. Error bars represent s.e.m. See also Figure S3.31 and Table S3.2.
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After filtering, we had 15,914 cells for analysis from Stage 6 hiPSC-islets, Stage 6 hESCislets, hESC-islet grafts from three mice, and hiPSC-islet grafts from two mice. Single-cell data
sets of the same condition, 3 hESC-islet grafts and 2 hiPSC-islet grafts, were pooled to obtain
sufficient cell numbers for subsequent analyses, comparable to previously published literature
(20, 23, 32, 33). Single-cell analysis revealed the majority of cell types to be pancreatic in nature
for both Stage 6 and Grafted cells. Within the individual sample tSNE projections, we identified
key pancreatic endocrine cell populations, including SC- , stem cell-derived

(SC- ), and stem

cell-derived (SC- ) cells. The SC- cells identified in the sequencing data appear to match
prior reports that defined SC- cells b the e pression of C-peptide and NKX6.1, while the
polyhormonal cells identified in prior reports appear to be within the SC- and SC- cell
populations in the sequencing data (6, 11). Other cell types, including exocrine, also persist to
some extent, as found in previous transplantation studies (11) (Figures 3.1E-1H and S3.1F). The
fate of these exocrine cells is hard to determine with our dataset, which has been similarly hard
in other data sets (34). Our cluster-matched cell types were assigned based on cell type-specific
genes found in published scRNA-seq literature for cadaveric and SC-islets (Table S3.2) (17, 21).
The fractional yields and defining genes of each cell type can be found in Table S3.2. SC- and
SC- cells are present in both Stage 6 and Grafted populations. We also identify populations of
proliferating SC- cells (GCG, ARX, CRYBA2, MKI67, PCNA, MCM2) in Stage 6 SC-islets
(Figure S3.2A), similar to as previously reported (15). These proliferative genes are not
expressed in other endocrine cell types. Similarly, identifiable SC- cell populations are only
present in Stage 6 SC-islets (Figures 3.1E-H). While SST+/HHEX+ cells are found in the Grafted
samples, their overall gene expression signatures are not sufficiently different from SC- cells to
cluster separately. Recently, SC-EC cells were found to be an off-target cell type generated from
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SC-islet differentiation protocols and have been implicated as an inhibitory cell type for SC-islet
in vitro function (17). These cells synthesize and secrete serotonin (TPH1, SLC18A1) and are
typically found in the gastrointestinal tract or gastric glands (35). We identify SC-EC cells in
Stage 6 and Grafted SC-islets (Figure 3.1E-H). Our analysis shows that many cell types
generated in vitro by our six-stage differentiation protocol persist in Grafted SC-islets.

3.3.2 SC- cells mature within transplanted grafts
To study gene expression changes that occur in SC- cells after transplantation, we
projected individually sequenced Stage 6 and Grafted cells onto a combined tSNE, separated by
cell line, and quantified the percentage of each cell type in the combined plots (Figure 3.2A). It is
important to note that combined plots are used for subsequent gene and gene set analysis, as the
dimensional reduction provided by tSNE plots depends on the samples used and absolute
distances should not be compared across different plots. Similarly, we designated cell types
based on literature of pancreatic cell types matched to upregulated genes within each cluster
(Figures S3.2A and Table S3.3) (17, 21). We detected 1,671 and 1,683

cells derived from

hESC and hiPSC lines, respectively. Focusing on the SC- cell population (Figure 3.2B), we
identify 5,867 genes with differential expression (adjusted p-value < 0.05) in Grafted compared
to Stage 6 SC- cells (Table S3.4). Despite some variations amongst SC- cells from hiPSC and
hESC sources (Figure S3.2B, S3.2C and Table S3.3), which we expected due to differences in
genetic background (33, 36), we observe substantial reductions in transcriptome variations
amongst SC- cells after transplantation hen compared bet een the t o lines (Figure S3.2D,
S3.2E, Table S3.3). Drastic and congruent transcriptome changes are observed in transplanted
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SC- cells when segmented by the original derivation line (Figures 3.2C, 3.2D, S3.2F, S3.2G,
Table S3.4).
Of particular interest, studied maturation genes such as INS, MAFA, SIX2, MNX1, and
G6PC2, are now more highly expressed in a greater fraction of cells within the Grafted SCcells, whereas they were previously missing or had lower expression in SC- cells in vitro
(Figure 3.2C-D and Table S3.4). Moreover, many additional genes associated ith mature

cells

are found more highly expressed in Grafted compared to Stage 6 SC- cells. UCN3, recognized
as a

cell maturation marker from mouse studies (37), is increased. KLF9 and HOPX, which

ere identified to be upregulated in adult

cells hen compared to fetal primar

cells, are

increased (38). FAM159B, ITM2B, and IGFBP7, which are regulators of physiological function
e pressed in cadaveric

cells (23, 39, 40), are found upregulated in our Grafted SC- cells.

Gene set enrichment analysis (GSEA) reveals higher expression of KEGG and REACTOME
pathwa s pertaining to

cell identit and processes in the Grafted SC- cells (Figure 3.2E,

S3.2H and Table S3.4).
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Figure 3.2 Comparison of Stage 6 and Grafted hiPSC- and hESC- cell transcriptomes.
(A) Unsupervised clustering tSNE projections of hESC-islets and hiPSC-islets with islet cell type
identification and cell proportions for each individual sample (grey). (B) Heat map of insulin
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(INS) gene expression to distinguish SC- cell population for both hESC-islet and hiPSC-islet
samples. (C) Normali ed e pression values for ke
cell identit , maturation, functional,
developmental, and newly identified gene sets compared between Stage 6 and Grafted SC- cells
for both hiPSC- and hESC- data sets. Percentage of cells positive for designated gene is
represented by circle size and saturation indicates low (grey) or high (blue/red) expression of the
gene (49). (D) Volcano plot displa ing fold change (FC) differences of cell genes bet een
Stage 6 and Grafted SC- cells of all hESC- and hiPSC-derived sampled combined. Dashed lines
are drawn to define restriction of log FC value of 0.25 and -log of adjusted p-value 0.001. Ke
cell genes are labeled and colored red. (E) KEGG and Reactome GSEA, quantified by the
normalized enrichment score (NES), for pathways upregulated in Grafted hESC- (red) and
hiPSC- (blue) compared to Stage 6 hESC- or hiPSC- cells, respectively. NES values and
gene lists are available in Table S3.4. (F) Immunostaining of Stage 6 and 6 month kidney grafts
containing SC-islets for identified cell maturation markers (red) co-stained with C-Peptide
(CP) (green). Scale bar, 100 µm. (G) Analysis of IAPP gene expression with real-time PCR (left;
n=4) and secreted IAPP protein (right; n=11, n=8, n=9 for Stage 6 hESC-islet, Stage 6 hiPSCislet, and human islets, respectively) in vitro. *p<0.05, ***p<0.001 by two-way unpaired t-test.
(H) IAPP protein in serum of mice transplanted with SC-islets for 3 and 26 wk (n=5).
****p<0.0001 by two-way unpaired t-test. EC, enterochromaffin; INS, insulin; CP, C-peptide;
MODY, Maturity Onset Diabetes of the Young; CHGB, Chromogranin B; IAPP, Islet Amyloid
Polypeptide; HI, Human Islet. Error bars represent s.e.m. See also Figures S3.1 and S3.2 and
Tables S3.3.

To verify our identified SC- cell maturation genes, we performed histology stains of in
vitro-derived and transplanted SC-islets. We stained the graft of transplanted cells for maturation
markers including MAFA, FAM159B, NAA20, and IAPP (Figure 3.2F). Transplanted SC- cells
show marked expression of protein products from these upregulated genes. Because IAPP
encodes a hormone that is also secreted by

cells, we confirmed that the transcript was lower

using real-time PCR and detected lower secretion of the protein in Stage 6 SC- cells compared
to primary islets (Figure 3.2G). To test if secreted IAPP protein could be a useful biomarker
correlating with maturation, we measured IAPP in the serum of transplanted mice 3 and 26 wk
after transplantation (Figure 3.2H). We found that IAPP secretion increased 10.1±2.6x,
correlating with the scRNA-seq results of increased IAPP transcript (Figure 3.2C). This is also a
greater dynamic range than what we observed with C-peptide, which only increased 2.7±0.5x
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during the same time period (Figure 3.1C). The protein analysis here is consistent with the
scRNA-seq data.
Other misexpressed genes have lower expression in SC- cells after transplantation
(Figure 3.2C-D and Table S3.4). We and others previously identified several genes (CHGA,
MAFB, GCK, GLUT1) that were overexpressed in Stage 6 SC-islets compared to cadaveric islets
(9, 11, 12, 17, 41) and here find that they have reduced expression in Grafted compared to Stage
6 SC- cells. We observe reductions in GCG and SST gene expression and other genes expressed
b

and cells (ALDH1A1, FTL, CRYBA2) with transplantation. Genes enriched in non-

functional stem cell-derived insulin-expressing endocrine compared to adult cadaveric

cells

(FOXA1, NR2F1, FEV, SOX11, ONECUT2, TCF3) (38) are lowly expressed in Grafted SCcells.
Next, we reconstructed the single-cell data from Stage 6 and Grafted SC- cells into
developmental trajectories to obtain a greater understanding of the d namic changes in

cell

maturation transcripts. Stage 6 SC- cells from hESC and hiPSC lines form separate branches at
the initial pseudo-time state, and merge to a single trajectory that consists mainly of Grafted SCcells (Figures 3.3A and 3.3B), suggesting that the transcriptomes amongst different cell lines
become more similar upon maturation. Reduction of GCG and SST is also observed with pseudotime, thus verif ing our observation of

cell fate commitment after transplantation (Figure

3.3C). Using the top 100 most differentially expressed genes, we were able to observe a
multitude of genes that trend similarly to GCG and SST including ADLH1A1, MAP1B, and
CRYBA2 (Figure 3.3D and Table S3.6). Conversel , ke

cell maturation genes, specificall

MAFA, and G6PC2, increase in expression with pseudo-time (Figures 3.3E and 3.3F). Of note,
we identified additional regulatory and identity genes including FXYD2, IAPP, MT1X, and SAT1
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to increase in concert with MAFA and G6PC2. When evaluating the most differentially
expressed genes, JUN, NEAT1, PPP1R1A, SLC30A1, and ASB9 are upregulated at the terminal
end of the trajectory (Figure 3.3D), indicating further

cell development.

Figure 3.3 Pseudo-time analysis projects Stage 6 SC- cell maturation into Grafted SCcells after transplantation. (A) Pseudo-time trajectory of Stage 6 and Grafted SC- cells ith
one branching point. (B) Distribution of SC- cells from Grafted hESC- (purple), Grafted
hiPSC- (pink), Stage 6 hiPSC- (orange), and Stage 6 hESC- cells (blue). (C) Changes in gene
expression of endocrine hormones insulin (INS), somatostatin (SST), glucagon (GCG) along
pseudo-time projection for SC- cells. Scale: RelativeE pression. (D) Analysis of top 100
branch-dependent genes determined based on clusters identified through pseudo-time analysis of
SC- cells, found in Table S3.4. Scale: RelativeExpression. (E) Relative expression level of
selected cell genes along SC- cell pseudo-time. (F) Gene e pression heat map of select cell
genes focused on function and maturation along pseudo-time. Scale: Normalized Expression. See
also Figure S.3 and Tables S3.34.

We also analyze additional gene sets pertaining to

cell function and maturation. We see

upregulation of KCNK3, SLC30A8, and IAPP, kno n to support

cell function (Figures 3.3E,

3.3F, S3.3) (11, 39). CACNA1C, a calcium channel subunit important for insulin secretion,
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lessens with maturation; VIPR1 and GPR119, potent GSIS activators (42, 43), have intermediate
activation; and ABCC9 and G6PC2, e pressed in functional

cells, are present at the final state

in Grafted SC- cells (Figure 3.3F). Consistent with previous human islet and SC- cell
comparison studies, we also observe reduced expression of GCK in the Grafted SC- cells.
Looking into identified

cell maturation gene sets (17), we observe all transcripts, with the

exception of MAFB, to increase with pseudo-time (Figures 3.3F and S3.3). Though categorized
as maturation genes, the expression pattern of MAFB trends similar to primar human

cells

(17, 38). Altogether, our clustering and pseudo-time ordering analyses suggest that transplanted
SC- cells displa d namic gene patterns leading to

cell maturit .

3.3.3 Grafted SC- cells closely resemble primary human

cells

Previous studies show that SC- cells are markedl different from native adult
possessing ke

cells,

cell identit genes but short of man other genes b global perspective (6). To

explore if our Grafted SC- cells acquired gene expression that better resemble native adult
cells, we performed subsequent comparisons by incorporating single cell RNA sequencing data
from three healthy cadaveric donor human islets (24) into a new combined tSNE projection. We
pooled 3,368 SC- cells (1,765 from hESC and 1,603 hiPSC) with cadaveric human islet
making a total of 4,696

cells,

cells for our anal sis. With a total of ten single cell sequencing

samples, we detected all cell populations identified previously in Figure 1 which includes
pancreatic endocrine and exocrine cell types (Figures 3.4A, 3.4B, S3.4A and Table S3.5) (17,
21). With the addition of primary islet data, we now identify endothelial cells marked by high
expression of PECAM1, CD34, and ENTPD1. Notably, we do not detect SC-EC nor proliferating
cells ithin cadaveric human islets (Figure 3.4A, 3.4B).
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Figure 3.4 Grafted SC- cells resemble primary human cells compared to Stage 6 SCcells. (A) Unsupervised tSNE projection from 10 islet data sets including Stage 6 hiPSC- and
hESC-islets, 3 Grafted hESC-islets, 2 Grafted hiPSC-islets, and 3 primary human islets. (B)
Individual location of different samples within combined tSNE projection. (C) Volcano plot
displa ing fold change (FC) differences of cell genes bet een Grafted SC- (left) and Human
Islet cells (right). Dashed lines are dra n to define restriction of log FC value of 0.25 and -log
of adjusted p-value 0.001. Ke
cell genes are labeled and colored red. (D) Heat map sho ing
gene expression values for Stage 6, Grafted SC- , and primar human islet (Donor) cells of the
100 most differentially expressed genes between Stage 6 and Grafted SC- cells listed in Table
S3.6. Scale: Normalized Expression. (E) Pearson correlation matrix and hierarchical clustering to
identif most similar populations amongst all cell samples using top 430 variable genes.
Pearson correlation values detailed in Table S3.6. EC, Enterochromaffin. Scale: Correlation
Coefficient. See also Figure S4 and Tables S3.4, S3.5, and S3.6.

We performed differential gene e pression anal sis of
native human islets.

cells from SC-islet grafts and

cell identit genes (INS, NEUROD1, and NKX2-2), maturation genes
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(MAFA and G6PC2), and other notable genes (ITM2B, PDX1, GCK, and STX1A) are strikingly
similar across the two conditions (Figure 3.4C, S3.4B, S3.4C and Table S3.6). Furthermore,
cells from native islets have similar transcriptome profiles when compared to Grafted SC- cells
(Figure 3.4D). Quantitativel , Pearson correlation sho s that native

cells are more similar to

Grafted SC- cells hen compared across all samples (Figure 3.4E and Table S3.6). These
results suggest that SC- cells have the abilit to acquire native adult

cell genes when placed in

an in vivo setting.
We also observe genes that are misexpressed in our Grafted SC- cells hen compared
to native adult

cells. Some ke functional and

cell identit genes e identified as reduced in

our Grafted SC- cells including NKX6-1, CHGA, IAPP, HOPX, and EROL1B, continue to have
higher expression when compared to native islet
Conversely,

cells (Figures 3.4C, S3.4B-C and Table S3.6).

cells from native islets have higher expression of multiple endocrine hormone

genes, specifically PPY, SST, and GCG (Figure 3.4C and S3.4B-C and Table S3.6). We also
observe HLA genes (B2M, HLA-B, HLA-A) and ribosomal protein small (RPS) and other large
(RPL) genes to be upregulated in native adult

cells (Table S3.6). Of note, no major

cell

identity genes were under expressed in our Grafted SC- cells hen compared to native adult
cells.
In addition to these marked differences, we refined our differentially expressed list of
genes upregulated in both Grafted SC- cells and native adult

cells (Table S3.4 and S3.6) and

established a curated list of genes that are shared across the two conditions (Table S3.6). In our
list, metallothionein (MT1E, MT1F, MT1X, MT2A) and

cell function regulatory (FAM159B,

G6PC2, IAPP) genes are highlighted. Notably, IAPP, FAM159B, and MT1X were previously
associated with adult human islets and are now confirmed as maturation genes (21, 39).
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Additional genes including PEBP1, MT2A, FXYD2, NAA20, RASD1, and SAT1 are also
upregulated. Pseudo-time ordering analysis also verified these identified genes to be upregulated
at similar expression values for both Grafted SC- cells and native adult

cells (Figure S3.4D-

F). We validated some of our identified maturation genes using qPCR (Figure S3.4G).
Furthermore, we observed that a very small fraction (2.09% and 1.20%) of Stage 6 SC- cells
expressed MAFA but still lacked expression of other important genes, such as G6PC2 (Figure
S3.4H-I). Collectively, the results support that our Grafted SC- cells have transcriptional
profiles that more closel resemble native

cells in cadaveric human islets compared to Stage 6

cells.

3.3.4 SC- cells mature within transplanted grafts
SC- cells are generated from our six-stage SC-islet differentiation protocol and account
for an average of 51.8 % and 11.1 % cell proportions in Stage 6 and Grafted SC-islets,
respectively (Table S3.2). While we see some variation in Stage 6 SC- cells from different
genetic backgrounds (33, 36), there is considerable convergence of Grafted transcriptome
profiles after transplantation (Figure S3.5A, Table S3.3). Further analysis of the SC- cell
population (Figure 3.5A) indicates Grafted SC- cells undergo significant transcriptome changes
with greater expression of specific maturation genes compared to Stage 6 SC- cells (Figures
3.5B-E and Table S3.6). However, the Grafted SC- cells are not as similar to human islet
as SC- cells are to human islet

cells

cells (Figures 3.4E and 3.5D and Table S3.6). A marked

difference is the reduced level of glucagon (GCG) and increased expression of insulin (INS) in
the Grafted SC- cells compared to native islet

cells (Figure 3.5C and 3.5E, S3.5B). In fact,

this degree of polyhormonality and higher expression of FEV, an immature
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cell marker (17),

are key characteristics reported in precursor
note, ARX, a key

cells, found in juvenile human islets (17, 44). Of

cell marker remains elevated in both Stage 6 and Grafted SC- cells

compared to human islet

cells (Figures 3.5E, S3.5B). The expression of proliferating genes

(MKI67, PCNA, MCM2) are also found predominantly in the Stage 6 SC- cell population
(Figure S2A), but we did not extensively study this population here. This population is not
detected in Grafted SC-islets (Figures 3.1E-H, S3.4A) nor adult human islets and not detectable
in other human islet

cell studies (18, 21). Despite these differences, differential gene

expression analysis indicates Stage 6 SC- cells are maturing to a transcriptional state similar to
primar islet

cells. For further examination of the SC- cell maturation state, we curated a

maturation gene list (Table S3.6) from upregulated genes in Grafted (Table S3.4) and human
islet

cells (Table S3.6) compared to Stage 6 SC- cells.
To dynamically visualize transcriptional changes, we reconstructed our Stage 6 and

Grafted SC- cell data into a pseudo-time trajectory (Figure 3.5G, 3.5H). Similar to SC- cells,
the hiPSC- the hESC- cells formed separate branches at the initial pseudo-time. hESC- cells
however, are more representative across the bulk of the trajectory. These branches merged to
form a population that consists mainly of Grafted hiPSC- and hESC- cells at the terminal
pseudo-time, as was observed in our

cell analysis. Of particular note, well-known (CHGB,

GCG, and LOXL4) and newly identified (SCG5, PARVB) genes from our

cell maturation gene

list increase with pseudo-time (Figure 3.5I and S3.5C). On the other hand, expression of CHGA
and FTL reduce with pseudo-time, following trends observed when incorporating primary islet
cells into the analysis (Figure S3.5C-G and Table S3.4). Altogether, our results support that
transplantation of SC- and SC- cells induce drastic transcriptome changes to more closely
resemble their respective islet endocrine cell type.
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Figure 3.5 Single-cell transcriptome and pseudo-time analysis indicates Stage 6 SC- cells
mature during transplantation to more closely resemble human Islet cells. (A) Heat map
of glucagon (GCG) gene expression to distinguish SC- cell populations ithin tSNE plot from
Figure 4A. (B) Normalized gene expression values for 2 Stage 6 SC- , 5 grafted SC- , and 3
primar human islet (Donor) cells of the 100 most differentiall e pressed genes bet een
Stage 6 and Grafted SC- cells listed in Table S3.6. Scale: Normalized Expression. (C) Volcano
plot displa ing fold change (FC) differences of cell genes bet een Grafted SC- (left) and
Human Islet cells (right). Dashed lines are dra n to define restriction of log FC value of 0.25
and -log of adjusted p-value 0.001. Ke
cell genes are labeled and colored red. (D) Pearson
correlation matri and hierarchical clustering to identif most similar populations among all
cell samples using top 430 variable genes. Pearson correlation values detailed in Table S3.6.
Scale: Correlation Coefficient. (E) Normali ed e pression values for ke
cell identit ,
function, and newly identified genes between Stage 6 SC- , Grafted SC- , and primar human
cells. Percentage of cells positive for designated gene is represented by circle size and saturation
indicates low (grey) or high (blue) expression of the gene. (F) Immunostaining of Stage 6 and 6
month kidney graft containing SC-islets for cell markers. Scale bar, 50 m. (G and H)
Pseudotime trajectory (G) and distribution (H) of SC- cells from 7 hPSC- samples. (I) Relative
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e pression level of selected cell genes along SC- cell pseudo-time. Scale: Relative
Expression. Each dot represents a different cell. GCG, Glucagon; CP, C-Peptide. See also Figure
S3.5 and Tables S3.3, S3.4, and S3.6.
3.3.5 Transcriptional changes of enterochromaffin cells within transplanted grafts
We identify SC-EC cells, an off target of SC-islet and SC- cell differentiation protocols,
in all stem cell derived samples. However, we did not detect EC cells in cadaveric human islet
samples (Figure 3.6A and S3.6A), consistent with prior reports (17). We performed a
comparison of the SC-EC cells before and after transplantation. Several transcriptional changes
occur after transplantation (Figure 3.6B) and interestingly, transcriptome similarity between the
Grafted SC-EC cells has the highest Pearson correlation compared to other interrogated cell
types (Figure 3.6C and Table S3.4). Following transplantation, EC cell genes, including MME,
DDC, ITPR3, TAC1, CHGA, SLC18A1, and CHGB, are upregulated, and TPH1 protein is
expressed (Figure 3.6D-3.6E and Table S3.4) (17, 35). We also identify new EC cell genes that
increase after transplantation, such as DUSP1 and ZFP36. Conversely, islet endocrine genes
(INS, GCG, SST) are reduced, suggesting further commitment to the EC cell fate.
Pseudo-time ordering analysis reveals similar reconstruction patterns observed with SCcells and SC- cells (Figure 3.6F and 3.6G). The Grafted SC-EC cell populations continue to
overlap at the terminal point in pseudo-time, suggesting a uniform commitment to EC cell fate.
Genes previously found upregulated in SC-EC cells following transplantation from differential
gene expression analysis, are also increased with pseudo-time (Figures 3.6H, S3.6B-C and Table
S3.4). ZFP36 and MME are initially lowly expressed in a few cells. However, along the pseudotime, they are upregulated in a greater number of cells. Elevated genes in the Grafted SC-EC
cells (Table S3.4) may serve as maturation markers. Yet, we are unable to validate this list as
human islets do not have EC cell populations and there is limited EC cell primary data available.
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Overall, we establish SC-EC cells are present in our differentiated SC-islets and following
transplantation, they continue to exist and change gene expression in vivo.

Figure 3.6 Analysis of pseudo-time and single-cell transcriptomes of Stage 6 hPSC-EC and
Grafted hPSC-EC cells following transplantation. (A) Heat map of TPH1 gene expression to
distinguish SC-EC cell population within tSNE plot from Figure 4A. (B) Gene expression values
for 2 Stage 6 SC-EC and 5 grafted SC-EC for the 100 most differentially expressed genes
between Stage 6 and Grafted SC-EC cells listed in Table S3.6. Scale: Normalized expression.
(C) Pearson correlation matrix and hierarchical clustering to identify most similar populations
amongst all EC cell samples using top 430 variable genes. Scale: Correlation Coefficient. (D)
Expression values for key EC cell identity, function, development, and newly identified genes
between Stage 6 and Grafted SC-EC cells. (E) Immunostaining of Stage 6 and 6 month kidney
graft containing SC-islets for EC cell marker TPH1. Scale bar, 50 µm. (F and G) Distribution (F)
of SC-EC cells along pseudo-time trajectory (G) from 7 SC-EC samples. (H) Relative expression
of select EC cell genes along SC-EC cell pseudo-time. Scale: Relative Expression. Each dot
represents a different cell. TPH1, Tryptophan Hydroxylase 1; CP, C-Peptide; CHGA,
Chromogranin A. See also Figure S3.6 and Table S3.4.
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3.4 Discussion
The ability to robustly generate pancreatic islets from hPSCs marks an important
accomplishment in developmental science and bioregenerative medicine. Nonetheless, SCcells generated from current protocols have transcriptome and functional attributes that resemble
juvenile, immature

cells rather than adult mature

cells (6, 11, 12). Herein, we demonstrate

that SC- cells, derived from both ES and iPS cell lines, can develop into mature

cells after

transplantation. Previous publications display enhanced insulin secretion with prolonged
transplantation times, which we replicate in our study. Herein, we use scRNA-seq to characterize
and explore the transcriptome changes within these functionally improved cells, which has not
previously been explored. We performed scRNA-seq on in vitro-generated Stage 6 and Grafted
SC-islets following 6 months transplantation in diabetic mice. In our SC-islets, we identify key
pancreatic and islet cell types, including SC- , SC- , SC- , and exocrine cells. After
transplantation, the Grafted SC- cell population acquired expression of adult human islet

cell

genes, expressing known maturation markers, including MAFA and G6PC2.
The e pression of genes important to

cell phenotype changed with transplantation of

SC- cells. MAFA is widely considered a marker of

cell maturation, but function in SC- cells

in vitro has been achieved with low to no MAFA (9, 11, 12, 45). Thus, the precise role of MAFA
in

cell maturation is unclear. As we show SC- cells can further mature to e press MAFA in

vivo, our platform could be used in the future to interrogate transcriptional changes in this and
other genes. We also observe reduction of endocrine genes overexpressed in SC- cells in vitro
(CHGA, MAFB, GCK, GLUT1) to be more consistent with primary human islets and reduction of
GCG and SST gene expression. An interesting observation was that GCG and SST gene
expression was actually lower in Grafted SC- cells compared to primar human islets, likel
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due in part to isolation of these primary cells (46). While prior reports have demonstrated GCG
and SST transcript in
primar

cells from primary human islets (23, 40, 46), their molecular role in

cells and SC- cells is unclear. Furthermore, in our study, we have also provided a

new list of genes corresponding with SC- cell maturation in vivo. We validated protein
expression of some new and pre-defined

cell maturation genes. A limitation of this study and

opportunities for further investigation are further validation of other

cell and newly identified

and EC cell markers. Another limitation of this study is that we did not trace individual cells
across different comparisons through the report.
While the focus of this stud is on

cells,

and EC cells are also e plored as the

constitute major endocrine cell populations with current differentiation methodologies. Stage 6
SC- cells mature after transplantation, indicated by increased

cell maturation marker

expression. However, the SC- cells do not resemble human primar

cells as closel as SC-

cells do to their primary counterparts. This may be a result of our six-stage differentiation
protocol targeting the generation of SC- , rather than SC- , cells. Nonetheless, we have
generated a list of

cell maturation markers that provides insight on enhancing

cell function

and targeting further maturation in SC-islet differentiations. EC cells are an intestinal, serotoninsecreting endocrine off-target cell type generated during (17). They are present in both the Stage
6 and Grafted SC-islet populations but their effects on SC-islet function and maturation is
unknown.
Gene set enrichment analysis and pseudo-time ordering analysis revealed multiple
transcriptional genes and gene sets enriched in Grafted SC-islet subpopulations. A shared
observation in Grafted SC- , SC- , and SC-EC cells is the increased expression of
metallothionein and FOS/JUN genes. Enrichment of these pathways indicate further
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development and terminal differentiation of these cell types. Interestingly, several identified SCcell maturation genes are highl e pressed prior to MAFA expression in pseudo-time, possibly
indicating they regulate MAFA expression. Potentially, prolonged exposure to factors associated
with these signaling components may lead to SC-islet, namely SC- and SC- cell, maturity in
vitro. Targeting these pathways could result in improved in vitro differentiation protocols.
The approach in this study involved the transplantation SC- cells into mice ith pre-existing
STZ-induced diabetes. However, the conditions of optimal maturation, such as transplantation
time, diabetic model, STZ induction before or after transplant, is unknown and would be an
interesting study. Cells in an in vivo setting, particularly when not in their natural organ, may
undergo de-differentiation or trans-differentiation to become other cell types (46, 47). Because
we did not observe progenitor populations in our sequencing data, we believe that the majority of
our transplanted populations are retained to their identity. However, it may be possible that some
SC- cell or exocrine cell populations may trans-differentiate into insulin-producing cells as
demand for blood insulin and glucagon changes overtime (47), and this study did not utilize
lineage tracing. An additional limitation of this study was the yields of SC- cells e recovered
from individual mice, ranging for 111-560 SC- cells. This prompted us to pool the results from
5 mice for most of the analysis in this study, but improvements, such as better purification,
additional mice, and more differentiations, would better enable robust studies. Furthermore,
incorporating the primary human islet data sets caused small variations in identified cell types,
although overall gene expression differences were not meaningfully affected. An additional
limitation is the technical processing of single-cell RNA sequencing, which conceivably may
yield free-floating mRNA transcripts yielding false positives (48). However, our analysis here of
the cell-defining and hormone transcripts comparisons among cell types were significantly
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different between endocrine and non-endocrine cell types, as we have shown previously (16),
making this possibility unlikely.
In conclusion, we provide a resource thoroughly detailing the maturation of SC- cells
through in vivo transplantation. SC- cells derived from both hiPSC and hESC lines are capable
of developing into cells transcriptionally similar to primary human

cells. This data set provides

valuable information on potential genes and target pathways that may contribute to
understanding human

cell maturation following transplantation. More importantly, it can lead

to further developments in SC- cell generation for cell replacement therapies.

3.5 Materials and Methods
3.5.1 Resource Availability
Materials Availability: HUES8 cell line is available through Harvard Stem Cell Institute (HSCI).
The WS4corr cell line is available upon request to Lead Contact with required MTA.
Data and Code Availability: The single cell RNA sequencing data from this study is made
available at the Gene Expression Omnibus (GEO). The accession number for the raw and
processed Stage 6 hESC-islet and all Grafted SC-islet data is GSE151117. The accession number
for the raw and processed Stage 6 hiPSC-islet data is GSE139535. The accession number for the
raw and processed human islet data is GSE114297.

3.5.2 Animal models
Male, 7 wk old, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (Jackson Laboratories; stock no.
005557) were used in this study. Mice were fed on chow diet and on a 12 hour light/dark cycle.
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Animals were randomly assigned to experimental groups. All animal studies performed in this
research were in accordance with Washington University International Care and Use Committee
(IACUC) regulations.

3.5.3 Human cell lines
Two human PSC lines were used in this study including an hESC line (HUES8) and an hiPSC
(WS4corr) line. Both cell lines are authenticated and have normal karyotype. The sex of HUES8
and WS4corr are male and female, respectively. The cells were cultured in mTeSR1 (StemCell
Technologies; 05850) in a 5% CO2 incubator at 37 C (12, 16). Cells were single cell dispersed
with TrypLE (Life Technologies; 12-604-039) and passaged every 3-4 days. A Vi-Cell XR
(Beckman Coulter) counted viable single cells and we seeded 1.1x105 cells/cm2 cells onto tissue
culture-treated flasks, coated with DMEM-diluted (Gibco, 11965-084) Matrigel-coated (Fisher,
356230) for propagation in mTeSR1 with 10µM Y27532 (Abcam; ab120129). All work for this
study was performed in accordance with the Embryonic Stem Cell Research Oversight (ESCRO)
committee through Washington University in St. Louis.

3.5.4 Primary cell culture
Cadaveric human islets were purchased from Prodo Labs and cultured in islet media (CMRL
Supplemented (Mediatech; 99-603-CV) with 10% Fetal Bovine Serum (GE Healthcare;
SH3007003)). For RNA, donor islets were from a 54 year-old Hispanic female. Details for donor
islets for sequencing comparison are as follows (1) Caucasian, 32 years, female, (2) Hispanic, 23
years, male, (3) Caucasian, 49 years, male.
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3.5.5 Stem cell-derived

cell differentiation

The differentiation is based on our previous publication (12). Undifferentiated hPSCs were
single cell dispersed, counted, and seeded onto tissue culture plastic treated flasks with mTeSR1
and 10µM Y27532 at 5.2x105 cells/cm2. After 24 hours, differentiation began using medias and
added factors. The differentiation protocol including base media formulation and differentiation
factors is available in Tables 3.1-3.3. 7 days into stage 6, cells were dispersed with TrypLE and
seeded ~5x106 cells into an individual well of a 6-well plate with 4 mL of ESFM media on an
OrbiShaker (Benchmark) at 100 RPM. Cells were used for transplantation between day 13-16 in
stage 6.

Table 3.1 Additional Methods Details: Base Media Formulations
Reagent

BE1

BE2

BE3

S5

S6

Company

MCDB131

500 mL

500 mL

500 mL

500 mL

500 mL

Cellgro

Glucose
NaHCO3
FAF-BSA
ITS-X
Glutamax
Vitamin C
Heparin
Pen/Strep

0.8 g
0.587 g
0.5 g
N/A
5 mL
N/A
N/A
N/A

0.4 g
0.587 g
0.5 g
N/A
5 mL
22 mg
N/A
N/A

0.22 g
0.877 g
10 g
2.5 mL
5 mL
22 mg
N/A
N/A

1.8 g
0.877 g
10 g
2.5 mL
5 mL
22 mg
5 mg
5 mL

0.23 g
N/A
10.5 g
N/A
5.2 mL
N/A
10 µg/mL
5.2 mL

MilliporeSigma
MilliporeSigma
Proliant
Invitrogen
Invitrogen
MilliporeSigma
MilliporeSigma
Cellgro

NonEssential
Amino
Acids
ZnSO4

N/A

N/A

N/A

N/A

5.2 mL

Corning

N/A

N/A

N/A

N/A

1 µM

MilliporeSigma

10883

Trace
N/A
Elements A
Trace
N/A
Elements B

N/A

N/A

N/A

523 µL

Corning

N/A

N/A

N/A

523 µL

Corning

25-021CI
25-022CI
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Catalog
#
15-100CV
G7528
S3817
68700
51500056
35050079
A4544
H3149
30-002CI
25-025CI

Table 3.2 Additional Methods Details: Differentiation Protocol

Stage 0

Day
1

Media
Factor
mTeSR1 Y27632

Stage 1

Day
2

Media
BE1

Stage 1
Stage 1
Stage 1

3
4
5

Stage 2

Final
Concentration
10 M

BE1
BE1
BE1

Factor
Activin A
CHIR99021
Activin A
Activin A
Activin A

Final
Concentration
100 ng/mL
3 M
100 ng/mL
100 ng/mL
100 ng/mL

Day
6
7

Media
BE2
BE2

Factor
KGF
KGF

Final
Concentration
50 ng/mL
50 ng/mL

Stage 3

Day
8

Media
BE3

Stage 3

9

BE3

Factor
LDN193189
KGF
SANT1
RA
TPPB
LDN193189
KGF
SANT1
RA
TPPB

Final
Concentration
200 nM
50 ng/mL
0.25 M
2 M
200 nM
200 nM
50 ng/mL
0.25 M
2 M
200 nM

Stage 4

Day
10

Media
BE3

11

BE3

Factor
KGF
SANT1
RA
TPPB
LDN193189
KGF
SANT1
RA
TPPB
LDN193189

Final
Concentration
50 ng/mL
0.25 M
0.1 M
200 nM
200 nM
50 ng/mL
0.25 M
0.1 M
200 nM
200 nM
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Stage 5

12

BE3

13

BE3

Day
14

Media
S5

15

S5

16

S5

17

S5

18

S5

KGF
SANT1
RA
TPPB
LDN193189
KGF
SANT1
RA
TPPB
LDN193189

Factor
SANT1
RA
XXI
Alk5i
T3
Latrunculin
A
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin

50 ng/mL
0.25 M
0.1 M
200 nM
200 nM
50 ng/mL
0.25 M
0.1 M
200 nM
200 nM
Final
Concentration
0.25 M
0.1 M
1 M
10 M
1 M
1 M
20 ng/mL
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
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19

S5

20

S5

Stage 6

SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin

0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL

Feed S6 every other day

Table 3.3 Additional Methods Details: Differentiation Factors
Compound
Activin A
CHIR99021
KGF
LDN193189
Retinoic Acid
SANT1
Y27632
Latrunculin A
Alk5 inhibitor type II
Betacellulin
T3
XXI
TPPB

Company
R&D Systems
Stemgent
Peprotech
Reprocell
MilliporeSigma
MilliporeSigma
Abcam
Cayman Chemical
Enzo Life Sciences
R&D Systems
Biosciences
MilliporeSigma
Tocris

Part #
338-AC
04-0004-10
AF-100-19
40074
R2625
S4572
ab120129
10010630
ALX-270-445-M005
261-CE-050
64245
595790
53431

3.5.6 Mouse Transplants
All animal studies performed in this research were in accordance with Washington University
International Care and Use Committee (IACUC) regulations. Prior to transplantation of cells,
male, 7 wk old, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (Jackson Laboratories; stock no.
005557) were treated with 45 mg/kg streptozotocin (STZ; R&D; 1621500) in 0.9% sterile saline
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(Moltox; 51-405022.052) for 5 consecutive days. Mice were diabetic (blood glucose >500
mg/dL) 8 days after the final STZ injection. Surgery and assessments were performed by
unblinded individuals and mice were randomly assigned to experimental groups. For SC-islet
transplantation, mice were anesthetized with isoflurane and injected with ~5x106 SC-islet cells
under the kidney capsule, from either hiPSC (n=3) or hESC (n=2) derived SC- cells. Mice were
monitored for 6 months after transplantation before removal of the transplanted kidney for SCislet retrieval. For glucose tolerance tests (GTT) and in vivo glucose stimulated c-peptide
secretion, mice were fasted for 4 hr and injected with 2 g glucose/kg body weight. For GTT,
blood glucose was measured every 30 min from 0 to 120 min with a Contour Blood Glucose
Monitoring System (Bayer; 9545C). For in vivo glucose stimulated c-peptide secretion, serum
was collected before and 1 hr after glucose stimulation. Hormones were quantified by collecting
serum and measuring C-peptide and IAPP with the Human Ultrasensitive C-Peptide ELISA kit
(Mercodia; 10-1141-01) and Human Amylin ELISA kit (Miltenyi; EZHA-52K), respectively.

3.5.7 Immunostaining
Stage 6 clusters and excised transplant kidneys were fixed overnight in 4% paraformaldehyde
(PFA) (Electron Microscopy Science; 15714) at 4 C. Fi ed kidne s and Stage 6 clusters,
suspended in Histogel (Thermo Scientific; hg-4000-012), were further processed by the Division
of Comparative Medicine (DCM) Research Animal Diagnostic Laboratory Core at Washington
University. Histoclear (Electron Microscopy Sicences; 64111-04) removed paraffin from slides
containing both Stage 6 and kidney sections. Sections were then rehydrated and antigens were
retrieved in a pressure cooker (Proteogenix; 2100 Retriever) with 0.05 M EDTA (Ambion;
AM9261). Slides were blocked and stained with primary antibodies diluted in immunostaining
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solution (PBS (Fisher; MT21040CV) with 0.1% Triton X (Acros Organics; 327371000) and 5%
donkey serum (Jackson Immunoresearch; 017000-121)) overnight at 4 C, stained ith diluted
secondary antibodies for 2 hr at room temperature, and stained for DAPI (SouthernBiotech;
0100-20). The immunostained cells and grafts were imaged with a Nikon A1Rsi confocal
microscope. Antibody details and dilutions are available in Table 3.4.

Table 3.4 Additional Methods Details: Antibodies
Antibody Target
Company
C-peptide
DSHB
NKX6-1
DSHB
Glucagon
Cell Marque
PDX1
R&D Systems
CHGA
Abcam
LifeSpan Bioscience
MAFA
Invitrogen
FAM159B
Invitrogen
NAA20
Sigma Aldrich
IAPP
Invitrogen
ARX
Chemicon
TPH1
R&D
Trypsin
Dako
KRT19
anti-rat-alexa fluor 488
Invitrogen
anti-rabbit-alexa fluor 488
Invitrogen
anti-mouse-alexa fluor 594
Invitrogen
anti-rabbit-alexa fluor 594
Invitrogen
anti-goat-alexa fluor 594
Invitrogen
anit-sheep-alexa fluor 594
Invitrogen
DSHB=Developmental Studies Hybridoma Bank

Part #
GN-ID4-S
F55A12-S
259A-18
AF2419
ab15160
LP9872
PA5-52855
PA5-66574
PA5-84142
PA5-47896
AB1541
AF3586
M088
a21208
a21206
a21203
a21207
a11058
a11016

Dilution
1:300
1:100
1:2
1:300
1:1000
1:100
1:20
1:50
1:1000
1:20
1:100
1:100
1:100
1:300
1:301
1:300
1:300
1:300
1:300

3.5.8 Tissue and Cell Preparation for Sequencing
Stage 6 SC-islet preparation: At stage 6 day 14, SC-islets were washed with PBS and single cell
dispersed ith Tr pLE at 37 C for 20 minutes. The dispersed cells ere centrifuged, counted,
and resuspended in DMEM for library prep.
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Grafted SC-islet cell retrieval: Transplanted mice were euthanized through cervical dislocation
and the kidney transplanted with SC-islets were removed. Excess scar tissue and fat was
removed from around the kidney. Images were taken of the kidneys to visualize the transplanted
cells. The kidney was sliced into several small pieces with a razor blade and placed into a
solution of 2mg/mL collagenase D (Sigma; 11088858001) in RPMI (Gibco; 11875-085). The
tissue as incubated at 37 C for 45 min. PBS as added to the solution and additional breakup
was enforced with a pipette before filtering the cells through a 70µm cell strainer (Corning;
431751). Collected flow through was centrifuged, supernatant was removed, and resuspended
with MACS buffer (0.05% BAS in PBS). A Miltenyi mouse cell isolation kit (kit, 130-104-694;
LS column, 130-042-401) was used to remove excess mouse cells from the cell solution. Cells in
flow through were collected, centrifuged, counted, and resuspended in DMEM for library prep.

3.5.9 Single-cell RNA sequencing preparation
Single-cell transcriptome barcoding and library preparation for 10x Illumina sequencing
Single cell dispersed cells were delivered to Washington University in St. Louis Genome
Technology Access Center (GTAC) for library preparation and sequencing. For library
preparations, the Chromium Single Cell 3 Librar and Gel Bead Kit v2 as used following the
provided protocol. In summary, a microfluidic platform is used to profile digital gene expression
for individual cells by creating an emulsion for each cell with a unique barcoded cDNA,
breaking the emulsion, and amplifying the cDNA. The library was sequenced with a NovaSeq
6000 System (Illumina) at the recommended 26x98bp. Gene expression levels found in violin
plots and heatmaps are displayed in Log(normalized read count) and normalized average gene
expression, respectively.
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3.5.10 Single-cell RNA sequencing data analysis
Raw Data Processing
Seurat v2.3.4 was used for single cell analyses and comparison between all groups (49). Monocle
v2.12.0 was used for pseudotime analysis between Stage 6 and grafted SC- cells (50, 51) and
WS4corr Stage 6 data is from Maxwell et al. (DOI: 10.1126/scitranslmed.aax9106) SC-islet
samples were aligned to the human genome and filtered out low gene counts (<500 for grafted
and <3000 for Stage 6) and high mitochondrial percentages (>20%) for further data analysis,
indicating doublets, debris, and dying cells. This filtering removed several mouse cells present in
the grafted SC-islet samples. The minimum number of genes is lower for the grafted compared to
Stage 6 SC-islet samples to filter out the mouse cells, because our data sets are aligned to the
human genome, therefore the mouse cells have low gene counts. Therefore, we clustered the
grafted SC-islet samples and identified the clusters with low gene counts. We identified TTC36,
a kidney gene which is present in both mouse and human genomes, to also be highly expressed
in the low gene number clusters. We removed all cells with TTC36 log-normalized expression >
3, to remove all remaining mouse cells from further analysis. The genes defining the cell cluster
that was identified as mouse cells can be found in supplemental table 1. Each sample data set
was normalized with global-scaling normalization. FindVariableGenes function removed outlier
genes using a scaled z-score dispersion.
Clustering
For individual tSNE plots, cells with similar gene expression patterns were plotted near each
other based on PCA using the FindClusters function. We used a resolution of 0.2 and 5
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dimensions to generate tSNE plots for each individual sample (Stage 6 iPS SC-islets, Stage 6 ES
SC-islets, 3 Grafted ES SC-islets, 2 Grafted iPS SC-islets). The top 50 genes that separated each
cluster within the individual samples were identified with FindAllMarkers and these gene sets
were used to designate the different SC-islet cell types including beta, alpha, and delta cells.
These gene lists can be found in supplemental table 2. The FeaturePlot function was used to
visualize expression of specific genes across the different clusters, represented in tSNE plots.
Violin plots were generated to compare the expression of specific genes for the SC- cell
populations within the SC-islets for each sample.
DE between Stage 6 and Grafted SC-islets
We combine datasets for the same hPSC source using canonical correlation analysis (CCA) with
RunMultiCCA (num.ccs = 10). The CCA subspaces are aligned with AlignSubspace.
Unsurpervised tSNE plots were generated for the combined dataset with RunTSNE using 17
dimensions. Clusters were designated specific cell types based on differentially expressed genes
in each cluster compared to all other clusters, identified with FindMarkers. These gene lists can
be found in supplemental table 3. For further analyses, we compare Stage 6 and Grafted SCcells b onl comparing the most enriched INS

cell cluster. Additionall , e do this for SC-

and SC-EC cells. We are able to identify all differentially expressed genes for SC- , SC- , and
SC-EC cells between conditions using FindMarkers with a log fold change threshold of 0.25;
these genes can be found in supplemental table 4. We generate a heat map for the top
differentially expressed genes.
Pathway Enrichment
Genes defining branch points in pseudotime analysis and between sample groups were analyzed
for KEGG and GO pathway enrichment and differential expression of HALLMARK gene sets
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by GSEA (4.0.2). Top enriched genes for the identified pathways and gene sets, with NES scores
above 1.0 or below -1.0 and FDR q-value < 0.25 for either or both of the derived cell line
conditions, were considered in our analysis.
Pseudotime Trajectory with Monocle
Filtered scRNA-seq data containing onl

, , or EC cells from Seurat as transferred for

subsequent pseudotime trajectory analysis using Monocle v 2.12.0 (51). The data was reanalyzed
by clustering the datasets using clusterCells to identify Stage 6 and Grafted populations.
Differentially expressed genes between the two identities were calculated using
differentialGeneTest. We used the top 800, 1000, 1500 genes by lowest q-value to reduce
dimensions using DDRTree method for , , or EC cells, respectively. Cells were ordered using
the orderCells function and pseutdotime was defined by selecting states representative of Stage 6
cells being the initial state. The pseudotime heatmap and gene plots were generated using
plot_pseudotime_heatmap and plot_genes_in_pseudotime, respectively. The top differentially
e pressed genes bet een branches of pseudotime ere defined for , , and EC cell populations.
The list of genes can be found in supplemental table 4.
Comparison to human islets
Next, we compare our Stage 6 and Grafted SC-islets, and specifically SC- and SC- cells, to
primary human islets from cadaveric donors. The human islet data sets come from Xin et al.
2018 (DOI: 10.2337/db18-0365) and can be found at Gene Expression Omnibus database with
accession number GSE114297. We selected three human islet patients for our comparison
analysis. As previously described, 10 data sets (Stage 6 SC-islets (iPSC and ESC), grafted SCislets (iPSC (n=2) and ESC (n=3)), human islet donors (n=3)) were normalized and subspaces
were aligned using CCA to generate unsupervised tSNE plots with resolution of 0.1 and 30
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dimensions. Clusters were designated specific cell types based on differentially expressed genes
in each cluster compared to all other clusters, identified with FindMarkers. These gene lists can
be found in supplemental table 5. The combined tSNE plot is used to specificall compare , ,
and EC cells among samples, by selecting cells containing the INS, GCG, or TPH1 gene
(low.thresholds = c(0.1)). In addition e anal ed MAFA+

cells from ithin the

cell

enriched cluster (MAFA log-normali ed e pression > 0.2). Differential e pression of the ,
MAFA+ , and

cells from each sample (Stage 6, Grafted, Human Islet) ere identified. A heat

map and/or correlation matri

as generated reflecting each sample s e pression of the

differentially expressed genes or transcriptome similarity, respectively. A list of the genes
differentially expressed for a specific cell type, between human islet and Stage 6 or human islet
and Grafted stem cell-derived cells can be found in supplemental table 6. For correlation matrix,
the average expression levels of the most differentially expressed genes were used and generated
by Pearson method using cor. Values for the correlation matrix can be found in supplemental
table 6. Pseudotime trajector construction ith monocle as also used for

and

cells in

combination with human islet data to generate branching trajectories and gene plots in pseudotime.

3.5.11 Real-Time PCR
RNA from human islets and Stage 6 hiPSC- and hESC- cells as e tracted using an RNeas
Mini Kit (Qiagen; 74016) and DNase treatment (Qiagen; 79254). cDNA was synthesized using
the High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems; 4368814) and a
thermocycler (Applied Biosystems; A37028). PowerUp SYBR Green Master Mix (Applied
Biosystems; A25741) generated real-time PCR reactions in a StepOne Plus (Applied
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Bios stems). Data as anal ed ith the

Ct methodolog . TBP and GUSB ere used for

normalization and primer sequences are available in Table 3.5.

Table 3.5 Additional Methods Details: Oligonucleotides
Oligonucleotides
REAGENT or RESOURCE
qPRC-G6PC2-F,R: TGGTATGTCATGGTAACCGC,
CACTCCAAAGAAATGACCAGG
qPRC-TBP-F,R: GCCATAAGGCATCATTGGAC,
AACAACAGCCTGCCACCTTA
qPRC-GUSB-F,R: GCCATAAGGCATCATTGGAC,
AACAACAGCCTGCCACCTTA
qPCR-MAFA-F,R: TTCTCCTTGTACAGGTCCCG,
GAGAGCGAGAAGTGCCAACT
qPCR-ITM2B-F,R: TACAAACTGCAACGCAGAGAA,
AAATGCCGAATTGCGAAACAA
qPRC-IAPP-F,R: ACATGTGGCAGTGTTGCATT,
TCATTGTGCTCTCTGTTGCAT
qPCR-FAM159B-F,R:
CCTACAAGCACAGCTACATGTGGAGC,
GGACACAGACACTGATGACAAAGGCGAG
qPCR-HN1-F,R: ATAGCTCCCGAGTTTTGCGG,
CTTCCTCACAGGTTGTTCTGTT
qPCR-SAT1-F,R: TGCAACCTGGCTTAGATTCTTC,
GACGACCTGTTCCGCTTCAA
*F=Forward Primer
*R=Reverse Primer

SOURCE

IDENTIFIER

This study
Maxwell et al.,
2020
Maxwell et al.,
2020
Hogrebe et al.,
2020

N/A

This study

N/A

This study

N/A

This study

N/A

This study

N/A

This study

N/A

N/A
N/A
N/A

3.5.12 Software
Data was analyzed using Rstudio version 3.6.1 with Seurat version 2.3.4 (49) and Monocle
version 2.12.0 (50, 51).

3.5.13 IAPP Secretion in vitro
To quantify IAPP protein secretion in vitro, the cells were cultured on transwells in a solution of
128 mM NaCl, 5 mM KCl, 2.7 mM CaCl2, 1.2 mM MgSO4, 1 mM Na2HPO4, 1.2 mM
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KH2PO4, 5 mM NaHCO3, 20 mM glucose, 10 mM HEPES (Gibco; 15630-080) and 0.1%
bovine serum albumin (Proliant; 68700) for 1 hr. The solution was collected and IAPP quantified
with the Human Amylin ELISA kit.

3.5.14 Quantification and Statistical Analysis
GraphPad Prism 8.2.1 was used to calculate two-sided unpaired and paired t-tests. P<0.05 was
considered statistically significant. Data is displayed as mean±s.e.m. Sample size, n, represents
total biological replicates. Tests used for individual panels, sample size (n), and statistical
parameters are detailed in figure legends.
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3.7 Supplemental Figures

Figure S3.1. Kidney cell removal from grafted SC-islet datasets. Related to Figure 3.1. (A)
Quantified fraction of cells and (B) representative flow cytometry dot plots expressing or coe pressing pancreatic progenitor (PP) and cell (C-Peptide, NKX6.1) or endocrine (CHGA)
markers for hESC-PP (n=4) and hiPSC-PP (n=4) or Stage 6 hESC-islets (n=4) and hiPSC-islets
(n=4), respectively. n.s., not significant by two-way unpaired t-test. (C) Unsupervised tSNE
projection for individual Grafted SC-islet samples, identifying different cell type clusters. (D)
Feature tSNE plot displaying number of genes (nGene) per cell, represented by individual dots.
(E) Violin plots representing high TTC36 expression in individual clusters for each tSNE
projection in (C). Scale: Log(Normalized read counts). (F) Immunostaining of sectioned Stage 6
and Grafted SC-islets for e ocrine cell markers. Scale bar, 100 m. Error bars represent s.e.m.
See also Table S3.1.
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Figure S3.2. Identification and characterization of hiPSC-islet and hESC-islet cell types.
Related to Figures 3.1 and 3.2. (A) Heat map displaying gene expression profiles of individual
cell types represented in Figures 3.1A and 3.1C for cell type-specific genes (bottom x axis, gene
name; top x axis, cell type-matched to genes). Each row is associated with a cell type (left y axis)
and sample (right y axis). Scale: Normalized Expression (B) Volcano plot displaying fold change
(FC) differences and (C) violin plots of cell genes bet een Stage 6 hiPSC- and hESC- cells.
Scale: Log(Normalized read counts). (D) Volcano plot displaying FC differences and (E) violin
plots of cell genes bet een Grafted hiPSC- and hESC- cells. Scale: Log(Normali ed read
counts). Volcano plot displaying FC differences between Stage 6 and Grafted (F) hESC- and
(G) hiPSC- cells. Dashed lines are dra n to define restriction of log FC value of 0.25 and -log
of adjusted p-value 0.001. Ke
cell genes are labeled and colored red. (H) KEGG and
Reactome GSEA, quantified by the normalized enrichment score (NES), for pathways
upregulated in Stage 6 hESC- (pink) and hiPSC- (ro al blue) compared to Grafted hESC- or
hiPSC- cells, respectivel . NES values and gene lists are available in Table S4. EC,
enterochromaffin. See also Tables S3.2 and S3.3.
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Figure S3.3. Additional pseudo-time characterization of SC- cells. Related to Figure 3.3.
(A) E pression of additional kno n and ne l identified cell maturation genes along pseudotime. Each dot represents a different cell. Scale: Relative Expression.
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Figure S3.4. Cell cluster identification and additional characterization of primary human
islets, Grafted, and Stage 6 SC-islets. Related to Figure 3.4. (A) Heat map displaying gene 9
expression profiles of individual cell types represented in Figure 3.4A for cell type-specific
genes (bottom x axis, gene name; top x axis, cell type associated with specific gene). Each row is
associated with a cell type (left y axis) and sample (right y axis and colored legend). Scale:
Normalized Expression. (B) Normalized e pression values for ke
cell identit , maturation,
functional, and ne l identified genes compared bet een all cell samples. Percentage of cells
positive for designated gene is represented by circle size and saturation indicates low (grey) or
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high (purple) e pression of the gene. (C) Violin Plots of ke
cell identit genes compared
bet een all cell samples. Scale: Log(Normali ed read counts). (D) Pseudo-time trajectory of
Stage 6, Grafted, and Human Islet cells ith branching points. (E) Distribution of cells from
Grafted hESC- (purple), Grafted hiPSC- (pink), Stage 6 hiPSC- (orange), Stage 6 hESC(blue), and Human Islet (red) cells. (F) E pression of select cell genes along SC- cell
pseudo-time. Scale: Relative Expression. (G) Real-time PCR analysis of the total Stage 6 hiPSCislet (n=3; pink), hESC-islet (n=3; blue), and human islet (n=3; green) population measuring
e pression of identified cell genes that change ith maturation. (H) Violin plots of MAFA
expression show individual cells in each condition for the identified cell population from the
tSNE projection in Figure 3.4A. Dotted line represents cut off for cells to be considered
MAFA+ for analysis in the following panel. Stage 6 hESC- and Stage 6 hiPSC- onl had
2.09% and 1.20% MAFA+ cells, respectively, with this threshold. Scale: Log(Normalized read
counts). (I) Violin plot cell genes for MAFA+ cells in panel (H). Scale: Log(Normali ed read
counts). (J) Venn diagram highlighting number of cells identified in Figure 3.2 and Figure 3.4;
and correlation matri (using top 500 variable genes) highlighting similarities bet een cells
identified in Figure 3.2 and Figure 3.4. Error bars represent s.e.m. See also Tables S3.4, S3.5,
and S3.6.
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Figure S3.5. Additional characteri ation of primary human and SC- cells. Related to
Figure 3.5. (A) Volcano plot displa ing fold change (FC) differences of cell genes bet een
Stage 6 (left) and Grafted (right) hiPSC- and hESC- cells. Dashed lines are dra n to define
restriction of log FC value of 0.25 and -log of adjusted p-value 0.001. Ke
cell genes are
labeled and colored red. (B) Violin Plots of ke
cell identit genes compared bet een all cell
samples. Scale: Log(Normalized read counts). (C) Relative e pression of select cell genes
along pseudo-time. Each dot represents a different cell. Scale: Relative Expression. (D) Analysis
of top 100 branch-dependent genes determined based on clusters identified through pseudo-time
analysis of SC- cells, found in Table S4. Scale: Relative Expression. (E) Pseudo-time trajectory
of Stage 6, Grafted, and Human Islet cells ith branching points. (F) Distribution of cells
from Grafted hESC- (purple), Grafted hiPSC- (pink), Stage 6 hiPSC- (orange), Stage 6
hESC- (blue), and Human Islet (red) cells. (G) Relative e pression of select cell genes
along SC- cell pseudo-time. Scale: Relative Expression. See also Tables S3.3, S3.4, and S3.6.
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Figure S3.6. Additional characterization of SC-EC cells. Related to Figure 3.6. (A) Figure
3.4A with each dot representing individual sample. (B) Expression of select EC cell genes along
pseudo-time. Each dot represents a different cell. Scale: Relative Expression. (C) Analysis of 13
top 100 branch-dependent genes determined based on clusters identified through pseudo-time
analysis of SC-EC cells, found in Table S3.4. Scale: Normalized Expression. See also Table
S3.4.
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Chapter 4
Maturation of transplanted stem cell-derived islets
and pancreatic progenitors in mice
4.1 Abstract
Stem cell-derived pancreatic progenitors (SC-PPs) and islets (SC-islets) are both
unlimited cell sources for diabetes replacement therapy. Each cell type differentiates into mature
stem cell-derived

(SC- ) cells when transplanted into mice. To further understand the

functional capabilities and transcriptome of the in vivo matured SC- cells, we transplanted SCPPs and SC-islets into nondiabetic mice for 9 months. The

cells from both grafted cell t pes

displayed enhanced C-peptide secretion at 30 weeks compared to 2-week timepoints following
transplantation, and were able to prevent hyperglycemia after inducing diabetes in mice with
STZ. Three grafts from mice transplanted with each cell type underwent scRNA-seq to analyze
the

cell transcriptome. SC-PP2 grafts had several cysts and overgrowths caused by majority of

cells being proliferative pancreatic exocrine and a small number of SC- cells. SC-islets grafts
contained majority endocrine cell types with the largest population comprised of SC- cells. The
cells derived from each grafted cell t pe had similar gene expression for
however, maturation

cell genes were greater in SC-islet grafted

and islet cell genes,

cells. Differentially

expressed gene signatures were able to distinguish SC-islet (MT1X, MT2A, MT1E) and SC-PP2
(PRSS2, SPINK1, CEL)

cells. Our findings reveal functional and transcriptome differences

between the SC-islet and SC-PP2 transplanted

cells.
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4.2 Introduction
Diabetes is a prevalent disease worldwide caused by the death and dysfunction of insulinproducing, pancreatic beta cells. Standard treatment includes insulin injections for patients with
type 1 diabetes (T1D) and insulin-dependent patients. However, complications may result from
long term exogenous insulin, including increased kidney and cardiovascular risk (1). An and
innovative treatment is islet allotransplantation (2, 3). This treatment remains experimental and
typically only occurs in patients who are unresponsive to standard treatments or undergoing a
pancreas and kidney transplantation. Ongoing clinical trials in Europe and the United States
(NCT03163511) aim to use cell therapy as a standard of care for insulin-dependent patients (4).
Islet transplantation is a novel course of treatment but is limited by the necessity for multiple
donors and patient immunosuppression (2). Stem cell-derived islets (SC-islets) overcome these
disadvantages and present an alternative cell source with great potential as a diabetes cell therapy
(5).
Differentiation of human pluripotent stem cells (SC) into insulin-secreting SC-derived
(SC- ) cells provide an unlimited source of cells to replace the absent cell type in patients with
diabetes (6). Initial differentiation protocols created stem cell-derived pancreatic progenitors
(PPs) with small molecules and growth factors (7, 8); additional stages were then defined to
generate endocrine progenitors and SC- cells which were immature compared to primary
human

cells (9-15). Recent developments have elucidated additional steps needed to create SC-

islets containing the three major islet endocrine cell types
derived (SC- ) cells

SC- , SC-derived

(SC- ), SC-

with dynamic glucose stimulated insulin secretion, similar to primary

human islets (16). Our protocol is robust for multiple SC lines, both induced pluripotent stem
cells (iPSC) and embryonic stem cells (ESCs), enabling autologous cell therapy (16, 17). After
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transplantation in mice, SC- cells are capable of reversing pre-existing diabetes and maturing
both in gene expression and function, revealing a transcriptome with high similarity to primary
human islets (18). Further analysis of the transplanted cell transcriptome curated a gene list to
evaluate

cell maturation (18). The transcriptome of SC- cells derived from SC-PPs

transplanted in mice is unknown.
The use of both SC-islets and SC-PPs are both proposed for use as a diabetes cell
replacement therapy (5). Ongoing clinical trials are testing the utility and safety of SC-PPs in
patients with T1D (NCT03163511) (4). SC-PPs are committed to the pancreatic cell fate and
mature into

cells in vivo (8, 19, 20). SC-islets contain cell fate-committed, functional SC-

cells before transplantation which are known to become ver similar to primar human

cells in

vivo (16, 18). The function and transcriptome of SC- cells derived from SC-PPs compared to
SC-islets transplanted in mice is unknown. Here, we studied SC-islets and SC-PPs transplanted
into mice for 9 months to evaluate functional and transcriptome maturation and ability to prevent
diabetes in mice. These results elucidated the key differences between SC- cells derived from
SC-PPs compared to SC-islets.

4.3 Results
4.3.1 Characterization of Pancreatic Progenitor and Stem Cell-Derived Islets
We differentiated the HUES8 human embryonic stem cell (hESC) line using our six-stage
protocol into stage 4 pancreatic progenitor (SC-PP2) cells and the terminal, stage 6 stem cellderived islets (SC-islets), which contain stem cell-derived

(SC- ) cells (Figures 4.1A, 4.1B)

(15). SC-PP2 cells were designated to the pancreatic lineage (PDX1+) on stage 4 day 1 and can
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differentiate into any pancreatic or islet cell type (Figures 4.1C-4.1E). However, they were not
defined hormone secreting cell types, indicated by the lack of C-Peptide, glucagon, and
somatostatin immunostaining (Figure 4.1C-E, S4.1A). SC-islets contained all major islet
endocrine cell types including insulin-secreting SC- , glucagon-secreting stem cell-derived
(SC- ), and somatostatin-secreting stem cell-derived (SC- ) cells (Figure 4.1C-4.1E, S4.1A).
SC-islets also retained PDX1, a pancreatic marker (75.78 ± 0.21%), but also gained C-peptide
(CP) and NKX6.1. SC- cells were defined by co-positive immunostaining of CP and NKX6.1
(36.18 ± 0.50%). SC-PP2 cells contained a small amount of insulin but were unable to respond to
glucose stimulated insulin secretion (GSIS) (Figure 4.1F). SC-islets were high functioning and
released large quantities of insulin in response to glucose stimulation (Figure 4.1F). Insulin
content was also lower in SC-PP2 cells compared to SC-islets (Figure 4.1G), as expected due to
their progenitor state. Islet and

cell marker expression and function of SC-islets is comparable

to primary human islets (Figure S4.1B-S4.1D).
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Figure 4.1 In vitro characterization of Stage 4 Pancreatic Progenitor (SC-PP2) and Stage 6
Islets (SC-islets) derived from human pluripotent stem cells (hPSCs).
(A) Schematic of differentiation protocol from hPSC to targeted stem cell-derived (SC- ) cell.
(B) Representative of brightfield images of SC-PP2 and SC-islet (SC-I). Scale bar, 250 µm. (C)
Representative immunostained, sectioned SC-PP2 (left) and SC-I (right) clusters for DAPI
(blue), C-peptide (CP, green), and pancreatic marker PDX1 (red, top) or cell marker NKX6-1
(red, bottom). Scale bar, 100 µm. (D) Representative flow cytometry plots dot plots and (E)
quantified fraction of cells expressing or co-expressing PDX1, NKX6-1, and CP positive cells
(n=4 differentiation replicates). (F) Static glucose stimulated insulin secretion (GSIS) of SC-PP2
and SC-islets (n=4 differentiation replicates). *p<0.05 by two-way paired t-test, normalized to
106 cells. (G) Total insulin content of SC-PP2 and SC-islets (n=4 differentiation replicates).
***p<0.001 by two-way unpaired t-test, normalized to 106 cells. Error bars represent SEM.
4.3.2 Transplantation of SC-PP2 cells and SC-islets in mice
We transplanted 3 million SC-PP2 cells, SC-islet cells, or 3,000 IEQ of primary human
islets under the kidney capsule of 10-week-old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
immunodeficient mice from Jackson Laboratories (Figure 4.2A). The SC-PP2 cells and SC-islets
were transplanted as clusters from stage 4 day 1 or stage 6 day 14 of the differentiation. Weight
and random blood glucose measurements were recorded at least every 4 weeks (Figure S4.2A-
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S4.2B). Mouse serum was collected from the mice every 4 weeks, starting at 2 weeks following
transplantation to quantify the human C-peptide secreted by the transplanted cells. Highlighted
time-matched C-peptide levels demonstrate maturation of the stem cell-derived cells (Figure
4.2B). For SC-PP2 transplanted cells, there was an increase in the amount of C-peptide
compared to the initial 2 week measurement starting at 30 weeks (p = 0.0484, 2 weeks, 24.98 ±
24.5, 30 weeks, 472.2 ± 127.3) and more pronounced at 36 weeks (p < 0.0001, 2 weeks, 24.98 ±
24.5, 36 weeks, 879.7 ± 197.2). SC-islets also matured relative to their 2 week C-peptide
measurement starting at 18 weeks (18 weeks, p = .0078, 2 weeks, 344 ± 65.7, 18 weeks, 1250 ±
111.9; 30 weeks, p = .0001, 2 weeks, 344 ± 65.7, 30 weeks, 1663 ± 94.5; 36 weeks, p = .0002, 2
weeks, 344 ± 65.7, 36 weeks, 1605 ± 314.8). At 18 weeks, SC-islets matched levels of human
islet transplant serum C-peptide (p = 0.2588, SC-islet, 1250 ± 111.9, HI, 994.8 ± 179.3). As
expected, human islet transplants maintained serum C-peptide relative to initial transplantation
(p>0.29, 2 weeks, 1205 ± 176.8, 18 weeks, 994.8 ± 179.3, 30 weeks, 2184 ± 694.3, 36 weeks,
2112 ± 425.6). We observed large variation for the human islet transplants at later time points,
which is commonly seen due to heterogeneity of donor human islets. There remained a
difference in serum C-peptide between SC-PP2 and SC-islet transplants for 30 weeks post
transplantation (2 weeks, p = 0.0006, SC-PP2, 24.98 ± 24.5, SC-islet, 344 ± 65.7; 18 weeks, p
<0.0001, SC-PP2, 259.4 ± 60.6, SC-islet, 1250 ± 111.9; 30 weeks, p <0.0001, SC-PP2, 472.2 ±
127.3, SC-islet, 1663 ± 94.5) and SC-PP2 cell transplants were not able to reach human Cpeptide levels similar to human islet transplants (36 weeks, p=0.0184, SC-PP2, 879.7 ± 197.2,
HI, 2112 ± 425.6).
We rendered the mice diabetic by injecting 3 mice from each transplantation condition
with low dose streptozotocin (STZ) for 5 consecutive da s. STZ killed the mouse
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cells,

targeting the GLUT2 receptor, leaving only human SC- cells or primary human islets to secrete
insulin and maintain mouse blood glucose. Depletion of mouse

cells was confirmed b

measuring total C-peptide content of the mouse pancreas after sacrifice (Figure S4.2C). Serum
C-peptide remained different for the SC-PP2 and SC-islet transplants (p = 0.0327, SC-PP2 613.6
± 278, SC-islet 1732 ± 211) following diabetes induction (Fig 4.2C). The human islets following
STZ treatment had varying effects, causing a mouse with low levels of human C-peptide before
STZ to become undetectable following diabetes induction (Figure 4.2C). We have observed this
variable function in human islets in previous cohorts (16, 17). Blood glucose remained
euglycemic for all stem cell derivative transplanted mice and HI mice had two that remained
euglycemic and one which became hyperglycemic (Figure 4.2D). Islet amylin polypeptide
(IAPP) is secreted b

cells and increases with maturation of SC- cells in vivo (18). Following

STZ treatment we measured IAPP for the SC-PP2 and SC-islet transplants (Figure 4.2E).
We evaluated function of the transplants throughout in vivo maturation. After a 4 hour
fast, we injected the mice with 2 mg/kg of glucose to determine the function of transplanted cells
through in vivo GSIS. At 16 and 36 weeks, we measured serum C-peptide in response to glucose
stimulation for each transplant condition (Figure 4.2F). The transplanted SC-islets increased
GSIS capacity at 36 weeks compared to 16 weeks (p = 0.0028; 16 weeks, 774.9 ± 116.6 pM, 36
weeks, 1856 ± 286.8 pM). No increase was observed for the SC-PP2 cell nor HI transplants.
Furthermore, the GSIS capacity for transplanted SC-islets increased following STZ (p = 0.0179;
36 weeks, 1856 ± 286.8 pM, 44 weeks/Post-STZ, 3504 ± 536 pM), which was not observed for
other groups. After the mice were rendered diabetic, the SC-islets demonstrated greater Cpeptide secretion after glucose stimulation compared to SC-PP2 cell transplants (p = 0.0123; SCPP2, 1009 ± 278 pM, SC-islet, 3504 ± 211 pM). Proinsulin to insulin ratio was quantified
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following transplantation at 18 weeks; mice with SC-PP2 transplants not yet secreting insulin
were removed from analysis (Figure 2G). The ratio was similar for all transplant conditions (p =
0.2502).
Mice were sacrificed at 38 weeks to remove the transplanted kidney and determine
composition and maturation of the sectioned grafts. Representative images of the explanted
kidneys revealed large overgrowths in the SC-PP2 transplants, found in all 7 sacrificed SC-PP2
transplanted mice. The SC-islet transplanted mice did not contain any overgrowths or cyst
formation, as observed in previous cohorts (21)(21)from our group (Figure S4.2D) (15-18).
Representative images of SC-PP2 transplants displayed few C-peptide+ SC- cells, whereas SCislet transplanted kidneys were composed of majority C-peptide+ SC- cells. Glucagon+ SCand somatostatin+ SC- cells were also found in transplanted kidneys. SC- cells populated the
majority of the SC-PP2 kidney. PDX1+ cells remained the majority composition of the
transplants, as seen in the in vitro immunostaining for SC-PP2 and SC-islet clusters (Figures
4.1C-4.1E, 4.2H). NKX6.1, a

cell marker, is co-expressed with C-peptide+ cells in both grafts.

Stem cell-derived enterochromaffin (SC-EC) cells are a common off target generated in SC-islet
differentiations (18, 22), identified by TPH1. We found TPH1+ SC-EC cells in the SC-PP2 and
SC-islet transplants, indicating the fate of SC-EC cells is defined prior to stage 4 of the
differentiation protocol and PP2 designation. SC-EC cells are not found in primary human islets
(18, 22). In summary, SC- cells were found in both SC-PP2 and SC-islet grafts and maintained
a nondiabetic state after diabetes induction. However, SC- cells in SC-PP2 transplanted mice
had lower functional capabilities and made up a small proportion of cells within the SC-PP2
grafts which contain overgrowths and cysts.
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Figure 4.2 Assessment of transplanted human islets (HI), SC-PP2, or SC-islets in mice.
(A) Schematic of mouse transplantation of three cell types. (B) Human C-peptide measurements
from mouse serum of transplanted SC-PP2 (green), SC-islet (purple), and HI (gray) cells at
multiple time points (n=6-8). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n.s., not
significant, comparing 2 weeks to later weeks for each transplant condition by one-way ANOVA
with Tuke s multiple comparisons test. Comparing time-matched C-peptide measurements
between SC-PP2 and SC-islet transplants by two-way unpaired t-test, a, p<0.001, b, p<0.0001.
(C) Human C-peptide measurements of transplanted SC-PP2, SC-islets, and human islets before
(pre) and after (post) STZ treatment (n=3). *p<0.05. (D) Random blood glucose measurements
before and after STZ treatment of mice transplanted with SC-PP2, SC-islets, and human islets.
(E) Amylin (IAPP) measured from mouse serum with SC-PP2, SC-islets, and human islets
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transplants. (F) In vivo GSIS of mice transplanted with SC-PP2, SC-islets, and human islets at 16
(left) and 36 (middle) weeks post transplantation and after STZ (right) treatment (n=3-8).
*p<0.05 by two-way unpaired t-test. Comparing time point between SC-PP2 and SC-islet
transplants by two-way unpaired t-test for C-peptide secretion after glucose stimulation, a,
p<0.001, b, p<0.0001. (G) Proinsulin to insulin ratio for mice transplanted with SC-PP2, SCislets, and human islets at 18 weeks post transplantation. SC-PP2 mice with no insulin detected
were removed from analysis. n.s. not significant by one-wa ANOVA with Tuke s multiple
comparisons test. (H) Representative images of sectioned grafts from SC-PP2 (top) and SC-islet
(bottom) for DAPI (blue), C-peptide (green), and islet (GCG, glucagon, SST, somatostatin),
pancreatic (PDX1), (NKX6-1), and off target endocrine (TPH1) cell markers. Scale bar, 100
µm. Error bars represent SEM.
4.3.3 Transcriptome analysis of transplanted SC-PP2 and SC-islet grafts
We performed single cell RNA sequencing of the kidney capsule transplants after 36
weeks in vivo to further analyze the grafted cells (Figure 3A). In total, we sequenced 3 mice
from each stem cell-derived transplant totaling to 38,949 cells, of which 15,550 were from SCPP2 transplants and 23,399 were from SC-islet transplants (Table 4.1). Residual mouse cells
were removed from the analysis by aligning the sequenced cells to the human genome and
establishing a threshold for the number of human genes found in individual cells. In addition,
cells with a relative gene expression greater than 0.2 for TTC36, a mouse and human kidney
gene, were removed from further analysis.
SC-PP2 and SC-islet transplanted cells were defined based on top upregulated
differentially expressed genes in each cluster compared to all others (Figures S4.3A, S4.3B,
Tables S4.1, S4.2). The SC-PP2 cells had numerous off targets, indicated by overgrowths in
representative kidney images, and confirmed by single cell analysis of transplanted cells (Figures
4.3B, S4.2D, S4.3B). All human mapped cells were from the posterior foregut lineage including
pancreatic endocrine

cells, pancreatic exocrine acinar and duct, pancreatic mesenchyme and

epithelial, as well as esophagus and duodenum cells. For SC-islet transplanted cells, we
identified endocrine cell t pes , , and EC cells, as well as pancreatic exocrine duct. Residual
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mouse cells were found in both populations and excluded from further analysis. SC-islets had a
greater proportion of INS+

cells within their explanted grafts compared to SC-PP2 cells

(Figures 4.3C-4.3E, S4.3C, Table 4.2). Additionally, SC-islets resulted in a greater fraction of
endocrine cells (Figure 4.3C, S4.3C). Whereas, the SC-PP2 grafts had a greater percentage of
exocrine and pancreatic cell types (Figure 4.3C, 4.3E). This difference in pancreatic cell
proportions was largely due to SC-EC cells making up 14% of the SC-islet grafts, a cell type not
found within the human pancreas. An additional mouse was sacrificed at the time of sequencing
for immunostaining the graft and confirming sequencing results. The grafts revealed majority of
cells staining positive for pancreatic marker, PDX1, which is co-expressed in all C-peptide+ cells
(Figure 4.3E). There were very few C-peptide+NKX6-1+ cells in the SC-PP2 graft, matching the
low proportion found in the sequencing analysis. Overall, there are many proliferative off targets
generated from the SC-PP2 transplanted cells that are not present in the SC-islet transplanted
cells, yet all remain within the posterior foregut lineage.
Table 4.1 Sequencing details of transplanted mice.
Estimated Number of
Cells
Mean Reads per Cells
Median Genes per Cell
Number of Reads
Total Genes Detected
Chemistry
Transcriptome

Estimated Number of
Cells
Mean Reads per Cells
Median Genes per Cell
Number of Reads

PP2 MS 1
3434

PP2 MS 2
4479

PP2 MS 3
7637

166332
1018
571184671
24768
Single Cell 3'
v3
GRCh382020-A
St6 MS 1
11051

94780
1733
424517911
26232
Single Cell 3'
v3
GRCh382020-A
St6 MS 2
5975

61401
1896
468920718
27033
Single Cell 3'
v3
GRCh382020-A
St6 MS 3
6373

51855
568
573050403

65774
513
392998911

73683
465
469580819
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Total Genes Detected
Chemistry
Transcriptome

Estimated Number of
Cells
Mean Reads per Cells
Median Genes per Cell
Number of Reads
Total Genes Detected

23943
Single Cell 3'
v3
GRCh382020-A
Total
38949

20758
Single Cell 3'
v3
GRCh382020-A

17329
Single Cell 3'
v3
GRCh382020-A

85637.5
793
2900253433
140063

Table 4.2 Number and proportion of cells for each SC-islet and SC-PP2 grafts.
Cell Type
BETA
EC
ALPHA
DUCT
MOUSE
UNKNOWN

SC-islet
Number
Proportion of
of Cells
Cells
1451
43.6%
466
14.0%
272
8.2%
173
5.2%
262
7.9%
707
21.2%

Total 3331

Cell Type
DUCT
MESENCHYME
ACINAR
EPITHELIAL
MOUSE
UNKNOWN
BETA
DUODENUM
ESOPHAGUS
Total

143

SC-PP2
Number
Proportion of
of Cells
Cells
4723
40.6%
2696
23.2%
1306
11.2%
1178
10.1%
757
6.5%
547
4.7%
221
1.9%
109
0.9%
106
0.9%
11643

Figure 4.3 Transcriptome analysis of transplanted SC-PP2 and SC-islets.
(A) Schematic of workflow to sequence transplanted cells after 9 months of in vivo maturation in
the mouse kidney capsule. (B) Individual unsupervised UMAP projections of the transplanted
SC-PP2 (left) and SC-islet (right) transplanted cells with listed populations sequenced from graft.
EC, enterochromaffin. (C) Pie charts representing proportion of , endocrine, exocrine, and
pancreatic cell t pes present in the grafted cells. Endocrine includes , , and EC cells; exocrine
includes duct and acinar; pancreas includes , , mesench me, epithelial, and duct and acinar
cells. (D) Heatmap of INS gene expression to identif the cell population in both the SC-PP2
and SC-islet grafts. (E) Immunostaining of 9-month kidne grafts identif ing cell (NKX6-1,
CP) and pancreatic (PDX1) markers. CP, C-Peptide. Scale bar, 100µm.
4.4.4 Comparison of SC- cell fo nd in SC-PP2 and SC-islet transplanted grafts
Clusters defining SC- cells from the two graft conditions were projected in a separate
unsupervised UMAP, detailing the large difference in number of
(Figures 4.4A, 4.4B). Ke

cells from the graft conditions

cell maturation and defining genes were compared between the SC-

cell populations revealing higher insulin (INS) transcript, G6PC2, and MAFA in the SC-islet
compared to SC-PP2

cells (Figures 4.4C, 4.4D, S4.4A, Table S4.4). Additional recently
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identified

cell maturation markers (ASB9, MT1X, NAA20, SAT1) are also higher in SC-islet

cells (Figures 4.4C-4.4E). Furthermore, there are 100 differentially expressed genes between the
two t pes of

cells (Figure 4.4D). A

cell maturation gene list was recentl identified, and we

evaluated all genes within the list for our in vivo matured

cells (Figure 4.4E). SC-PP2

cells

have greater CHGA and lower IGFBP7, PPP1R1A, and HOPX which are common signatures of
immature

cells, typically seen with in vitro-derived SC- cells (18) (Figures 4.4D, 4.44E).

Of importance, the metallothionein (MT) genes (MT1X, MT2A, MT1G, MT1E, MNX1)
were upregulated in the

cells for all SC-islet transplants compared to SC-PP2 cell transplants

(Table S4.4, Figure 4.4D). MT genes have protective properties against DNA damage and
manage redox state, specifically in response to reactive oxygen species (ROS) in pancreatic
cells (23). SPINK1, PRSS2, and CEL are all genes associated with pancreatic exocrine but found
highly upregulated in a large proportion (>70%) of the grafted SC-PP2
islet

cells compared to SC-

cells (Table S4.4, Figure 4.4D).
Next, we performed GSEA on the top 430 differentially expressed genes found in

primar human islet donor
islet

cells compared to in vitro SC- cells (18) (Table S4.3). Grafted SC-

cells had greater similarit to primar

cells, compared to SC-PP2

cells (p = 0.0029,

NES = 1.458) (Figure 4.4F). Furthermore, we analyzed the global transcriptome profiles of the
cells when comparing the top 430 differentially expressed genes. Overall the SC-islet

cells

appear more similar to primary donor islets based on the analyzed gene set compared to the SCPP2

cells, which have low expression (blue) for many targets within the gene set (Figure

4.4G). To summarize, the differences in function of transplanted

cells from different progenitor

types is also seen within the transcriptome. MT genes and exocrine markers are defining genes
that differentiate SC-islet and SC-PP2 grafted

cells, respectivel .
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Figure 4.4 Comparison of SC-PP2 and SC-i le an lan ed cell an c i ome .
(A) Unsupervised UMAP projection of all SC- cells from both SC-PP2 and SC-islet grafts.
(B)Fraction bar representation of graft proportion in total SC- cell population. Details in Table
4.2. (C) Violin plots of ke
cell markers compared between grafted SC- cells. Scale:
Log(Normalized read counts). (D) Volcano plot displaying FC differences of cell genes
between SC-islet (left) and SC-PP2 (right) grafted SC- cells. Dashed lines define restrictions of
log FC value 0.5 and -log of adjusted p value 0.05. Ke
cell genes are labeled and colored in
red. Full list of differentially expressed genes in Table S4.4. (E) Heatmap of SC-islet and SCPP2 grafted cells for defined list of mature cell genes (18). Scale: normalized expression. List
of genes labeled on heat map. (F) GSEA Enrichment plot with NES and p value for the 430 most
differentially expressed genes between in vitro and primary human islets as defined by
Augsornworawat et al., 2020. List of genes detailed in Table S4.3. (G) Normalized gene
expression values for SC- cells from SC-PP2 and SC-islet grafts for the defined list of mature
cell genes (18). (H) Hallmark (left), KEGG, and Gene Ontology (GO) (right) GSEA, quantified
by normalized enrichment score (NES), for pathways upregulated in the SC- cells compared
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between the SC-PP2 and SC-islet grafts. NES, p values, and pathway details provided in Table
4.3.
4.4.5 Diffe en ial a h a anal i and cell la me aboli m anal i of g af ed
To further investigate differences between the

cell

cells, we used GSEA of established

Hallmark, KEGG, and Gene Ontology (GO) pathways (Figure 4H, Table 4.3). We found T2DM,
T1DM, and negative cellular response to insulin stimulus Hallmark gene sets upregulated in the
SC-PP2

cells, while pancreas development, insulin signaling, and calcium and TGF were

upregulated in the SC-islet
known to be critical for

cells (Figure 4.4H, Table 4.3). Calcium and TGF signaling are

cell function. KEGG and GO GSEA revealed upregulation of IFN and

IFN responses in SC-PP2

cells, commonl affiliated with inflammation. SC-islet

upregulated protein secretion, pancreatic

cells have

cells, and NFkB and TNF signaling gene sets.

In addition, we focused on cellular metabolism of the grafted

cells and detected

upregulation of several KEGG and HALLMARK gene sets related to mitochondrial metabolism,
glycolysis, and oxidative phosphorylation (Figure 4.5A, Table 4.3). We quantify relative gene
expression of genes specifically related to metabolic function (G6PC2, PKM, ATP2A3,
ATP5PO), Golgi apparatus stress (ATF3, ARF4, CREB3, COG6), and oxidative stress (TXNiP,
BiP, MAF) (Figure 4.5B). Grafted SC-islet

cells have upregulated G6PC2, PKM, ATP5PO,

and MAF indicating a higher degree of cellular metabolism. Alternatively, SC-PP2

cells have

upregulated TXNiP associated with oxidative stress. The Golgi apparatus stress markers were
similar amongst all

cells.

As a follow up, we evaluated the oxygen consumption rate (OCR) SC-PP2 cells and SCislets before transplantation, as mitochondria are critical for glucose sensing. As expected, based
on GSIS results, SC-PP2 cells did not increase OCR in response to glucose stimulation but
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shifted OCR in response to other mitochondrial agitators including oligomycin, FCCP, antimycin
A, and rotenone (Figure 4.5C). SC-islets increased OCR in response to glucose stimulation and
responded to mitochondria chemical interrogation (Figure 4.5C). The baseline OCR was higher
in SC-islets compared to SC-PP2 cells (Figure 4.5D). Furthermore, we quantified the free fatty
acids within mouse serum, which increased in the human islet transplanted mice compared to the
stem cell derivative transplants, similar to that of no transplant controls (Figure S4.5A). To
conclude, GSEA reveals upregulation of ke pathwa s and gene sets related to
and overall cellular metabolism in the SC-islet

cell function

cells.

Figure 4.5 Oxidative metabolism of SC-PP2 cells and SC-islets.
(A) Hallmark and KEGG GSEA pathway analysis upregulated in the SC- cells compared
between the SC-PP2 and SC-islet grafts, quantified by normalized enrichment score (NES).
NES, p values, and pathway details provided in Table 4.3. (B) Violin plots of key metabolic
function (G6PC2, PKM, ATP2A3, ATP5PO), golgi apparatus stress (ATF3, ARF4, CREB3,
COG6), and oxidative stress (TXNiP, BiP, MAF) markers compared between SC-PP2 and SCislet grafted SC- cells. Scale: Log(Normalized read counts). (C) Mitochondrial respiration of
SC-PP2 cells and SC-islets (n= 4) presented as oxygen consumption rate measurements
normalized to µg of DNA. Respiration was perturbed by changing OCR response to 20mM
glucose (Gl), oligomycin (OM), FCCP, Antimycin A (AA), and rotenone (R). (D) Quantification
of baseline oxygen consumption rate quantified as area under the curve in basal conditions for
SC-PP2 (green, n =4) and SC-islet (purple, n =4) clusters. ****p<0.0001 by two-way unpaired ttest.
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Table 4.3 Details on GSEA analysis.
Reference in
Figure
IFN Response

GSEA Name

SIZE

HALLMARK_INTERFE
RON_GAMMA_RESPO
NSE
IFN Response
HALLMARK_INTERFE
RON_ALPHA_RESPON
SE
Pancreatic
HALLMARK_PANCRE
Cells
AS_BETA_CELLS
NFkB TNF
HALLMARK_TNFA_SI
Signaling
GNALING_VIA_NFKB
Protein
HALLMARK_PROTEIN
Secretion
_SECRETION
Glycolysis
HALLMARK_GLYCOL
YSIS
Ox Phos
HALLMARK_OXIDATI
VE_PHOSPHORYLATI
ON
Ox Phos
KEGG_OXIDATIVE_P
HOSPHORYLATION
Glycolysis
KEGG_GLYCOLYSIS_
Gluconeogenesis GLUCONEOGENESIS
Galactose
KEGG_GALACTOSE_
Metabolism
METABOLISM
TGF Signaling KEGG_TGF_BETA_SIG
NALING_PATHWAY
Insulin Signaling KEGG_INSULIN_SIGN
ALING_PATHWAY
Calcium
KEGG_CALCIUM_SIG
Signaling
NALING_PATHWAY
T2DM
KEGG_TYPE_II_DIAB
ETES_MELLITUS
T1DM
KEGG_TYPE_I_DIABE
TES_MELLITUS
Pancreas
GO_PANCREAS_DEVE
Development
LOPMENT
Neg Cell
GO_NEGATIVE_REGU
Response to
LATION_OF_CELLUL
Insulin Stimulus AR_RESPONSE_TO_IN
SULIN_STIMULUS
Fatty Acid
KEGG_FATTY_ACID_
Metabolism
METABOLISM
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ES

NES

199

-0.377

NOM FDR FWER
p-val q-val p-val
-1.198 0.086 0.135
0.676

97

-0.464

-1.379

0.020

0.055

0.293

40

0.472

1.186

0.208

0.134

0.760

200

0.478

1.312

0.076

0.060

0.453

96

0.495

1.368

0.047

0.039

0.321

200

0.521

1.571

0.000

0.003

0.041

200

0.754

1.940

0.000

0.000

0.000

129

0.808

1.992

0.000

0.000

0.000

62

0.705

1.877

0.000

0.000

0.000

26

0.620

1.484

0.018

0.032

0.582

85

0.520

1.473

0.004

0.034

0.616

137

0.489

1.411

0.011

0.052

0.785

177

0.425

1.361

0.028

0.074

0.876

47

-0.276

-0.765

0.966

0.908

1.000

41

-0.414

-0.934

0.540

0.780

1.000

79

0.404

1.140

0.205

0.260

1.000

32

-0.385

-1.021

0.400

0.888

1.000

42

0.707

1.790

0.000

0.001

0.004

4.4 Discussion
Here, we identify differences in the

cells generated from SC-PP2 cells and SC-islets

after 9 months of in vivo maturation in mice. Mice transplanted with SC-PP2 cells had detectable
human C-peptide in the mouse serum starting 18 weeks after transplantation. SC-islet
transplanted mice displayed a large increase in human serum C-peptide, matching that of mice
transplanted with human islets after 18 weeks in vivo. C-peptide values continue to rise until
leveling out at 36 weeks when grafts of three mice from each stem cell derivative transplant
condition were dissociated and sequenced to analyze the single cell transcriptomes. Images of the
SC-PP2 transplants and transcriptome cell type designation revealed proliferative pancreatic
exocrine and posterior foregut-derived off targets, yielding cysts and overgrowths on the mouse
kidney. SC-islet cells consisted of majority endocrine and a small portion of pancreatic exocrine
cell types. Gene expression of SC- cells from each graft condition were compared and show
distinct genes that distinguish the SC-islet and SC-PP2

cells including MT and acinar markers,

respectively.
Diabetes cell therapy from either SC-PP2 or SC-islets has immense advantages to current
therapeutics. Clinical trials are currently ongoing with SC-PP2 cells and proposed for 2021 with
SC-islets (4). There is little known about the differences in

cells derived from SC-PP2 and SC-

islets which mature in vivo, other than findings from histology and in vivo function assessments
(19, 20). Now, we detail differences in the transcriptome of these

cells and provide a resource

of transcriptome information for all cell types identified within the SC-PP2 and SC-islet grafts.
This will be critical to determine if there is a superior cell type and whether the existing
differences influence the therapeutic potential for patients.
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We identified genes specific to each t pe of grafted

cells including MT genes

upregulated in SC-islet transplants and acinar markers in SC-PP2 transplants. MT genes are
involved in Zn2+ homeostasis, a metal released during insulin exocytosis, and is of great
importance to regulate cytosolic Zn2+ levels (24). The MT genes have posed a protective role in
diabetes, increased oxidative defense for pancreatic

cells, and protection against oxidative

damage (23, 24). The SC-PP2 cells generate majority pancreatic exocrine cells which are highly
proliferative (MKi67, TOP2A) and also ield

cells with elevated levels of acinar markers

(SPINK1, PRSS2, CEL) (25). The CEL, carboxyl ester lipase, gene is associated with maturity
onset diabetes of the young when mutations in CEL cause exocrine pancreas dysfunction (26).
Pancreatic exocrine markers in

cells was previously observed from groups transdifferentiating

pancreatic exocrine into -like cells (27-29).
In relation to cellular metabolism, oxidative phosphorylation gene sets are upregulated in
the grafted SC-islet

cells compared to SC-PP2

cells. When evaluating specific golgi stress

signature genes they are not differentially expressed between the two t pes of

cells. OCR is

predictive of successful alloislet transplantation in patients with diabetes (30). Typically,
function, islet equivalents per patient weight, and OCR capabilities are considered when
transplanting islets into patients. Out of these parameters, OCR is the best indicator of a patient
to become insulin independent following transplantation (30). SC-PP2 cells have low OCR
compared to SC-islets before transplantation, which may be problematic if clinics want to use
OCR to predetermine patient outcome success.
In conclusion, we utilize the differentiation of stem cells into early-state SC-PPs and
terminal-fate SC-islets, containing high-functioning SC- cells, to study

cells in vivo. We

compare functional differences of the grafts and demonstrate both cell types are capable of
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preventing diabetes in mice. The transcriptomes of the grafted SC-islet and SC-PP2
with distinct gene signatures, although majorit of

cells differ

and islet cell genes remain similarly

expressed. This study will be influential in determining if there is a superior cell type for diabetes
cell replacement therapy.

4.5 Methods and Materials
4.5.1 Animal models
Male, 8 wk old, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (Jackson Laboratories; stock no.
005557) were used in this study. Animals were randomly assigned to transplanted groups. All
animal studies performed in this research were in accordance with Washington University
International Care and Use Committee (IACUC) regulations.

4.5.2 Human cell lines
The human ESC line (HUES8, male) was used in this study and authenticated with a normal
karyotype. The stem cells were cultured in mTeSR1 (StemCell Technologies; 05850) in a 5%
CO2 incubator at 37 C (6). A Vi-Cell XR (Beckman Coulter) counted viable single cells and we
seeded 0.6x105 cells/mL mTeSR1 with 10µM Y27532 (Abcam; ab120129) in spinner flasks
(REPROCELL; ABBWVS03A) on a rotator stir plate (CHEMGLASS) at 60 RPM for
propagation. Cells were single cell dispersed with TrypLE (Life Technologies; 12-604-039) and
passaged every 3-4 days. All work for this study was performed in accordance with the
Embryonic Stem Cell Research Oversight (ESCRO) committee through Washington University
in St. Louis.
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4.5.3 Primary cell culture
Cadaveric human islets were purchased from Prodo Labs and cultured in 6 well plates (Corning;
3512) on an Orbi-Shaker (Benchmark) at 100 RPM in islet media (CMRL Supplemented
(Mediatech; 99-603-CV) with 10% Fetal Bovine Serum (GE Healthcare; SH3007003)). Media
was refreshed every other day.

4.5.4 Stem cell-derived islet differentiation
The differentiation is based on our previous publication (15). Undifferentiated hPSCs were
single cell dispersed, counted, and seeded into spinner flasks mTeSR1 and 10µM Y27532 at
6x105 cells/mL. After 24 hours, differentiation began using added factors and base medias. The
differentiation protocol including base media formulation and differentiation factors are available
in Tables 4.4 - 4.6. On stage 6 day 1, cells were dispersed with TrypLE and seeded ~5x106 cells
into individual wells of a 6-well plate with 4 mL of ESFM media, replenished every other day,
on an OrbiShaker (Benchmark) at 100 RPM. Cells were used for transplantation either stage 4
day 1 for pancreatic progenitors or stage 6 day 14 for SC-islet transplants.

153

Table 4.4 Differentiation and feeding schedule
Day
Stage 0 1
2
3

Media
Factor
mTeSR1 Y27632
mTeSR1
-

Final Concentration
10 M

Day
Stage 1 4

Media
S1

Stage 1 5
Stage 1 6

S1
-

Factor
Activin A
CHIR99021
Activin A
-

Final Concentration
100 ng/mL
3 M
100 ng/mL
-

Day
Stage 2 7
8
9

Media
S2
S2
-

Factor
KGF
KGF
-

Final Concentration
50 ng/mL
50 ng/mL
-

Day
Stage 3 10

Media
S3

Factor
LDN193189
KGF
SANT1
RA
PDBu
Y27632

Final Concentration
200 nM
50 ng/mL
0.25 M
2 M
500 nM
10 M

Day
Stage 4 11

Media
S3

Factor
KGF
SANT1
RA
Y27632
Activin A
KGF
SANT1
RA
Y27632
Activin A
KGF
SANT1
RA
Y27632
Activin A
-

Final Concentration
50 ng/mL
0.25 M
0.1 M
10 M
10 ng/mL
50 ng/mL
0.25 M
0.1 M
10 M
10 ng/mL
50 ng/mL
0.25 M
0.1 M
10 M
10 ng/mL
-

Factor
SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin
-

Final Concentration
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
0.25 M
0.1 M
1 M
10 M
1 M
20 ng/mL
-

12

S3

13
14

S3

15

-

Day
Stage 5 16

Stage 6

Media
S5

17

S5

18
19

S5

20
21

S5

22

-

Feed S6 every other day
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Table 4.5 Media formulation details
Company
Cellgro
MilliporeSigma
MilliporeSigma
Proliant
Invitrogen
Invitrogen
MilliporeSigma

Catalog #
15-100-CV
G7528
S3817
68700
51500056
35050079
A4544

5 mg
5 mL

S6
500 mL
0.23 g
N/A
10.5 g
N/A
5.2 mL
N/A
10
µg/mL
5.2 mL

MilliporeSigma

H3149

Cellgro

30-002-CI

N/A

N/A

5.2 mL

25-025-CI

N/A

N/A

N/A

1 µM

Corning
MilliporeSigma

N/A

N/A

N/A

N/A

523 µL

Corning

25-021-CI

N/A

N/A

N/A

N/A

523 µL

Corning

25-022-CI

Reagent
MCDB131
Glucose
NaHCO3
FAF-BSA
ITS-X
Glutamax
Vitamin C

S1
500 mL
0.22 g
1.23 g
10 g
10 µL
5 mL
22 mg

S2
500 mL
0.22 g
0.615 g
10 g
10 µL
5 mL
22 mg

S3
500 mL
0.22 g
0.615 g
10 g
2.5 mL
5 mL
22 mg

S5
500 mL
1.8 g
0.877 g
10 g
2.5 mL
5 mL
22 mg

Heparin
Pen/Strep
NonEssential
Amino
Acids

N/A
5 mL

N/A
5 mL

N/A
5 mL

N/A

N/A

ZnSO4
Trace
Elements A
Trace
Elements B

N/A
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Table 4.6 Differentiation factor details
Compound
Activin A
CHIR99021
KGF
LDN193189
Retinoic Acid
SANT1
Y27632
Alk5 inhibitor type II
Betacellulin
T3
XXI
PDBu

Company
R&D Systems
Stemgent
Peprotech
Reprocell
MilliporeSigma
MilliporeSigma
Abcam
Enzo Life Sciences
R&D Systems
Biosciences
MilliporeSigma
MilliporeSigma
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Part #
338-AC
04-0004-10
AF-100-19
40074
R2625
S4572
ab120129
ALX-270-445-M005
261-CE-050
64245
595790
524390

4.5.5 Mouse Transplants
All animal studies performed in this research were in accordance with Washington University
International Care and Use Committee (IACUC) regulations. Surgery and assessments were
performed by unblinded individuals and mice were randomly assigned to experimental groups.
The mice were male, 8 wk old, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (Jackson
Laboratories; stock no. 005557). XX weeks post transplantation of cells, the mice were treated
with 45 mg/kg streptozotocin (STZ; R&D; 1621500) in 0.9% sterile saline (Moltox; 51405022.052) for 5 consecutive days. Mice were diabetic (blood glucose >500 mg/dL) 8 days
after the final STZ injection, confirmed by acid ethanol extraction for insulin content of mouse
pancreas, quantified by mouse C-Peptide ELISA (Mercodia; 10-1146-01).
For SC-islet transplantation, mice were anesthetized with isoflurane and injected with either
~3x106 SC-islet (n=7) or pancreatic progenitor cells (n=7) under the kidney capsule. Mice were
monitored for 9 months after transplantation before removal of the transplanted kidney for
submission of kidneys for histology and scRNA-sequencing. For in vivo glucose stimulated cpeptide secretion and glucose tolerance tests (GTT), mice were fasted for 4 hr and injected with
glucose, 2 g/kg body weight. For GTT, every 30 min from 0 to 120 min blood glucose was
measured with a Contour Blood Glucose Monitoring System (Bayer; 9545C). For in vivo
glucose stimulated c-peptide secretion, serum was collected before and 1 hr after glucose
stimulation. Hormones were quantified by collecting serum and measuring C-peptide and IAPP
with the Human Ultrasensitive C-Peptide ELISA kit (Mercodia; 10-1141-01) and Human
Amylin ELISA kit (Miltenyi; EZHA-52K), respectively.
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4.5.6 Immunostaining
PP2 (Stage 4) clusters, Stage 6 clusters, and excised transplant kidneys (PP2, Stage 6, HI) were
fixed overnight in 4% paraformaldehyde (PFA) (Electron Microscopy Science; 15714) at 4 C.
Fixed clusters were suspended in histogel (Thermo Scientific; hg-4000-012) and fixed kidneys
were sliced down the center of the visible cell transplant under the kidney capsule. The samples
were further processed by the Division of Comparative Medicine (DCM) Research Animal
Diagnostic Laboratory Core at Washington University. For all samples, Histoclear (Electron
Microscopy Sicences; 64111-04) removed the paraffin coating on the sectioned slides.
Rehydration and antigens retrieval was performed with a pressure cooker (Proteogenix; 2100
Retriever) with 0.05 M EDTA (Ambion; AM9261). Slides were blocked with immunostaining
solution (PBS (Fisher; MT21040CV) with 0.1% Triton X (Acros Organics; 327371000) and 5%
donkey serum (Jackson Immunoresearch; 017000-121)) for 45 min RT and stained with primary
antibodies diluted immunostaining solution overnight at 4 C. Next, diluted secondary antibodies
stained the slides for 2 hr at room temperature followed by and DAPI (SouthernBiotech; 010020). The immunostained cells and grafts were imaged with a Leica DMI4000 fluorescence
microscope.
Similarly, for Flow Cytometry, cells were single cell dispersed with TrypLE and fixed for 30
min RT with 4% PFA. Cells were washed with PBS and blocked with immunostaining solution
for 45 min RT and stained with diluted primar antibodies overnight in 4 C. Cells were washed
with immunostaining solution and resuspended in diluted secondar antibodies for 2 hr at 4 C
and analyzed on BD LSR Fortessa X-20 or BD LSR Fortessa (BD Biosciences). Antibody details
and dilutions are available in Table 4.7.
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Table 4.7 Antibody details
Antibody Target
Company
C-peptide
DSHB
NKX6-1
DSHB
Glucagon
Cell Marque
CHGA
Abcam
MAFA
LifeSpan Bioscience
Invitrogen
FAM159B
MAFA
LifeSpan Bioscience
FAM159B
Invitrogen
IAPP
Sigma Aldrich
SST
Santa Cruz Biotechnology
PDX1
R&D Systems
TPH1
EMD Millipore
anti-rat-alexa fluor 488
Invitrogen
anti-mouse-alexa fluor 594
Invitrogen
anti-rabbit-alexa fluor 594
Invitrogen
anti-goat-alexa fluor 594
Invitrogen
anit-sheep-alexa fluor 594
Invitrogen
DSHB=Developmental Studies Hybridoma Bank

Part #
GN-ID4-S
F55A12-S
259A-18
ab15160
LP9872
PA5-52855
LP9872
PA5-52855
PA5-84142
sc-55565
AF2419
AB1541
a21208
a21203
a21207
a11058
a11016

Dilution
1:300
1:100
1:2
1:1000
1:100
1:20
1:100
1:20
1:1000
1:300
1:300
1:100
1:300
1:300
1:300
1:300
1:300

4.5.7 Tissue and Cell Preparation for Sequencing
Grafted cell retrieval: Transplanted cells were removed from the kidney after the mouse was
euthanized through cervical dislocation. Scar tissue and fat was removed from around the kidney
and kidney images were taken to document the transplanted cells. The kidney was sliced into
small sections with a razor blade, placed into a solution of RPMI (Gibco; 11875-085) with
2mg/mL collagenase D (Sigma; 11088858001), incubated at 37 C for 45 min, and further
dispersed by pipetting up and down with additional PBS. The solution was filtered through a
70µm cell strainer (Corning; 431751) and flow through was centrifuged. The single cells were
resuspended with MACS buffer (0.05% BAS in PBS) and excess mouse cells were removed
from the solution using a Miltenyl mouse cell isolation kit (kit, 130-104-694; LS column, 130042-401). Cells in flow through were collected and centrifuged at 300 RPM for 3 minutes. The
cells were resuspended in DMEM and counted for library prep.
158

4.5.8 Single-cell RNA sequencing preparation
Single-cell transcriptome barcoding and library preparation for 10x Illumina sequencing
Single cell dispersed cells were delivered to Washington University in St. Louis McDonnell
Genome Institute (MGI) for library preparation and sequencing on a NovaSeq 6000 System
(Illumina) at the recommended 26x98bp. For library preparations, the MGI used the Chromium
Single Cell 3 Librar and Gel Bead Kit v3 following the suggested protocol. Gene expression
levels found in violin plots and heatmaps are displayed in Log(normalized read count) and
normalized average gene expression, respectively.

4.5.9 Single-cell RNA sequencing data analysis:
Raw Data Processing
Seurat v3.2.1 was used for single cell analyses and comparison between all groups (31, 32). All
samples were aligned to the human genome and filtered out low gene counts, high mitochondrial
percentages, and high expression of TTC36 for further data analysis, indicating doublets/debris,
dying, and mouse cells, respectively. Mouse cell removal is detailed in our previous publication
(18). Each sample data set was normalized with global-scaling normalization. We normalize the
data for each sample using NormalizeData and FindVariableFeatures functions to remove
outlier genes using a scaled z-score dispersion.
Clustering
For individual UMAP plots, cells with similar gene expression patterns plotted near each other
based on PCA using the FindNeighbors and FindClusters functions. We used a resolution of 0.3
and 30 dimensions to generate UMAP plots for each transplant type (SC-PP2 and SC-islets). All
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genes that separated each cluster based on differential gene expression were identified with
FindAllMarkers and these gene sets were used to designate the different pancreatic, endocrine,
exocrine, and off target cell types. The top 25 genes from these lists in each cluster population
are in Tables S4.1 and S4.2. The RunUMAP and DimPlot functions were used to visualize the
different clusters in UMAP plots. Violin plots and FeaturePlot UMAPs were generated to
display the expression of specific genes.
DE between Grafted St6-islets and PP2-islets
We identified the

cells from the individual graft UMAPs and merged the cells to present on a

single UMAP with the same normalization as described previously. The fraction of cells from
each graft type was determined with as.data.frame. Violin plots and feature heatmaps were used
to display gene expression among the cells and visual representation of the differential gene
expression. The FindAllMarkers function identified all differentially expressed genes for all
sequenced SC- cells. The EnhancedVolcano function generated a volcano plot with a log fold
change threshold of 0.5 and p value of 0.5. Heat maps highlight a

cell maturation gene list

defined in Augsornworawat et al, 2020 and a gene list of 430 differentially expressed genes
between primar human islet

cells and in vitro stage 6 SC- cells.

Pathway Enrichment
We analyze HALLMARK, KEGG, and GO gene set enrichment using GSEA (4.1.0). Top
enriched genes for the identified pathways and gene sets are displayed in study results and NES
scores and FDR q-values provided in Table 4.3. We performed GSEA on a curated list of 430
differentiall expressed genes between primar human islet

cells and in vitro stage 6 SC- cells

(18). Genes from list considered in core enrichment analysis are listed in Table S4.3 with gene
rank and metric score.
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4.5.10 Seahorse Mitochondrial Respiration
Mitochondrial respiration was analyzed with a Seahorse XFe24 extracellular flux analyzer
(Agilent). Stage 4/SC-PP2 or Stage 6/SC-islet cells were seeded on Seahorse microplates
(Agilent) overnight in designated media on Matrigel-coated plates. Media was replaced with
RPMI 1640 (Sigma) at 7.4 pH with 2mM glucose for each well and placed in analyzer. After 4
baseline measurements, cells were exposed to sequential injections of 20mM glucose, 3 M
oligomycin (Calbiochem), 0.25 M carbon l c ande-4-(trifluoromethoxy) phenylhydrazone
(FCCP) (Sigma) and 1 M rotenone (Calbiochem) and 2 M antim cin A (Sigma). OCR was
recorded for 4 measurements following each injector. OCR measurements were normalized to µg
DNA in each well, quantified using a Quant-iT PicoGreen dsDNA Assay kit (Invitrogen). Basal
OCR was quantified as area under the curve for the first four baseline OCR measurements.

4.5.11 Software, Quantification, and Statistical Analysis
Data was analyzed using Rstudio version 3.6.1 with Seurat version 3.2.1 (31). For statistical
analysis, GraphPad Prism 8.2.1 calculated two-sided unpaired, paired t-tests, and one-way
ANOVA. Statistical significance was designated by P<0.05. Data is displayed as mean ± s.e.m.
Sample size, n, represents total biological replicates. Tests used for individual panels, sample
size (n), and statistical parameters are detailed in figure legends.
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4.7 Supplemental Figures and Tables

Figure S4.1 Additional analysis of in vitro SC-PP2 cells and SC-islets.
(A) Representative images of SC-PP2 (left) and SC-islet (right) clusters stained with C-peptide
(CP, green), other islet endocrine cell markers (GCG, glucagon, SST, somatostatin, red), and
DAPI (blue). Scale bar, 100µm. (B-C) Representative flow cytometry dot plots of (B) negative
control stained stem cells (top) and human islets (bottom) and (C) Stage 6 SC-islets used for
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transplants in stud . Cells are stained with (C-Peptide, NKX6.1) and endocrine (CHGA) cell
markers. (D) Static GSIS for Stage 6 SC-islets used for transplants in study (n=4). ****p<0.0001
by two-way paired t-test, normalized to 106 cells.

Figure S4.2 Additional transplanted mouse details.
(A) Random blood glucose measurements of mice transplanted with SC-PP2 (green), SC-islet
(purple), and HI (gray) cells at multiple time points (n=6-8). (B) Weight measurements of mice
transplanted with SC-PP2 (green), SC-islet (purple), and HI (gray) cells at multiple time points
(n=3-8). (C) Mouse C-peptide content from pancreas of transplanted mice after STZ treatment
and no transplant mice without STZ (No TXP, No STZ) to confirm lack of mouse cells (n=2).
(D) Representative images of explanted kidneys and grafts after 9 months in vivo.
Error bars represent SEM.
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Figure S4.3 Additional transcriptome analysis of off target populations.
(A) Violin plots of ke
cell genes to identif the cell cluster in the unsupervised UMAP. (B)
Violin plots of off target, population defining genes used to identify and designate the off-target
clusters in the unsupervised UMAP. Details on defining genes in Tables S4.1 and S4.2. (C)
Heatmap of endocrine (CHGA) and (IAPP) cell genes with low (gra ) to high (red) expression.
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Figure S4.4 Additional heatmap analysis.
(A) Heatmap of ke
cell genes with low (gra ) to high (red) expression.
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Figure S4.5 Additional metabolic analysis.
(A) Free fatty acid (FFA) in serum from mice transplanted with SC-islets (purple, n=6), SC-PP2
cells (green, n=5), human islets (gray, n=6), and no transplant controls (black, n=6). P<0.05
unpaired t test comparing two groups as noted by overhead bars.
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Table S4.1 Top genes expressed in individual clusters for SC-islet UMAP.
BETA

EC

UNKNOWN

ALPHA

MOUSE

UNKNOWN

DUCT

UNKNOWN

INS

TPH1

RPL3

APOH

MT-CO3

LMO2

AGR2

MTRNR2L6

NPTX2

AC068587.4

RPS3A

ARX

MT-CYB

PRG4

SLPI

MTRNR2L10

MAFA

FEV

RPL7A

IRX1

MT-ND3

ECEL1

CEACAM6

TIMP3

HADH

UCP2

RPS4X

GCG

MT-ATP6

TM4SF41

TM4SF1

DDX5

PCP4

SPOCK1

RPL34

C5orf38

MT-CO21

AMN

PIGR

ATP5MC3

SCD5

CHGA

ATP5F1E

DPP4

MT-ND1

UGT2B71

MMP7

UBB

IAPP

DDC

RPL12

TTR

MT-CO11

BACE2

LGALS3

SLC4A4

HHATL

VSTM2A

RPS12

SERPINA1

MT-ND41

TM4SF5

TACSTD2

YBX1

G6PC2

COL5A2

EEF1A1

IRX2

MT-ND51

APOC3

DEFB1

SERF22

ASB9

ESR1

RPLP1

SERPIND1

MT-ND21

PLAGL1

CFH

FAU1

SHISAL2B

CBLN1

RPL17

TMEM236

MT-ND4L1

ALDH1A11

EFEMP1

PTMA1

PPP1R1A

SLC18A1

RPS23

CRYBA21

MT-ND6

AGPAT21

NUPR1

ATP1B1

DHRS2

SYT13

RPL19

LOXL4

ABCC8

PLIN21

CXCL17

ZFP36L11

MT1X

GRIP2

RPS27A

FXYD5

ATP5MC1

PCDH7

YBX3

ZNF90

GAD2

C1QL1

TPT1

HLA-A

MALAT11

UGT2A3

AGR3

HIST3H2A

MAFB

NFASC

RPS3

PCSK21

MT-ATP8

EGFL71

ADGRF1

RPS192

NEFM

MME

RPS18

VIM

TTC36

ERO1B2

MLPH

ATP5F1B

MT1E

CAMK1D

RPS2

CLU

ERO1B1

ASPH

LAMB3

RPS201

MT2A

MDGA1

RPL14

PTGER3

HOOK31

CALML4

PPIC

EIF11

UCHL1

MCOLN3

RPL23A

TMSB4X

ARID1B1

CD361

S100A14

SLC25A3

SLC30A8

KCNS3

GNAS

SPTSSB

SNHG141

AKR1C3

IFITM3

HNRNPA2B11

SERPINE2

KCNJ3

RPS14

SPATS2L

GREM2

EHF

GPC4

SLC30A1

ITPR3

COX7C

SPOCK3

DUSP9

PRSS8

RPL35A2

ERO1B

GTF2I

RPL32

KCTD121

GABRA2

TPBG

RPLP21

MT1F

RAB3B

RPL5

GC

ITGA1

TGIF1

ATP5MC11
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UBC

DDIT3

SERPINB5

ATF3

HES1

JUNB

RPLP1

MYC

MT1X

SFN

DAPL1

DUSP1

TSC22D1

TACSTD2

CD9

KRT17

PMAIP1

ID1

KRT19

AQP3

MIR205HG

S100A2
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CALD1
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COL6A3
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IGFBP7
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MGST11
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CP

KLK111
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LYPD2

MSLN

CXCL81

KRT41

KRT7
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CXCL17

CYP2F1

CXCL1

PIGR
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FCGBP

FABP51

SLPI

WFDC2

BPIFB1
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MEG8

GATM
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SPINK1
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CTRB2
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CLPS
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Table S4.3 Core enrichment genes for GSEA of curated
maturation gene set
RANK
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GENE
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GENE
LIST

RANK
METRIC
SCORE

RUNNING
ES

NR1D2

1453

0.230

0.377

Yes

Yes

SYT11

1471

0.228

0.379

Yes

0.031

Yes

ERRFI1

1483

0.227

0.382

Yes

0.040

Yes

PCBP4

1487

0.227

0.386

Yes

RANK
METRIC
SCORE

RUNNING
ES

6

0.862

HOPX

45

HSPA1B
HADH

SYMBOL
SLC30A1

S100A10

CORE
ENRICHMENT

SYMBOL

0.013

Yes

0.652

0.021

46

0.651

57

0.624

CORE
ENRICHMENT

67

0.609

0.049

Yes

FIP1L1

1501

0.226

0.388

Yes

MCL1

105

0.531

0.055

Yes

HSD17B7

1517

0.225

0.391

Yes

IGFBP7

130

0.507

0.062

Yes

PPM1B

1579

0.219

0.392

Yes

RGS2

141

0.496

0.069

Yes

SMIM15

1589

0.219

0.395

Yes

SCD5

157

0.483

0.075

Yes

KCNK1

1599

0.218

0.398

Yes

RPL31

163

0.479

0.082

Yes

ID3

1636

0.215

0.400

Yes

NEK1
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0.473

0.089

Yes

SESN1

1694

0.212

0.401

Yes

KCNK17

186

0.460

0.096

Yes

HLA-E

1737

0.210

0.402

Yes

RRAGC

208

0.451

0.102

Yes

C1orf127

1798

0.207

0.403

Yes

RRAGD

209

0.451

0.108

Yes

PROC

1802

0.207

0.406

Yes

GNPDA1

219

0.445

0.115

Yes

POLR3GL

1812

0.206

0.408

Yes

RAMP1

231

0.439

0.121

Yes

NDUFAF4

1839

0.205

0.410

Yes

RPL37A

236

0.437

0.127

Yes

C1orf174

1845

0.205

0.413

Yes

G6PC2

247

0.434

0.133

Yes

MTHFD2

1847

0.205

0.416

Yes

RPS14

250

0.433

0.140

Yes

AMACR

1913

0.201

0.417

Yes

GC

277

0.422

0.145

Yes

SLC16A10

1945

0.200

0.418

Yes

RPL9

284

0.420

0.151

Yes

CRTAP

1946

0.199

0.421

Yes

IRX2

286

0.419

0.158

Yes

MPHOSPH10

1951

0.199

0.424

Yes

JUN

288

0.419

0.164

Yes

SMPDL3A

1979

0.197

0.426

Yes

MAT2A

303

0.414

0.169

Yes

PHGDH

2017

0.195

0.428

Yes

ADH6

354

0.395

0.173

Yes

GYG1

2061

0.192

0.429

Yes

BTG2

381

0.387

0.178

Yes

SDHB

2062

0.192

0.432

Yes

GAS5

417

0.373

0.182

Yes

CCDC127

2076

0.191

0.434

Yes

PLEKHM2

431

0.370

0.187

Yes

LDLRAP1

2086

0.191

0.436

Yes

SQSTM1

451

0.362

0.192

Yes

AKIRIN2

2093

0.191

0.439

Yes

PDGFA

455

0.361

0.197

Yes

MTRNR2L12

2152

0.187

0.440

Yes

FHIT

465

0.359

0.202

Yes

TARDBP

2167

0.186

0.442

Yes

MAP2

490

0.353

0.207

Yes

PFKFB2

2192

0.184

0.444

Yes

UGT2B7

522

0.347

0.211

Yes

PUM1

2193

0.184

0.446

Yes

RAP1A

524

0.346

0.216

Yes

PRKAR2A

2213

0.183

0.448

Yes

ACVR1C

529

0.345

0.221

Yes

ARHGEF10L

2221

0.183

0.451

Yes

DPH5

536

0.343

0.226

Yes

MAPKAPK2

2230

0.182

0.453

Yes

KCNJ3

551

0.341

0.230

Yes

ROBO2

2296

0.180

0.453

Yes

BASP1

583

0.334

0.234

Yes

PLCXD2

2340

0.179

0.454

Yes

DEGS1

587

0.334

0.239

Yes

QPCT

2358

0.178

0.456

Yes
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DAPL1

595

0.332

0.244

Yes

GCG

2411

0.175

0.457

Yes

RAB3C

609

0.330

0.248

Yes

GPM6A

2412

0.175

0.459

Yes

DTNBP1

612

0.329

0.253

Yes

STX7

2478

0.172

0.459

Yes

SPEG

630

0.326

0.257

Yes

TMEM41A

2558

0.168

0.459

Yes

S100A13

647

0.323

0.262

Yes

SMN2

2601

0.166

0.459

Yes

EVA1B

709

0.313

0.264

Yes

NUDT9

2656

0.164

0.460

Yes

PLK2

715

0.312

0.268

Yes

C5orf38

2668

0.163

0.462

Yes

SERPINE2

718

0.312

0.273

Yes

CFLAR

2707

0.162

0.463

Yes

TAF9

732

0.309

0.277

Yes

NR4A2

2736

0.161

0.464

Yes

TSPYL1

755

0.305

0.281

Yes

TUBB2A

2751

0.160

0.466

Yes

LPGAT1

772

0.302

0.285

Yes

OXCT1

2824

0.157

0.465

Yes

EGR4

781

0.301

0.289

Yes

MAD2L1BP

2826

0.157

0.467

Yes

SNHG5

789

0.301

0.293

Yes

SPTSSB

2864

0.156

0.468

Yes

ID2

886

0.287

0.293

Yes

AGT

2897

0.155

0.469

Yes

BCAS2

975

0.275

0.294

Yes

PPP1R11

2900

0.155

0.472

Yes

STMN1

985

0.274

0.298

Yes

ACTR1B

2950

0.153

0.472

Yes

RHOB

1017

0.271

0.301

Yes

RASGEF1B

2957

0.152

0.474

Yes

CITED2

1022

0.270

0.305

Yes

GLUL

2977

0.151

0.475

Yes

ANKRD37

1060

0.266

0.307

Yes

TIPARP

2983

0.151

0.477

Yes

EGR1

1068

0.265

0.311

Yes

C1orf116

3008

0.150

0.479

Yes

FNIP2

1117

0.259

0.313

Yes

ATP1B1

3019

0.150

0.481

Yes

AP3B1

1143

0.258

0.316

Yes

RPIA

3070

0.148

0.481

Yes

TUBB2B

1174

0.255

0.318

Yes

PTBP2

3136

0.146

0.480

Yes

RGS4

1186

0.254

0.322

Yes

ELF3

3162

0.146

0.481

Yes

ATF3

1187

0.254

0.325

Yes

PLEKHA6

3195

0.145

0.482

Yes

HSPA1A

1193

0.253

0.329

Yes

MPC1

3251

0.144

0.482

Yes

C6orf136

1216

0.251

0.332

Yes

SOX11

3265

0.143

0.484

Yes

RMND5A

1227

0.249

0.335

Yes

DUSP12

3272

0.143

0.486

Yes

RAB29

1250

0.247

0.338

Yes

ITGA1

3366

0.140

0.484

Yes

DPH3

1297

0.243

0.340

Yes

TMEM42

3367

0.140

0.486

Yes

SKIL

1312

0.242

0.343

Yes

QRICH1

3395

0.139

0.487

Yes

CD24

1316

0.241

0.346

Yes

PPP2R5A

3402

0.139

0.489

Yes

PPIE

1326

0.240

0.350

Yes

CSRNP1

3404

0.139

0.491

Yes

ATG3

1327

0.240

0.353

Yes

DRAM2

3486

0.136

0.490

Yes

COPS8

1344

0.238

0.356

Yes

SAMD11

3491

0.136

0.492

Yes

PSMD6

1370

0.236

0.359

Yes

RABIF

3493

0.136

0.494

Yes

AKAP12

1371

0.236

0.362

Yes

RPA2

3550

0.134

0.493

Yes

IGSF21

1405

0.234

0.364

Yes

PLSCR1

3584

0.133

0.494

Yes

BAG2

1414

0.233

0.368

Yes

KIDINS220

3597

0.132

0.496

Yes

HMGCL

1441

0.231

0.370

Yes

CYB5R4

3684

0.130

0.494

Yes

DUSP1

1447

0.230

0.373

Yes

CCDC28A

3691

0.129

0.496

Yes

C2orf69

3765

0.127

0.495

Yes

CAST

3787

0.127

0.496

Yes

LRFN2

3818

0.126

0.496

Yes
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Chapter 5
Differential function and maturation of human stem
cell-derived islets after transplantation
5.1 Abstract
Insulin-producing stem cell-derived islets (SC-islets) could be a virtually unlimited cell
source for diabetes cell replacement therapy. While SC-islets are less functional when first
differentiated in vitro compared to isolated cadaveric islets, transplantation into mice has been
shown to increase their maturation. To understand the effects of transplantation on maturation
and function of SC-islets, we examined cell dose, transplantation site, mouse recipient sex, and
diabetic state in immunocompromised mice. Transplantation of 2 and 5 but not 0.75 million cells
underneath the kidney capsule successfully reversed diabetes in mice with pre-existing diabetes.
Subcutaneous and intramuscular injections failed to reverse diabetes at all doses and had
undetectable expression of maturation markers, such as MAFA and FAM159B. SC-islets had
similar function and maturation marker expression regardless diabetic state of male mice, which
was lower in non-diabetic female mice. Our results illustrate that transplantation parameters are
linked to SC-islet function and maturation.

5.2 Introduction
Diabetes is a metabolic disorder resulting from the death and dysfunction of insulinproducing

cells found within pancreatic islets. Cell replacement therapy is a potential treatment

for patients with diabetes. Human pluripotent stem cell-derived islets (SC-islets) that
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transcriptionally and functionally resemble primary human islets is a potential renewable source
of replacement cells (1-4). Recent advances have enabled differentiation of SC-islets with high
endocrine purity, including hormone-secreting , , and cells, that undergo glucose-stimulated
insulin secretion (GSIS), and are able to treat or prevent diabetes in mice (5-9). These SC-islets
have also facilitated strategies to study SC-islets derived from patients or with disease-causing
gene variants and used to study molecular control of differentiation and maturation (10-16).
However, despite these advances, SC-islets, particularly the

cells, are still immature

when compared to isolated islets from cadavers both in terms of function and marker expression
in vitro. We and others have described maturation that occurs after transplantation in mice in
terms of function and marker expression (17-19). Both non-diabetic mice and mice with preexisting diabetes are used in studies (5, 6, 10-12, 14, 17, 18, 20-24). The use of nondiabetic mice
allows transplanted cells to prevent subsequent induction of diabetes, such as by subsequent
injection with streptozotocin (STZ), but does not establish their ability to reverse it. The reported
cellular doses transplanted varies widely in reports (12, 17, 18, 20, 23, 25-27). Location is also
variable, with common transplantation sites including subcutaneous, intramuscular, and kidney
capsule (11, 14, 22, 27, 28). Generally, male mice are used for transplantation studies, perhaps
due to female mouse tolerance to STZ-induced diabetes (29). In a comparison of recipient mouse
sex using early-stage stem cell-derived pancreatic progenitors, the transplanted cells were found
to be more functional in nondiabetic female compared to male mice (30). The effects of dose,
location, diabetic state, and recipient sex on function and maturation of SC-islet is unknown and
is relevant for clinical translation.
Here, we report the effects of dose, location, diabetic state, and recipient sex on
transplanted SC-islets in immune compromised mice. We generated SC-islets using our in vitro
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6-stage differentiation protocol (5) and monitored transplanted animals up to 22 weeks.
Transplantation with as few as 2 million cells underneath the kidney capsule reversed preexisting STZ-induced diabetes while 0.75 million cells was insufficient. We demonstrated that
recipient sex and the site of transplantation had a large effect on SC-islet function and
maturation. However, the recipient mice having pre-existing diabetes did not affect human Cpeptide levels in the serum nor maturation marker expression.

5.3 Results
5.3.1 In vitro differentiation of SC-islets before transplantation
HUES8 human embryonic stem cells (hESCs) were differentiated into SC-islets with our
recent differentiation protocol (Figure 5.1A) (5). The SC-islets resembled primary human islet
morphology, composition, and function (Figure 5.1B-E) (5). This differentiation protocol
produced SC-islets composed primarily of endocrine cells, including SC- and SC- cells as
shown by monohormonal C-peptide+ and Glucagon+ cells, respectively, as well as a limited
number of polyhormonal C-peptide+/Glucagon+ cells (Figure 5.1C-D). SC- cells were the
largest cell type generated in SC-islets, defined by C-Peptide+/NKX6.1+ cells (Figure 5.1D).
The SC-islets were able to undergo GSIS (Figure 5.1E) (6, 10).
SC-islets were transplanted to investigate the impact multiple sites (kidney capsule,
intramuscular, subcutaneous), doses (5, 2, 0.75 million), effect of diabetic state (STZ and no STZ
control), and recipient sex (male, female) on maturation and function (Figure 5.1F-G). SC-islet
transplant conditions were all performed in 8-10 week old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) immunodeficient mice from Jackson Laboratories. We utilized low dose STZ injections
over 5 d to render diabetes in the NSG mice. STZ-induced diabetic mice with sham transplants
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were established as controls throughout the study. The STZ-induced diabetic mice were
sacrificed at week 14 due to health concerns. The mice were studied for 22 weeks to investigate
the maturation, function, and ability to return blood glucose levels to euglycemia.

Figure 5.1 Characterization of SC-islets in vitro.
(A) Schematic of six-stage differentiation protocol to generate SC-islets. (B) Brightfield images
of Stage 6 SC-islets generated in vitro. Scale bar, 250 µm. (C) Immunostained sections and (D)
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representative flow cytometry plots of Stage 6 SC-islets for islet and cell markers. Scale bar, 50
µm. CP, C-peptide, green; GCG, glucagon, red; DAPI, DAPI, 4 ,6-diamidino-2-Phenylindole,
blue. (E) Static GSIS of SC-islets in vitro (n = 4). (F) Schematic of different transplantations
assessed in the study. (G) Images of explanted grafts in kidney capsule (KC), subcutaneous (SQ),
and intramuscular (IM) locations. Black boxes frame graft and white arrows point to blood
vessel formation. Error bars represent SEM.
5.3.2 Kidney capsule transplantation reversed diabetes in mice
For this study, we transplanted 5 million SC-islet cells into mice for each location
evaluated including kidney capsule , intramuscular, and subcutaneous (Figure 5.1G). Weekly
fasting blood glucose measurements revealed kidney capsule transplants (blue) as the only
location to reverse diabetes at 6 weeks post transplantation (Figure 5.2A). The subcutaneous
(green) and intramuscular (orange) transplanted mice remained hyperglycemic with the lowest
fasted weekly blood glucose measurement observed as 355 ± 19 mg/dL at week 14 and 340 ± 32
mg/dL at week 3, respectively. Interestingly, the intramuscular site showcased high and low
blood glucose spikes from weeks 1 to 12 until the values plateaued averaging 578 ± 14 mg/dL
from week 12 onward (Figure 5.2A). Furthermore, the subcutaneous location, averaging blood
glucose 458 ± 40 mg/dL, had some reduction in blood glucose, maintaining less severe
hyperglycemia than the intramuscular transplants from week 3 until the conclusion of the study
(Figure 5.2A). Weight remained similar between transplanted mice however, the diabetic no
transplant (grey) mice weighed less beginning at week 2 compared to all transplanted groups (p
= 0.02) (Figure S5.1A). Furthermore, vascularization and SC-islet grafts were visible in all
explanted sites (Figure 5.1G).
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Figure 5.2 Transplantation of SC-islets in diabetic mice at multiple sites.
(A) Blood glucose before and after STZ treatment and transplantation of 5 million SC-islet cells
into the kidney capsule (STZ, KC 5M; blue), subcutaneous space (STZ, SQ 5M; green), or in the
muscle (STZ, IM 5M; orange), and diabetic (STZ, No TxP; dark grey, n =4) controls (n = 4). (B)
Random serum human C-peptide measurement in all transplant sites. **** p < 0.0001 by twoway unpaired t test. (C) In vivo GSIS at 6 weeks post transplantation for all transplant sites in
diabetic mice at 0 and 60 min following 2 g/kg intraperitoneal glucose injection (n = 4pp). * p <
0.05 by two-way paired t test comparing 0 and 60 min time points. # p < 0.05, ## p < 0.01 by
two-way unpaired t test comparing 60 min timepoint from IM and SQ to KC. (D) Glucose
tolerance test (GTT) blood glucose and area under the curve (AUC) quantification at 6 weeks
after transplant (n = 4). ** p < 0.01, *** p < 0.001 by two-way unpaired t test compared between
transplantation sites. (E) Immunostaining of sectioned grafts explanted from mouse
transplantation locations at 14 weeks post transplantation for islet and beta cell maturation
markers. Scale bar, 100 µm. SST, Somatostatin. Error bars represent SEM.
We performed glucose tolerance test (GTT) and in vivo GSIS to determine glucose
tolerance and glucose-responsive insulin secretion, respectively. We conducted the assays after 4
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hour fasts with an intraperitoneal injection of 2 mg/kg glucose. Random serum was collected,
and human C-peptide measurements indicated a reduction in C-peptide secretion for
intramuscular and subcutaneous transplants compared to the kidney capsule (Figure 5.2B).
Remarkably, all sites had functional SC-islets at 6 weeks post transplantation yielding a
stimulation index greater than 1.00 (kidney capsule, 3.55 ± 0.95; intramuscular, 10.23 ± 5.612;
subcutaneous, 1.92 ± 0.68; p = 0.2097) (Figure 5.2C). However, subcutaneous and intramuscular
sites had lower insulin secretion at both low and high glucose compared to kidney capsule
transplants (Figure 5.2C). As expected from weekly blood glucose monitoring and random Cpeptide values, the only glucose tolerant mice at 6 weeks post transplantation were from the
kidney capsule conditions, whereas intramuscular and subcutaneous sites remained
hyperglycemic throughout the 120 min assay (Figure 5.2D).
One animal per condition was sacrificed at week 14 to determine composition and
maturation of the sectioned grafts. For all locations, C-peptide expressing SC- cells were
present as well as glucagon+ SC- and somatostatin+ SC- cells (Figure 5.2E). For the
intramuscular and subcutaneous transplants, fewer C-peptide+ SC- cells were present and the
glucagon protein presence was weak compared to the subcutaneous and kidney capsule sites. To
determine maturation of the SC-islets in vivo, we immunostained FAM159B and MAFA, both of
which are maturation markers for

cells and associated with post-transplantation maturation for

SC- cells (31, 32). They are also specific to pancreatic endocrine, distinguishing cells from
exocrine (33) which are present in the grafts, as previously reported (5). Several C-peptide cells
coexpressed FAM159B in the kidney capsule graft indicating maturation of the SC- cells
(Figure 5.2E). The intramuscular location had no FAM159B expression and surprisingly, the
subcutaneous graft had several FAM159B+ cells however few are coexpressed with C-peptide
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(Figure 5.2E). FAM159B encodes a membrane protein which regulates exocytosis therefore the
FAM159B+C-peptide- cells may be other endocrine hormone-secreting cell types (Figure 5.2E).
MAFA is a well-known maturation marker for

cells (5, 17, 32, 34) and is present in a high

percentage of C-peptide+ SC- cells when transplanted in the kidney capsule (32) (Figure 5.2E,
Figure S5.1B). Alternatively, the intramuscular and subcutaneous grafts contained no MAFA+CPeptide+ cells, implying a lack of maturation at these sites (Figure 5.2E, Figure S5.1B). In
summary, the kidney capsule transplantation location was more advantageous compared to
intramuscular and subcutaneous when testing the potential of SC-islets as a cell therapy due to its
ability to reverse diabetes in mice and mature SC-islets in vivo.

5.3.3 Two million SC-islet cells reversed diabetes in mice
In previous reports, we transplanted 5 million cells into the kidney capsule (5, 6, 10). To
determine if fewer cells could produce similar results, we reduced the number of transplanted
cells in this study, surveying the cell therapy potential of 5 (dark blue), 2 (medium blue), and
0.75 (light blue) million SC-islet cells transplanted into the kidney capsule of mice with preexisting diabetes. Weekly blood glucose measurements revealed the reversal of diabetes in mice
with 5 and 2 million transplanted SC-islet cells (Figure 5.3A, 5.3B). Alternatively, the 0.75
million SC-islet transplants were unable to reverse diabetes throughout the 22 week study
remaining severely hyperglycemic and displaying significant weight loss (27.15 ± 0.97 g, week
7) which started at week 7 until the completion of the study compared to the 2 (30.50 ± 0.61 g,
week 7, p = 0.045) and 5 (31.15 ± 0.81 g, week 7, p = 0.016) million SC-islet transplanted mice
(Figure 5.3A, 5.3B, Figure S5.1C).
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Circulating human C-peptide in the mouse serum 2 weeks post-transplant was greater in
the 2 and 5 million doses compared to the 0.75 million cells transplanted mice (Figure 5.3C). At
6 weeks post transplantation, 2 and 5 million transplanted mice attained euglycemia and in vivo
GSIS displayed glucose-responsive C-peptide secretion for the nondiabetic transplanted mice
(Figure 5.3D). Furthermore, the mice transplanted with 2 and 5 million cells had
indistinguishable glucose tolerance indicated by GTT at week 6 (Figure 5.3E); whereas the 0.75
million transplanted mice had dysfunctional, low insulin-secreting cells lacking glucose
tolerance with a GTT profile similar to the diabetic controls (grey) (Figure 5.3E). We performed
nephrectomy on two 2 million and three 5 million transplanted mice following diabetes reversal
and observed a return to hyperglycemia 3 days following the nephrectomy in all mice (Figure
5.3F).
Excised grafts after 14 weeks in vivo further emphasized the similarity between 5 and 2
million transplanted mice. In both conditions, C-peptide, glucagon, and somatostatin positive
cells indicated the presence of three major endocrine cell types in vitro post engraftment (Figure
5.3G). The 0.75 million graft had a smaller width for cell detection, as seen in the grafted kidney
(Figure 5.3G), containing very few C-peptide expressing SC- cells and even less glucagon
expressing SC- cells compared to the larger dose transplants (Figure 5.3G). In contrast, several
somatostatin expressing SC- cells remained (Figure 5.3G). Together, these results indicate 2
million SC-islet cells generated with our differentiation protocol provide a similar therapeutic
effect as 5 million transplanted cells.
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Figure 5.3 Various doses of SC-islets transplanted into kidney capsule of diabetic mice.
(A) Blood glucose and measurements before and after STZ treatment and transplantation of
either 5 (STZ, KC 5M; dark blue; n = 4), 2 (STZ, KC 2M; medium blue; n = 3), and 0.75 (STZ,
KC 0.75M; light blue; n = 4) million SC-islet cells under the kidney capsule or diabetic (STZ,
No Txp; dark grey; n = 4) controls. (B) Diabetes reversal curve for each mouse transplanted
mouse condition (STZ, KC 2M, n = 3; STZ, KC 5M and STZ, KC 0.75M n = 4).
(C) Human C-peptide quantification for random serum collection from transplanted mice (STZ,
KC 2M, n = 3; STZ, KC 5M and STZ, KC 0.75M n = 4). **** p < 0.0001 by two-way unpaired
t test. (D) In vivo GSIS of transplanted mice with various doses before and 60 min after 2 g/kg
glucose injection after 4 hr fast (STZ, KC 2M, n = 3; STZ, KC 5M and STZ, KC 0.75M n = 4). *
p < 0.05, ** p < 0.01 by two-way paired t test comparing 0 and 60 min time points. # p < 0.05,
by two-way unpaired t test comparing 60 min C-peptide levels between dose conditions. (E)
GTT blood glucose measurements every 30 min for 120 min following 2 g/kg glucose injection
and AUC quantification for transplant and control mice (STZ, KC 2M, n = 3; all other
conditions, n = 4). *** p < 0.001, n.s., not significant by two-way unpaired t test comparing
transplant conditions. (F) Blood glucose measurements after nephrectomy of two STZ, KC 2M
and three STZ, KC 5M mice. (G) Sectioned grafts were explanted and immunostained for all
doses at 14 weeks post transplantation with DAPI (blue) and islet markers. Scale bar, 100 µm.
Error bars represent SEM.
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5.3.4 Diabetic environment upon SC-islet transplantation did not affect maturation
To continue evaluating different mouse models, we determined the effect of a diabetic
environment on SC-islet function and maturation in vivo. We transplanted 5 million SC-islet
cells into the kidney capsule of STZ-induced diabetic and nondiabetic mice. The mice for both
transplanted conditions and nondiabetic controls gained weight similarly as they aged, indicating
healthy mice (Figure S5.1D) Weekly blood glucose measurements displayed a return to
euglycemia for the STZ-treated transplants at 6 weeks and similar blood glucose levels between
the STZ-treated and nondiabetic transplanted mice at 16 weeks (Figure 5.4A). C-peptide
measurements were similar between STZ-treated and nondiabetic mice (Figure 5.4B-C). To
evaluate potential stress on SC-islets transplanted into a diabetic environment, we quantified the
human proinsulin/insulin ratio in mouse serum at 2 weeks post-transplantation. We detected a
similar ratio for SC-islets in both mouse conditions (Figure 5.4D), implying a hyperglycemic
mouse environment does not affect insulin processing. Furthermore, the mice displayed similar
glucose tolerance 6 weeks following SC-islet transplantation (Figure 5.4E).
Grafted kidneys from both transplant conditions explanted at week 14 contained all
endocrine cell types represented by C-peptide, glucagon, and somatostatin positive cells (Figure
S5.1E). In both diabetic environments, the transplanted SC-islets had only monohormonal cells
in the graft (Figure S5.1E). Both STZ and no STZ grafts had FAM159B and MAFA
coexpression with C-peptide+ SC- cells, suggesting the diabetic environment is independent of
in vivo maturation (Figure 5.4F). The percentage of MAFA+/C-peptide+ cells was similar
between SC-islet transplants into diabetic compared to nondiabetic mice (Figure 5.4F, 5.4G). In
conclusion, transplanting high-functioning SC-islets into either STZ-induced diabetic or
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nondiabetic mice yields similar results for maturation of the SC- cells, human insulin
processing, and random C-peptide secretion in the mouse serum.

Figure 5.4 Diabetic environment effect on function and maturation of KC transplanted SCislets.
(A) Blood glucose and weight measurements for STZ-treated diabetic (STZ, KC 5M, blue, n =
4) and nondiabetic (No STZ, KC 5M, blue and white stripe, n = 4) mice transplanted with 5
million SC-islet cells and diabetic (STZ, No Txp, n =4) control mice. (B) Human C-peptide in
random mouse serum collected from transplanted mice at 2 (left) and 12 (right) weeks post
transplantation (n = 4). n.s., not significant by two-way unpaired t test. (C) In vivo GSIS of
transplanted mice following 4 hr fast and injected with 2 g/kg glucose. Human C-peptide is
quantified before and 60 min after glucose injection at 6 (left) and 13 (right) weeks post
transplantation (n = 4). * p < 0.05 by two-way paired t test comparing before and after glucose
injection. (D) Ratio of human proinsulin and insulin in mouse serum 2 (left) and 12 (right) weeks
post transplantation (n = 4). n.s., not significant by two-way unpaired t test. (E) GTT and AUC
quantification following 2 g/kg glucose injection and 4 hr fast for all transplanted and control
mouse conditions (n = 4). n.s., not significant by two-way unpaired t test between transplant
conditions. (F) Immunostaining of explanted KC grafts for DAPI (blue) and beta cell maturation
markers. Scale bar, 100 µm. (G) Quantification of MAFA+C-peptide+ cells from total C186

peptide+ cells presented as percentage for 5M SC-islet transplants in diabetic (STZ, KC 5M, n =
8) and nondiabetic (No STZ, KC 5M, n = 4) mice. n.s., not significant by two-way unpaired t
test.
Error bars represent SEM.
5.3.5 Females do not support SC-islet maturation and function in vivo
To further investigate the impact of recipient mouse sex on cell maturation and function,
we transplanted SC-islets derived from a male hESC line into male and female NSG mice. These
mice were rendered diabetic to avoid the complication of different sex response to STZ (29). The
mice were monitored for 26 weeks, where weight increased with age at similar rates for males
and females (Figure S5.2A). Weekly random blood glucose measurements remained lower (p <
0.05) in females as observed pre-transplant until 9 weeks when the blood glucose became similar
(p = 0.4), likely due to high functioning transplanted SC-islets (Figure 5.5A). Excised kidney
capsule grafts contained vascularization in both male and female transplants (Figure S5.2B).
We collected random serum every 4 weeks starting at week 2 post transplantation and
observed reduced levels of human C-peptide in female serum compared to male serum
throughout the study, with the exception of week 6 (Figure 5.5B). For male mice, serum human
C-peptide increased starting at 22 weeks (22 weeks, p < 0.01; 26 weeks, p < 0.05) compared to
initial transplantation (2 weeks). Female mice human C-peptide did not increase throughout the
study, suggesting a lack of maturation in the SC-islets (Figure 5.5B). As observed in additional
kidney capsule nondiabetic male mice cohorts, there was no significant increase of serum Cpeptide secretion in response to glucose stimulation (Figure 5.5C). However, the serum collected
60 minutes post glucose injection of male mice contained more human C-peptide in their
collected serum at 60 min post glucose injection compared to female (p < 0.001) (Figure 5.5C).
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Furthermore, the transplanted male mice had a larger stimulation index compared to female
mice, implying dysfunction of the SC-islets transplanted in female mice (Fig. 5D).

Figure 5.5 SC-islet maturation and function is dependent on recipient mouse sex.
(A) Blood glucose measurements for nondiabetic male (blue, n = 4) and female (red, n = 4) mice
transplanted with 3 million and 2 million SC-islet cells, respectively. (B) Human C-peptide from
random mouse serum collection every four weeks starting at 2 weeks post transplantation (n =
4). # p < 0.05, ## p <0.01 by one-way unpaired ANOVA with Dunnet s multiple comparison test
for all time points compared to week 2 C-peptide levels, specific to each sex. * p < 0.05, ** p <
0.01 by two-way unpaired t test comparing male and female at each time point. (C) C-peptide
secretion and (D) stimulation index from in vivo GSIS for male (blue, n = 4) and female (red, n
= 4) transplanted mice before and after 2 g/kg glucose injection following 4 hr fast. *** p <
0.001 by two-way unpaired t test comparing 60 min time points for male and female in vivo
GSIS. * p <0.05 by two-way unpaired t test for stimulation index. (E) Human proinsulin and
insulin ratio in mouse serum at 12 weeks post transplantation (n = 4). (F) Immunostained images
of sectioned KC SC-islet grafts with DAPI (blue) and islet and beta cell maturation markers.
Scale bar, 100 µm. (I) Quantified percentage of MAFA+C-peptide+ cells out of total C-peptide+
cells for male (blue, n = 4) and female (red, n =4) transplanted mice. *** p < 0.001 by two-way
unpaired t test. Error bars represent SEM.
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Grafts explanted from male and female mice at 14 weeks post transplantation both had
(glucagon+) and

(C-peptide+) cells (Figure 5.5E). Interestingly, we did not observe cells

(somatostatin+) in SC-islets transplanted in female mice (Figure 5.5E). The male mice
transplanted with SC-islets had more C-peptide+/FAM159B+ and C-peptide+/MAFA+ cells
compared to females, indicating a lack of maturation in the female transplanted SC-islets (Figure
5.5E, 5.5F). The increased random serum C-peptide with time and co-positive maturation
markers in the male transplanted mice indicated maturation of the SC-islets (32). Thus, the
recipient mouse sex impacts SC-islet maturation and function, with enhanced improvements in
male compared to female mice.

5.4 Discussion
Here, we demonstrate that common transplantation parameters affect the function and
maturation of SC-islets in mice. As few as 2 million SC-islet cells could reverse diabetes but
0.75 million was unable to do achieve reversal. Transplantation underneath the kidney capsule
resulted in higher serum C-peptide and better glycemic control than intramuscular and
subcutaneous injections. In addition, serum C-peptide was similar between STZ-treated and
nondiabetic mice but higher in male compared to female mice. Expression of the maturation
markers FAM159B and MAFA could only be achieved by transplantation into male mice and
underneath the kidney capsule, but this was unaffected by the diabetic state of the animal.
Diabetes cell therapy using insulin-producing stem cell-derivatives is considered to
potentially be one of the first most widespread uses of differentiation technology. In order to
bring this treatment to clinic, animal models are needed to test cell therapy potential of SC-islets.
This controlled study evaluated several transplantation parameters in mice. Our generated results
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provide a greater understanding of maturation and function of SC-islets impacted by
transplantation site, dose, diabetic state, and recipient mouse sex.
Research groups investigating diabetes cell therapy potential of SC-islets and related cell
types have varied transplantation parameters. Technical expertise can influence site preference
with intramuscular surgeries having a high failure (14) and operative mortality rate (35) while
subcutaneous transplants are a routine, easy to learn procedure. In addition, previous reports
transplanted larger quantities of cells ranging from 1 to 20 million, derived from various
differentiation protocols (12, 17, 18, 20, 23, 25-27). Reduced differentiation efficiency typically
required larger dosages, limiting the clinical translation. Progenitor-derived protocols and
diseased SC- cells (10) can also lead to overgrowths or tumor formation, which are not
observed in our transplants. An allogeneic cell therapy human recipient is estimated to need ~1
billion cells using an efficient differentiation protocol (36). In this study, we demonstrate that
lower cell numbers than routinely used for mouse models are sufficient. This lower dosage may
be reflected in larger animal and human cell therapy. Our results are different than a previous
study that had lower function in nondiabetic male SCID-beige mice compared to females
transplanted with the same number of hESC-derived

cells (23). This could be due to the

enhanced functional maturation that our cells achieved in vitro compared to the prior study and
the fact that here we account for the difference in body weight between the mouse sexes.
In this study, we characterize the maturation of SC- cells through elevated insulin
release and an increased fraction of C-peptide+/FAM159B+ and C-Peptide+/MAFA+

cells.

The impact of transplantation parameters on other islet endocrine cell function and maturation,
such as SC- , SC- , and SC-EC cells, remains unclear. Furthermore, the HUES8 hESC line used
in this study is from a male donor, therefore determining the effect of female SC-islets in male
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and female mice is an important future study. Additional limitations of our study include the
various unevaluated parameters. There are multiple strains of rodents used in previous studies to
evaluate diabetes cell therapy, including TCR

-/-

, B6-RAG-/-, non-obese diabetic-SCID, and

SCID-beige mice transplanted with SC-PP2 cells (37), and C57BL/6J mice and nude rats
transplanted with SC-PP2 and SC- cells (20). STZ and the alternate Alloxan (12) treatment to
render diabetes will need to be optimized due to variable sensitivity between rodent strains (38).
Alternate primary or SC-islet transplantation sites not evaluated in our study include the spleen,
intraperitoneal space, omentum, and portal vein (27, 39). Mice are not the most physiologically
relevant animal model to evaluate some sites which require larger animal models. Non-primates
and large non-human primate models, specifically, are of great importance for preliminary
clinical trial data.
Several other groups are also working to move the field forward for clinical translation of
diabetes cell therapy. A recent report has shown than a collagen hydrogel formulation can
improve islet efficacy upon transplantation subcutaneously (39). Encapsulation devices are being
tested to protect transplanted cells from the immune system and increase vascularization upon
transplantation (22, 27, 40). Macro- and microencapsulation strategies (8, 40, 41) and immune
cloaking through gene editing (42, 43) are also being employed to evade immunosuppression of
transplanted SC-islets and primary human islets. In addition to protecting the transplanted cells,
purifying the SC- cell population within SC-islets would require less cells for transplantation
and result in greater differentiation efficiency. Several groups are working on strategies to
generate a higher proportion of SC- cell by sorting pancreatic progenitor and

cells (7, 9, 34,

44). Combining advances in differentiation protocols, encapsulation methods, sorting for purified
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cell populations, and gene editing to evade the immune system will generate a diabetes cell
replacement therapy.

5.5 Materials and Methods
5.5.1 Cell culture and differentiation
Undifferentiated HUES8 human embryonic stem cells were graciously provided by Dr. Douglas
Melton (Harvard University), were cultured in mTeSR1 (StemCell Technologies; 05850) on
tissue culture plastic in a humidified 5% CO2 37 C tissue culture incubator. Every 3-4 d, stem
cells were passaged by single cell dispersion using TrypLE (Life Technologies; 12-604-039),
counted with Vi-Cell XR (Beckman Coulter), and seeded 0.52 x 106 cells/cm2 in mTeSR1+ 10
mM Y27632 (Abcam; ab120129) on Matrigel coated (Corning; 356230) plates. To initiate
differentiation, undifferentiated stem cells were seeded at 5 x 106 cells per well in a Matrigelcoated 6 well plate. Subsequent feeding schedule, media formulations, and differentiation factors
are provided in Tables 5.1 - 5.3. On day 7 of stage 6, cells are single cell dispersed using TrypLE
and seeded at 5 x 106 cells per well with 4 mL of stage 6 into a 6 well plate. The cells are
cultured on an orbi-shaker (Benchmark) rotating at 100 RPM in a humidified 5% CO2 37 C
tissue culture incubator. Brightfield images are taken throughout differentiation with a Leica
DMi1.
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Table 5.1 Differentiation Protocol

Stage 0

Day
1

Media
mTeSR1

Factor
Y27632

Final Concentration
10 μM

Stage 1

Day
2

Media
BE1

Stage 1
Stage 1
Stage 1

3
4
5

BE1
BE1
BE1

Factor
Activin A
CHIR99021
Activin A
Activin A
Activin A

Final Concentration
100 ng/mL
3 μM
100 ng/mL
100 ng/mL
100 ng/mL

Day

Media

Factor

Final Concentration

6
7

BE2
BE2

KGF
KGF

50 ng/mL
50 ng/mL

Stage 3

Day
8

Media
BE3

Stage 3

9

BE3

Factor
LDN193189
KGF
SANT1
RA
TPPB
LDN193189
KGF
SANT1
RA
TPPB

Final Concentration
200 nM
50 ng/mL
0.2 μM
2 μM
500 nM
200 nM
50 ng/mL
0.2 μM
2 μM
500 nM

Stage 4

Day
10

Media
BE3

11

BE3

12

BE3

Factor
KGF
SANT1
RA
TPPB
LDN193189
KGF
SANT1
RA
TPPB
LDN193189
KGF
SANT1
RA
TPPB
LDN193189

Final Concentration
50 ng/mL
0.2 μM
0.1 μM
500 nM
200 nM
50 ng/mL
0.2 μM
0.1 μM
500 nM
200 nM
50 ng/mL
0.2 μM
0.1 μM
500 nM
200 nM

Stage 2
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Stage 5

13

BE3

KGF
SANT1
RA
TPPB
LDN193189

50 ng/mL
0.2 μM
0.1 μM
500 nM
200 nM

Day
14

Media
S5

Factor
SANT1
RA
XXI
Alk5i
T3
Latrunculin
A
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin
SANT1
RA
XXI
Alk5i
T3
Betacellulin

Final Concentration
0.2 μM
0.1 μM
1 μM
10 μM
1 μM

15

S5

16

S5

17

S5

18

S5

19

S5

1 μM
20 ng/mL
0.2 μM
0.1 μM
1 μM
10 μM
1 μM
20 ng/mL
0.2 μM
0.1 μM
1 μM
10 μM
1 μM
20 ng/mL
0.2 μM
0.1 μM
1 μM
10 μM
1 μM
20 ng/mL
0.2 μM
0.1 μM
1 μM
10 μM
1 μM
20 ng/mL
0.2 μM
0.1 μM
1 μM
10 μM
1 μM
20 ng/mL
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20

S5

Stage 6

SANT1
RA
XXI
Alk5i
T3
Betacellulin

0.2 μM
0.1 μM
1 μM
10 μM
1 μM
20 ng/mL

Feed S6 every other day

Table 5.2 Differentiation Medias
Reagent
MCDB131
(mL)
Glucose
(g)
NaHCO3
(g)
FAF-BSA
(g)
ITS-X
(mL)
Glutamax
(mL)
Vitamin C
(mg)
Heparin
(µg/mL)
Pen/Strep
(mL)
NonEssential
Amino
Acids (mL)
ZnSO4
(µM)
Trace
Elements
A (µL)
Trace
Elements B
(µL)

Company

Catalog #

Cellgro

15-100-CV

MilliporeSigma

G7528

MilliporeSigma

S3817

Proliant

68700

Invitrogen

51500056

Invitrogen

35050079

MilliporeSigma

A4544

MilliporeSigma

H3149

Cellgro

30-002-CI

Corning

25-025-CI

BE1

BE2

BE3

S5

S6

500

500

500

500

500

0.8

0.4

0.22

1.8

0.23

0.587

0.587

0.877

0.877

N/A

0.5

0.5

10

10

10.5

N/A

N/A

2.5

2.5

N/A

5

5

5

5

5.2

N/A

22

22

22

N/A

N/A

N/A

N/A

5

10

N/A

N/A

N/A

5

5.2

N/A

N/A

N/A

N/A

5.2

N/A

N/A

N/A

N/A

1

N/A

N/A

N/A

N/A

523

Corning

25-021-CI

N/A

N/A

N/A

N/A

523

Corning

25-022-CI
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MilliporeSigma

10883

Table 5.3 Differentiation Factors
Compound
Activin A
CHIR99021
KGF
LDN193189
Retinoic Acid
SANT1
Y27632
Latrunculin A

Company
R&D Systems
Stemgent
Peprotech
Reprocell
MilliporeSigma
MilliporeSigma
Abcam
Cayman Chemical

Alk5 inhibitor type II
Betacellulin

Enzo Life Sciences
R&D Systems

Part #
338-AC
04-0004-10
AF-100-19
40074
R2625
S4572
ab120129
10010630
ALX-270-445M005
261-CE-050

T3
XXI
TPPB

Biosciences
MilliporeSigma
Tocris

64245
595790
53431

5.5.2 Immunostaining
SC-islets or transplanted cell extractions were fixed with 4% paraformaldehyde (Electron
Microscopy Science; 15714) overnight at 4 °C. SC-islet clusters were placed in Histogel
(Thermo Scientific; Hg-4000-012) and transplant extractions were cut in half and processed by
the Division of Comparative Medicine (DCM) Research Animal Diagnostic Laboratory Core at
Washington University. Paraffin was removed with Histoclear (Electron Microscopy Sciences;
64111-04) and ethanol (Decon; 2716), samples were rehydrated, and antigens were retrieved in a
pressure cooker (Proteogenix; 2100 Retriever) with 0.05M EDTA (Ambion; AM9261). Samples
were blocked and primary antibodies were diluted in immunostaining buffer (5% Donkey Serum
(Jackson Immunoresearch; 017-000-121) and 0.1% Triton-X (Acros Organics; 327371000) in
PBS (Corning; 21-040-CV)) overnight at 4 C in humidified box. Next, secondary antibodies
diluted in immunostaining buffer were added for 2 hr at RT and then samples were mounted with
DAPI Fluoromount-G (SouthernBiotech; 0100-20). Cells were imaged with a Leica DMI4000
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fluorescence or Nikon A1Rsi confocal microscope. Images were processed with ImageJ. Flow
cytometry was performed on single cell dispersed SC-islets with TrypLE, fixed at RT for 30 min,
and stained as described above. Cells were analyzed with BD LSR Fortessa X-20 (BD
Biosciences). FlowJo software generated population percentages and dot plots. Antibody details
and dilutions are available in Table 5.4.
Table 5.4 Primary and Secondary Antibodies
Primary Antibody Target
C-peptide
NKX6-1
Glucagon
CHGA
MAFA
FAM159B
SST

Company
DSHB
DSHB
Cell Marque
Abcam
LifeSpan Bioscience
Invitrogen
Santa Cruz Biotechnology

Secondary Antibody Target
Company
anti-rat-alexa fluor 488
Invitrogen
anti-rabbit-alexa fluor 488
Invitrogen
anti-mouse-alexa fluor 594
Invitrogen
anti-rabbit-alexa fluor 594
Invitrogen
anti-goat-alexa fluor 594
Invitrogen
anit-sheep-alexa fluor 594
Invitrogen
DSHB=Developmental Studies Hybridoma Bank

Part #
GN-ID4-S
F55A12-S
259A-18
ab15160
LP9872
PA5-52855
sc-55565

Dilution
1:300
1:100
1:2
1:1000
1:100
1:20
1:300

Part #
a21208
a21206
a21203
a21207
a11058
a11016

Dilution
1:300
1:301
1:300
1:300
1:300
1:300

5.5.3 GSIS
SC-islets were washed with KRB buffer (128 mM NaCl, 5 mM KCl, 2.7 mM CaCl2 1.2 mM
MgSO4, 1 mM Na2HPO4, 1.2 mM KH2PO4, 5 mM NaHCO3, 10 mM HEPES (Gibco; 15630080), and 0.1% BSA) and transferred to transwells in 2mM glucose KRB solution for 1 hr to
equilibrate. The solution is then replaced with 2mM glucose KRB for an additional 1 hr and
supernatant is collect. Last, solution is replaced with 20mM glucose KRB for final 1 hr and
supernatant is collected. Transwells are transferred to TrypLE for single cell dispersion,
incubated for 30 min, and counted with Vi-Cell XR to normalize insulin secretion. Insulin in
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supernatant is quantified with human insulin ELISA (ALPCO; 80-INSHU-E10.1). For all
incubations, cells were placed in a humidified incubator at 37°C 5% CO2.
5.5.4 Transplantation Studies
All transplantation studies adhered to Washington University Institutional Animal Care and Use
Committee regulations. All studies and surgeries were performed by unblinded individuals and
mice were randomly assigned to experimental groups. 7-week-old male and female NOD.CgPrkdcscid Il2rgtm1Wjl/SzJ (NSG) mice from Jackson Laboratories (005557). Male mice were
rendered diabetic (blood glucose > 500 mg/dL) with 5 consecutive days of 45 mg/kg STZ (R&D
systems; 1621400) injections. Diabetic and nondiabetic mice were anaesthetized and injected
with SC-islet cells according to their experimental group – [dose] 5 x 106, 2 x 106, or 0.75 x 106
into kidney capsule of diabetic mice; [site] 5 x 106 into kidney capsule, intramuscular,
subcutaneous, or intraperitoneal of diabetic mice; [diabetic state] 5 x 106 into kidney capsule of
diabetic and nondiabetic mice; [sex] 3 x 106 or 4 x 106 into kidney capsule of nondiabetic female
or male mice, respectively. Sham diabetic and nondiabetic mice were used as controls. Kidney
capsule transplants were performed with 25G butterfly needle (TERUMO; SV*25BLK). Cells
transplanted in IM, SC, or IP locations were injected with ~50 µL of Matrigel using a 27G
needle (BD; 309623). For IM, cells were transplanted into left thigh muscles. For SC, cells were
transplanted on left side of back at the midline.
Blood glucose was measured with Contour NEXT Blood Glucose Monitoring System (Bayer).
Random insulin serum was quantified throughout study by tail bleed collection into microvettes
(16.443.100, Sarstedt). Whole blood was centrifuged for 15 min at 2500rpm at 4 C, serum was
collected and stored at -80 C. Random weight measurements were taken on scale (Adam
Equipment; AE9CQ15186). Functional assessments included glucose tolerance test (GTT) and in
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vivo GSIS. For both assessments, mice were fasted for 4 hr and injected with 2 g/kg glucose in
0.9% saline (MOLTOX; 51-405022.052). For GTT, blood glucose was measured every 30 min
for 120 min. For in vivo GSIS, blood was collected using microvettes before and 1 hr after
glucose stimulation, centrifuged, and serum supernatant was transferred for storage at -80 C.
Serum hormones were quantified with Mouse C-peptide ELISA (ALPCO Diagnostics; 80CPTMS-E01), Human Ultrasensitive C-peptide ELISA (Mercodia; 10-1141-01), Human
Proinsulin ELISA, and Human Ultrasensitive Insulin ELISA (ALPCO Diagnostics; 80ENSHUU-E01.1). Nephrectomy was performed on mice with reversed diabetes by removing
kidney with transplanted SC-islets. The blood glucose, weight, in vivo GSIS, random C-peptide,
and GTT data for the STZ, 5M kidney capsule mouse (royal blue) condition and diabetic controls
(STZ, No Txp, grey) was repeatedly used in Figures 2-4 and Supplemental Figure 1 for multiple
different transplantation methodology comparisons.
5.5.5 MAFA Quantification
Sectioned slides were stained with MAFA, C-Peptide, and DAPI as described above. At least 3
representative images were taken for each transplant condition. The number of C-Peptide+
(green) and C-Peptide+MAFA+ (green and red) cells were counted. The ratio of CPeptide+MAFA+ to C-Peptide+ was calculated as a percentage.
5.5.6 Statistical Analysis
Statistical analysis was performed with GraphPad Prism 8.2.1. Two-sided unpaired and paired t
tests and one-way ANOVA with Dunnet s or Tukey s multiple comparison test were performed
when appropriate. Statistical tests are detailed in figure legends with sample size, n, indicating
total number of biological replicates. Data are shown as mean ± SEM. P<0.05 was considered
statistically significant.
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5.7 Supplemental Figures

Figure S5.1 Additional measurements for diabetic transplanted mice. Affiliated with Figures
2-4.
(A) Weight measurements before and after STZ treatment and transplantation of 5 million SCislet cells into the kidney capsule (STZ, KC 5M; blue), subcutaneous space (STZ, SC 5M;
green), or in the muscle (STZ, IM 5M; orange), and nondiabetic (No STZ, No TXP; light grey)
and diabetic (STZ, No TxP; dark grey) controls (n = 4). (B) Quantification of percentage of
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MAFA+C-peptide+ cells from total C-peptide+ cells in immunostained images (STZ, KC 5M, n
= 8; STZ, SC 5M, n = 4; STZ, IM 5M, n = 3). **** p < 0.0001 by two-way unpaired t test. (C)
Weight measurements for control and transplanted mice with various doses (STZ, KC 2M, n = 3;
all other conditions, n = 4) and diabetic controls (STZ, No Txp, n =4). (D) Weight measurements
of diabetic (STZ, KC 5M, n = 4) and nondiabetic (No STZ, KC 5M, n = 4) mice transplanted
with 5M SC-islets and diabetic controls (STZ, No Txp, n =4). (E) Immunostained sections of
explanted KC grafts for diabetic and nondiabetic transplanted mice for islet cell markers. Scale
bar, 100 µm. Error bars represent SEM.
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Figure S5.2 Additional measurements for male and female transplanted mice. Affiliated
with Figure 5.
(A) Weight measurements for nondiabetic male (blue, n = 4) and female (red, n = 4)
transplanted mice. (B) Images of explanted kidneys with transplanted SC-islets from male and
female mice outlined in black box and white arrow pointing to blood vessel formation in graft.
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Chapter 6
Generation of insulin-producing pancreatic
from multiple human stem cell lines

cells

Partially adapted from a submitted manuscript written by *Hogrebe, N. J., *Maxwell, K. G.,
*Augsornworawat, P., Millman, J. R. *Co-first Authors

6.1 Abstract
We detail a 6-stage planar differentiation methodology for generating human pluripotent
stem cell (hPSC)-derived pancreatic

cells (SC- cells) that secrete high amounts of insulin in

response to glucose stimulation. This protocol first induces definitive endoderm by treatment
with Activin A and CHIR99021, then generates PDX1+/NKX6-1+ pancreatic progenitors
through the timed application of keratinocyte growth factor (KGF), SANT1, TPPB, LDN193189,
and retinoic acid (RA). Endocrine induction and subsequent SC- cell specification is achieved
with a cocktail consisting of the cytoskeletal depolymerizing compound latrunculin A combined
with XXI, T3, ALK5 inhibitor, SANT1, and RA. The resulting SC- cells and other endocrine
cell types can then be aggregated into islet-like clusters for analysis and transplantation. This
differentiation methodology takes approximately 35 days to generate functional SC- cells, plus
an additional 1-2 weeks for initial stem cell expansion and final cell assessment. This protocol
builds upon a large body of previous work for generating -like cells. In this iteration, however,
we have eliminated the need for three-dimensional culture during endocrine induction, allowing
for the generation of highly functional SC- cells to be done entirely on tissue culture
polystyrene (TCP). This change simplifies the differentiation methodology, requiring only basic
stem cell culture experience as well as familiarity with assessment techniques common in
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biology labs. In addition to expanding protocol accessibility and simplifying SC- cell
generation, we demonstrate that this planar methodology is amenable for differentiating SCcells from a wide variety of cell lines from various sources, broadening its applicability.

6.2 Introduction
Diabetes results from the loss or dysfunction of insulin-producing

cells within the

pancreas, leading to deregulation of glucose homeostasis and the requirement for daily
exogenous insulin injections. Successful transplantation of cadaveric islets using the Edmonton
protocol has provided a proof-of-principle for a cell-based therapy, demonstrating that inserting
mature

cells into a diabetic patient can provide a functional cure for insulin-dependent

diabetes.1,2 Widespread success of this cell therapy depends upon generating a reliable supply of
highly functional

cells, however, as cadaveric islets are limited and often have decreased

function upon isolation from donors. To this end, substantial progress has been made in the
development of stem cell-derived

(SC- ) cells, providing a renewable supply of insulin-

producing cells for diabetic disease modeling and cell therapy.3

7

This road to a robust protocol for generating functional SC- cells has been a gradual
process resulting from the excellent work of various research groups developing sequential
differentiation stages, each of which utilize the timed application of growth factors and small
molecules to mimic developmental cues. The first step of this process specifies definitive
endoderm from stem cells, which was first worked out in 2005 by D Amour et al.8 and then
further refined.9

15

Subsequent stages of differentiation drive these endodermal cells through a

primitive gut tube intermediate to form PDX1+ pancreatic progenitors.9 While insulin positive
cells could originally be generated from these pancreatic progenitors in vitro, their insulin
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secretion was limited, they often also expressed the hormones glucagon or somatostatin, and they
lacked other key features of

cells.10,16 When PDX1-expressing pancreatic progenitors were

transplanted into mice or rats, however, they matured over the course of several months into
insulin positive cells that were glucose-responsive,17
pancreatic progenitors to produce genuine

20

illustrating the potential of these PDX1+

cells. An important advance from these

transplantation studies was the realization that functional SC- cells arise from pancreatic
progenitors that express the transcription factor NKX6-1.21,22 Other studies have further
illustrated the importance of NKX6-1 in

cell development,23

25

demonstrating that turning on

the transcription factor NEUROG3, which drives all endocrine specification, before NKX6-1
directs cells toward a polyhormonal state that ultimately produces

cells.26

28

. A breakthrough

occurred in 2014 and 2015 when several groups published protocols for specifying functional
SC- cells in vitro.29

31

This was achieved by introducing a differentiation stage that first induced

NKX6-1 expression in these PDX1+ pancreatic progenitors and then devising a chemical
cocktail to subsequently trigger NEUROG3-induced endocrine formation. The resulting SCcells were able to secrete insulin in response to glucose stimulation and protect against moderate
diabetes (<300 mg/dL) after transplantation into mice. Nevertheless, the cells generated with
these protocols lacked key features of genuine

cells, including first and second phase dynamic

secretion kinetics, and they exhibited lower overall insulin secretion compared with native
human islets.
Since then, however, several research groups have further iterated on these protocols to
improve SC- cell generation.26,32

36

Recently, we devised a new maturation stage of the

protocol, facilitating acquisition of the first and second phase dynamic insulin release exhibited
by primary human

cells.37 Furthermore, we improved generation of these cells with a new
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planar version of the protocol so that the cells are now capable of rapidly (1-2 weeks) curing
severe preexisting diabetes (>600 mg/dL) in mice,38,39 demonstrating the utility of these cells for
therapy. Here, we describe this efficient differentiation protocol for generating highly functional
SC- cells using traditional planar cell culture techniques. We showcase how to optimize this
protocol for different cell lines as well as demonstrate a simple method for aggregating these SCcells into functional clusters for use in downstream assays, such as transplantation into diabetic
mice. This latest iteration simplifies the differentiation procedure compared to alternative
protocols, can be adapted to a wide variety of cell lines, and produces highly functional SCcells. Our hope is that this protocol provides an easy-to-follow guide for both experienced
researchers and those new to the field to make quality SC- cells in an effort to accelerate
research in

cell development, maturation, and health.

6.2.1 Development of the protocol
To develop a planar methodology for generating insulin producing SC- cells from
hPSCs, we built upon the previously mentioned protocols that use the timed application of
growth factors and small molecules to drive cells through defined stages of development (i.e.,
definitive endoderm, primitive gut tube, pancreatic progenitors, endocrine, and

cells).29,30,37

Interestingly, while previous attempts to make SC- cells in planar culture could robustly
generate PDX1+/NKX6-1+ pancreatic progenitors that could mature in vivo after transplantation,
planar methodologies could only generate immature insulin positive cells from these progenitors
in vitro.16,21,25 In contrast, all previous protocols that successfully generated glucose-responsive
SC- cells in vitro that secreted high amounts of insulin utilized a three-dimensional arrangement
of cells either as suspension clusters29,37 or as aggregates on transwell culture inserts30 for the
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differentiation from pancreatic progenitors to SC- cells. The reason for this requirement had
been unknown, particularly in understanding the effects of the insoluble microenvironment on
pancreatic fate choice. These insoluble cues can include substrate stiffness, topography,
dimensionality, and the composition of extracellular matrix (ECM) proteins that a cell
experiences during culture. These microenvironmental factors have increasingly been shown to
influence a range of downstream signaling pathways within cells, such as those involving the
actin cytoskeleton, that lead to changes in stem cell fate.40

42

In order to explore how such insoluble microenvironmental cues influence SC- cell
specification, we plated suspension-derived PDX1-expressing pancreatic progenitors onto tissue
culture polystyrene (TCP) coated with a wide variety of ECM proteins.38 Surprisingly, we
observed that as long as pancreatic progenitors adhered firmly to any particular ECM-coated
TCP plate, NEUROG3-induced endocrine specification was strongly inhibited. We demonstrated
that the high stiffness of TCP monolayer culture promoted increased polymerization of the actin
cytoskeleton, which prevented premature NEUROG3 induction and facilitated expression of the
important

cell transcription factor NKX6-1. Subsequent endocrine specification, however,

continued to be blocked. To overcome this inhibition, we demonstrated that depolymerizing the
cytoskeleton with latrunculin A allowed for robust NEUROG3 expression in planar culture.
Through further optimization, we determined that a 1 µM latrunculin A treatment for the first 24
hours of the endocrine induction stage was sufficient to rescue SC- cell specification. Thus,
monolayer culture on TCP helped facilitate NKX6-1 expression and prevented premature
endocrine induction by promoting actin polymerization in pancreatic progenitors (stage 4), while
a 24 hour treatment with the actin depolymerizer latrunculin A was required for subsequent
endocrine induction (stage 5).
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This new understanding of the importance that the microenvironment and cytoskeletal
signaling have on endocrine induction allowed us to adapt cluster-based protocols for generating
highly functional SC- cells to a planar format, simplifying the differentiation methodology
while also improving outcomes for multiple cell lines.38,39 Our results are in agreement with the
excellent recent work of the Semb group43 and others44,45 that have demonstrated the importance
of YAP signaling in pancreatic progenitors, as the state of the cytoskeleton is well-known to
control the nuclear localization of YAP.46 The influence of the cytoskeleton on additional
signaling pathways during pancreatic differentiation cannot be ruled out, however, and can be
the subject of further study.

6.2.2 Applications of the method
The methodology described here allows for the production of highly glucose-responsive,
insulin-producing SC- cells. Transplantation of these cells into severely diabetic mice rapidly
restores normoglycemia,38,39 providing hope that these cells will eventually be utilized to
functionally cure insulin-dependent diabetes. In addition to such a cell-based therapy, SC- cell
generation can also be implemented to study diabetes pathogenesis and diabetic cell phenotypes.
Because this protocol can be adapted to generate SC- cells from a wide variety of cell lines with
different genetic backgrounds, it is amenable to both autologous cell therapy as well as
applications that extensively study diabetic disease states, such as defects in SC- cells generated
from patients with monogeneic diabetes.39 Furthermore, due to the flexibility in culture vessel
size, this methodology is conducive to small drug screening and protocol optimization
experiments as well as generating batches large enough for cell therapy. Importantly, this
protocol simplifies the differentiation procedure and eliminates more complicated and expensive
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3D culture systems, removing barriers for many researchers to generate and study these cells in
an effort to accelerate research in this field.

6.2.3 Comparison with other methods
In contrast to previous protocols that required a three-dimensional arrangement of cells
either as suspension clusters or as aggregates on transwells for the differentiation from pancreatic
progenitors to SC- cells, the key feature of our protocol is that it can generate highly functional
SC- cells entirely in traditional monolayer culture. This technique is enabled through the
discovery that the cytoskeleton is critical to pancreatic cell fate, and the use of the cytoskeletal
depolymerizer latrunculin A at the beginning of endocrine induction allows for robust
differentiation of SC- cells from pancreatic progenitors in planar culture.38 Our findings solved
a longstanding mystery in the field of why three-dimensional cell arrangements were required for
the generation of SC- cells, as prior studies were inadvertently modulating the cytoskeleton to
be favorable for SC- cell generation by use of these three-dimensional cell arrangements.
Several methods of 3D aggregate culture have been successfully used to generate SCcells, including magnetic spinner flasks,29 6-well plates on an orbital shaker, 31 and manually
pipetting cells during endocrine induction onto transwell culture inserts to form clusters.30 While
such cluster-based methods are certainly capable of producing functional SC- cells, there are
several unique advantages to the planar methodology described herein. First, this protocol can be
done entirely with traditional cell culture techniques, eliminating the need for these more
complicated and expensive 3D culture requirements. Specifically, this protocol does not require
additional training and expertise on stem cell suspension culture, expensive spinner flasks and
magnetic stirrers, or a time-consuming mid-differentiation manual clustering step. Rather, cells
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are plated onto standard Matrigel-coated plasticware (e.g., 6-well plate or T-75 flask), and the
differentiation media are simply added in the proper order. Because cells are in a monolayer
rather than clusters that are hundreds of micrometers in diameter, diffusion gradients of the
differentiation factors are minimized, allowing the differentiation to produce more cells per
volume of media and further reduce differentiation costs. Specifically, this planar methodology
typically produces between 0.5-0.75 million cells per cm2 and approximately 2-3 times more
cells per total media volume used throughout the differentiation than our previous suspension
protocol. Furthermore, this planar protocol can be more cost effective for small scale laboratory
experiments to test a wide range of conditions due to the ability to perform these differentiations
in small formats, such as 6 or 24 well plates, in contrast to larger suspension bioreactors.
While SC- cells are generated completely in planar culture, our methodology does allow
for the generation of islet-sized clusters so that the SC- cells can be used for additional assays,
such as dynamic GSIS and transplantation. A single-cell suspension can be generated during the
final stage of differentiation and then distributed into 6-well plates, and the rotational movement
of an orbital shaker induces clustering of these cells. We have found that mostly endocrine cells
aggregate together at this point in the differentiation after cell fate has already been specified in
planar culture, while non-endocrine cell types generated during this protocol26,39 tend to die off.
Therefore, this optional aggregation step can facilitate endocrine purification without the need
for a more expensive and time-consuming sorting procedure.
Importantly, this new planar methodology is more reproducible across multiple hPSC lines, as
many hPSC lines are often difficult or impossible to adapt to suspension culture. Furthermore,
hPSC differentiation protocols for many cell types, not just SC- cells, often work well with only
a single cell line, less well for other cell lines, and not at all for others. In contrast, we have been
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able to generate functional SC- cells from a wide variety of hPSC lines with unique genetic
backgrounds using this planar methodology. Here, we provide data for robustly generating SCcells from 10 cell lines, including 5 additional lines that were not presented in our previous two
publications.38,39 Importantly, the flexibility in cell line choice that this protocol provides is
potentially conducive to an autologous cell therapy to treat diabetes as well as facilitate the study
of a wide variety of diabetic phenotypes, as we have recently demonstrated.39
Finally, not only does this methodology simplify SC- cell generation and provide
flexibility in terms of cell line and culture size, it also improves their in vitro and in vivo
performance. The cells that we generated with this protocol in our most recent two
publications38,39 are some of the most functional yet presented in the literature. We were able to
achieve both first and second phase dynamic insulin secretion across 5 cell lines, with some lines
approaching the functional capabilities of human islets. Furthermore, these SC- cells were
capable of reversing severe pre-existing diabetes in mice within 2 weeks at a rate similar to
primary human islets, outperforming cells generated with a suspension-based protocol.
Importantly, these transplanted SC- cells were able to maintain normoglycemia indefinitely.

6.2.4 Experimental design
Here, we detail a step-by-step directed differentiation protocol for generating highly
functional SC- cells. This methodology consists of 6 stages that attempt to recreate phases of
pancreatic organogenesis by activating and repressing specific developmental pathways with
growth factors and small molecules in serum-free media. We detail methods to assess the cells
throughout differentiation, including quality assurance steps at critical points of the protocol as
well as in vitro functional assessment of the SC- cells. This methodology can be adapted to
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differentiate SC- cells from a range of stem cell lines, and we describe guidelines to optimize
the protocol when using a new cell source. This protocol takes about 5 weeks to complete, and
therefore we recommend that differentiations be started every week or so in many circumstances
to ensure a continuous supply of cells and avoid lag time between experiments.

HPSC culture (Stage 0, Steps 1-9). To propagate and expand cells for SC- cell differentiation,
hPSCs are seeded onto Matrigel-coated TCP plates at a density of 0.8 x 105 cells/cm2 and
cultured in mTeSR1. Once cells are 90% confluent after about four days, they are single cell
dispersed using TrypLE and seeded onto new Matrigel-coated plates with mTeSR1
supplemented with the Rho-kinase inhibitor Y-27632. A propagation flask can be thawed and
maintained for several weeks using this procedure. When a differentiation is needed, separate
flasks (e.g., T-75) or plates (e.g., 6-well plate) can be seeded during a passage of the propagation
flask. Unlike the propagation flask, differentiation plates should be seeded near confluency,
though the exact cell density must be optimized for each cell line.

Definitive endoderm (Stage 1, Steps 10-12). 24 hours after seeding a differentiation flask, the
stem cells should be confluent. To initiate differentiation, mTeSR1 is replaced with
differentiation media containing Activin A (TGF- superfamily member) and CHIR99021 (Wnt
agonist). After the first 24 hours in this media, only Activin A is added during the subsequent
three days of endoderm induction. At the end of this stage, cells should express >90% of the
endoderm markers FOXA2 and SOX17. Achieving high expression of these markers is critical to
the success of the protocol, and so this stage should be optimized for any given cell line before
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proceeding with the remainder of the differentiation. These markers can be checked visually with
immunocytochemistry or quantitatively with flow cytometry.

Primitive gut tube (Stage 2, Steps 13-15). After endoderm induction, these cells are converted to
primitive gut tube with two days of keratinocyte growth factor (KGF) treatment. We have not
found a reliable marker to distinguish the ability of these cells to subsequently make SC- cells,
and thus the effects of any stage 2 modulations are assessed in subsequent stages.

Pancreatic progenitors (Stage 3 and 4, Steps 15-20).The first pancreatic progenitor stage drives
cells towards a pancreatic lineage by turning on the transcription factor PDX1 with a high
concentration of RA accompanied by KGF, SANT1 (hedgehog inhibitor), TPPB (PKC
activator), and LDN193189 (BMP inhibitor). This media should induce >80% PDX1 expression
after two days. The second pancreatic progenitor stage continues culture of the cells for the next
four days in this media with the exception of drastically reduced RA concentration. This stage is
designed to allow these PDX1+ cells to turn on the important

cell transcription factor NKX6-1.

An important quality control step at the end of this stage is measuring the percentage of cells coexpressing NKX6-1+ and PDX1+ with flow cytometry, as these will be the cells that ultimately
produce functional, monohormonal SC- cells. This stage should generate >40% NKX61+/PDX1+ cells, but further increasing this percentage can be a major target of protocol
optimization.

Endocrine (Stage 5, Steps 21-24). To induce endocrine formation from these pancreatic
progenitors, Notch signaling must be downregulated with XXI ( -secretase inhibitor) in
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combination with T3 (thyroid hormone), ALK5II inhibitor, SANT1, and RA for one week of
culture. However, the increased cytoskeletal polymerization induced by monolayer culture on
stiff TCP blocks NEUROG3 expression even in the presence of these factors, preventing
initiation of the endocrine program. In order to overcome this inhibition, the actin cytoskeleton
must be chemically depolymerized with latrunculin A at the start of endocrine induction. Once
NEUROG3 has turned on, further cytoskeletal depolymerization is not needed. We have found
that a 1 µM treatment for the first 24 hours of stage 5 is sufficient to initiate endocrine
differentiation for most cell lines, though this dosing may need to be optimized when adapting
the protocol to other lines. Also worthy to note is that while our original suspension protocol
included the EGF family member betacellulin, we have found it to not be necessary in the planar
differentiations and have since omitted it from our protocol.

SC- cells (Stage 6, Steps 25-26). Once the endocrine cells have been specified, the SC- cells
need time to mature before they become glucose-responsive. We developed an enriched serumfree media (ESFM) that facilitates this process, allowing cells to develop a robust insulin
secretion response in 10-14 days.37 These cells can remain on the plate for the remainder of
differentiation and characterization. Alternatively, after one week into stage 6, cells can be
aggregated into islet-like clusters with a simple method that uses an orbital shaker after singlecell dispersion from the plate. There are several advantages to this aggregation step, including
the ability to do assays incompatible with plated cells, such as a dynamic glucose stimulated
insulin secretion (GSIS) assay or transplantation into diabetic mice. Furthermore, this
aggregation step can eliminate inefficiencies in the differentiation and improve SC- cell
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function, as mostly endocrine cells seem to form clusters while other non-endocrine cells tend to
die off.

SC- cell assessment and controls (Steps 27-102). Our standard set of assessments include static
and dynamic GSIS assays to measure glucose responsiveness, insulin content and
proinsulin/insulin ratio to determine intracellular insulin levels and processing, flow cytometry to
measure the percentages of the different hormone-producing cells, as well as qRT-PCR and
immunostaining to confirm the presence of

cell specific markers. In particular, SC- cells can

be identified by their co-expression of C-peptide and NKX6-1, while chromogranin A (CHGA)
marks the general endocrine population. After aggregation, the clusters should have >80%
CHGA positivity, with about 20-60% of these cells being C-peptide+/NKX6-1+. Aggregated
SC- cell clusters can also be transplanted into mice with strepto otocin (STZ)-induced diabetes
to determine their in vivo performance. This protocol was originally developed and optimized
with the HUES8 cell line, and therefore it can serve as a good baseline to determine the success
of a particular experimental setup. Other cell lines that we have reported on here or
previously38,39 can also serve as controls when adapting this protocol to new cell lines. Once the
protocol is running efficiently, primary human islets serve as the best comparison for the
functional performance of SC- cells.

6.2.5 Limitations
This differentiation protocol is a multi-stage process that takes 5 weeks to complete, and
therefore there are a number of possible failure points that can prevent successful generation of
SC- cells. We provide quality control steps to try to mitigate unsuccessful differentiations, but
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due to the length of the protocol, some issues can be time-consuming to troubleshoot. These
problems can be exacerbated when attempting to adapt this methodology to a new cell line, as
certain stages may need to be optimized for different cell lines. Although we outline points of
optimization that have led to good success with the 10 cell lines presented here, we cannot rule
out that some cell lines may need additional optimizations or that other lines may not even be
capable of differentiating to an SC- cell lineage, particularly those derived from patients with
various forms of diabetes. Nevertheless, this methodology has allowed for the generation of SCcells from cell lines that have not previously worked with other protocols.
While we demonstrate some of most functional SC- cells yet shown in literature, the
SC- cells generated with this protocol are still not quite as mature as primary

cells found in

the body. The insulin secretion per cell for many cell lines remains lower than primary human
islets, and they still lack expression of important maturation genes, such as MAFA. While this
protocol generates clusters that consist of more than 80% endocrine cells, it does not produce
pure SC- cells.39 We have not extensively studied the other endocrine cell types generated in
these differentiations, and it remains unclear if these other endocrine cells are necessary for SCcell maturation and function. The increased accessibility that this protocol provides, however,
will hopefully help accelerate research into maximizing maturation of SC- cells.
Another potential limitation with this planar methodology is its scalability when
compared with a suspension-based system. Though suspension systems may theoretically be
capable of higher throughput, we have scaled this planar protocol up to T-150 flasks with high
differentiation efficiency and function, and there does not seem to be any indication that it could
not be scaled further with hyperflask setups. Notably, our T-150 differentiations have been able
to generate cell yields comparable to the highest yet reported in literature.29 Furthermore, while a
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suspension-based system may ultimately allow for greater cell production on a commercial scale,
this planar methodology is more amenable to autologous cell therapy applications as well as
small scale laboratory exploration of SC- cell biology and diabetes pathogenesis.

6.3 Materials
Here, we list all materials and equipment needed to complete an SC- cell differentiation
as well as to perform a standard set of in vitro assessments.

6.3.1 Biological Materials
The SC- cell differentiation protocol detailed here requires a source of hPSCs. We have
successfully generated functional SC- cells using a variety of different genetic backgrounds of
both embryonic (ESC) and induced pluripotent stem cell (iPSC) origin. HUES8, 1013-4FA,
1016SeVA, 1026-3FC, and 1031SeVA were provided by Harvard University. The H1 line was
obtained from WiCell. AN1.1 was generated at the Washington University in St. Louis Genome
Engineering and iPSC Center, while T2D001A was generated by us from mesenchyme with the
Sendai virus kit. We have published previously on WS4corr and WS4unedit.39 When first
attempting this differentiation protocol, we suggest starting with one of the cell lines we provide
data for, particularly HUES8, in order to validate a new experimental setup. Once this setup has
been verified, investigators can use the guidelines we provide for adapting and optimizing this
protocol to new hPSC lines. We have had good success using these guidelines, though we cannot
guarantee that all new cell lines will be capable of generating functional SC- cells.
When assessing the in vitro performance of SC- cells generated with this protocol,
primary human islets can be used as controls and can be purchased from Prodo Laboratories, Inc
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(Aliso Viejo, CA). To assess in vivo performance, these SC- cells can be injected into the
kidney capsule of immunodeficient mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) with
streptozotocin-induced diabetes, though this procedure is not detailed here.
!CAUTION All experiments involving hPSCs and/or mice should be done in accordance
with the appropriate institutional approval. Relevant data presented here using human
stem cells was approved by the Washington University ESCRO committee (approval
#15-002) with appropriate consent and conditions.

6.3.2 Reagents
Stem cell culture
mTeSR1 complete kit (Stem Cell Technologies, 85850)
Y-27632 (Abcam, ab120129)
TrypLE Express (Life Technologies, 12-604-039) or Accutase (Stem Cell Technologies,
07922)
Matrigel (Corning, 356230)
Dulbecco s Modified Eagle Medium (DMEM) (MilliporeSigma, D5796-500ML)
Human ESC or iPSC line (Table 1 lists the lines used here, but this protocol can be
adapted to other stem cell lines)
!CAUTION: The cell lines used in your research should be regularly checked to
ensure they are authentic and are not infected with mycoplasma.
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Table 6.1 hPSC Lines
Cell Line
HUES8
H1
1013-4FA
1016SeVA
AN1.1
1026-3FC
1031SeVA
T2D001A
WS4corr
WS4unedit

RRID
CVCL_B207
CVCL_9771
CVCL_A9M5
CVCL_UK18
CVCL_A9K3
CVCL_A9L4
CVCL_A9M2
CVCL_A9K4
CVCL_A9K6
CVCL_A9K5

Base media components
500 mL MCDB 131 (Cellgro, 15-100-CV or Life Technologies, 10372019)
glucose (MilliporeSigma, G7528)
NaHCO3 (MilliporeSigma, S5761)
bovine serum albumin (BSA) (Proliant, 68700)
CRITICAL: It is important that the BSA is fatty-acid free. We strongly
recommend using this specific BSA product. We have not observed an effect of
different batches of this product on differentiation efficiency.
ITS-X (Invitrogen, 51500056)
GlutaMAX (Invitrogen, 35050079)
vitamin C (MilliporeSigma, A4544)
penicillin/streptomycin (P/S) solution (Cellgro, 30-002-CI)
heparin (MilliporeSigma, H3149)
MEM nonessential amino acids (Corning, 20-025-CI)
ZnSO4 (MilliporeSigma, 10883)
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Trace Elements A (Corning, 25-021-CI)
Trace Elements B (Corning, 25-022-CI
Differentiation factors.

CRITICAL: We recommend that the exact differentiation factors be

used from the specified vendors listed below. Although some substitutions from other vendors
may work, we have validated the listed factors to be compatible with this differentiation
protocol. Activin A is particularly sensitive to changes in vendor, and so we strongly recommend
using the specified product.
CHIR99021 (Stemgent, 04-0004-10)
Activin A (R&D Systems, 338-AC)
KGF (Peprotech, AF-100-19)
LDN193189 (Reprocell, 040074)
TPPB (Tocris, 53431)
retinoic acid (MilliporeSigma, R2625)
SANT1 (MilliporeSigma, S4572)
ALK5i II (Enzo Life Sciences, ALX-270-445-M005)
L-3,3 ,5-Triiodothyronine (T3) (MilliporeSigma, 64245)
XXI (MilliporeSigma, 595790)
latrunculin A (Cayman Chemical,10010630)
bFGF (StemCell Technologies, 78003)
7.5% BSA for diluting factors (MilliporeSigma, A8412)
dimethyl sulfoxide (DMSO) for diluting factors (MilliporeSigma, D2650)
sterile molecular biology grade water for diluting factors (Corning 46-000-CM)
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Antibodies. The following antibodies can be used for both flow cytometry and immunostaining
assays. However, note that different glucagon (GCG) and somatostatin (SST) antibodies should
be used for immunohistochemistry.
rat anti-C-peptide (Developmental Studies Hybridoma Bank

University of Iowa, GN-

ID4-S, RRID:AB_2255626)
mouse anti-NKX6-1 (Developmental Studies Hybridoma Bank

University of Iowa,

F55A12-S, RRID:AB_532379)
goat anti-PDX1 (R&D Systems, AF2419, RRID:AB_355257)
sheep anti-NEUROG3 (R&D Systems, AF3444, RRID:AB_2149527)
rabbit anti-CHGA (ABCAM, ab15160, RRID:AB_301704)
rabbit anti-SST (ABCAM, ab64053, RRID:AB_1143012)
(histology only) mouse anti-SST (Santa Cruz Biotechnology, sc-55565,
RRID:AB_831726)
mouse anti-GCG (ABCAM, ab82270, clone IMD-7, RRID:AB_1658481)
(histology only) rabbit anti-GCG (Cell Marque, 259A-18, RRID:AB_1158356)
mouse anti-SOX17 (R&D Systems, MAB1924, clone # 245013, RRID: AB_2195646)
rabbit anti-FOXA2 (MilliporeSigma, 07-633, RRID:AB_390153)
mouse anti-OCT-3/4 (Santa Cruz Biotechnology, sc-5279, clone C-10,
RRID:AB_628051)
goat anti-NANOG (R&D Systems, AF1997, RRID:AB_355097)
anti-rat alexa fluor 488 (Invitrogen, A21208, RRID:AB_141709)
anti-mouse alexa fluor 488 (Invitrogen, A21202, RRID:AB_141607)
anti-mouse alexa fluor 647 (Invitrogen, A31571, RRID:AB_162542)
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anti-mouse alexa fluor 594 (Invitrogen, A21203, RRID:AB_141633)
anti-goat alexa fluor 647 (Invitrogen, A21447, RRID:AB_2535864)
anti-sheep alexa fluor 594 (Invitrogen, A11016, RRID:AB_10562537)
anti-rabbit alexa fluor 647 (Invitrogen, A31573, RRID:AB_2536183)
anti-rabbit alexa fluor 488 (Invitrogen, A21206, RRID:AB_2535792)
anti-rat PE (Jackson ImmunoResearch, 712-116-153, RRID:AB_2340657)
KRB buffer
Milli-Q H2O
NaCL (Fisher BioReagents, BP358-1)
KCl (Fisher BioReagents, BP366-500)
CaCl2 (Acros Organics, 447325000)
MgSO4 (Sigma Aldrich, M7506-500G)
Na2HPO4 (Fisher Chemical, S369-500)
KH2PO4 (MilliporeSigma, PX1562)
NaHCO3 (MilliporeSigma, S5761)
HEPES buffer solution (Life Technologies, 15630080)
BSA (Proliant, 68700)
NaOH (MilliporeSigma, S8045)
Other assay reagents
phosphate-buffered saline (PBS, Corning, 21-040-CV)
human insulin ELISA (ALPCO, 80-INSHU-E10.1)
proinsulin ELISA kit (Mercodia, 10-1118-01)
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Rneasy Mini Kit (Qiagen, 74016)
DNAse kit (Qiagen, 79254)
High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems, 4368814)
PowerUp SYBR Green Master Mix (Applied Biosystems, A25741)
4% (wt/vol) paraformaldehyde (PFA) (Electron Microscopy Sciences, 157-4-100)
Triton X (Acros Organics, 327371000)
donkey serum (Jackson Immunoresearch, 017000-121)
DAPI nuclear stain (Invitrogen, D1306)
DAPI Fluoromount-G, for histology (SouthernBiotech, 0100-20)
200 proof ethanol (Decon, 2716)
HCl (MilliporeSigma, 258148)
TRIS buffer (MilliporeSigma, T6066)
EDTA (Ambion, AM9261)
Histo-clear II (Electron Microscopy Sciences, 64111-04)
HistoGel (Thermo Fisher Scientific, HG-4000-012)
Quant-iT PicoGreen dsDNA kit (Invitrogen, P7589)
6.3.3 Equipment
In contrast to many of the cell culture media components, the following equipment and
consumables can be substituted with suitable replacements. We provide some suggestions that
have worked well in our differentiations.
Pipet-aid
pipettors (P10, P20, P200, and P1000)
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multi-channel pipettor, 200 µL
forceps
automated (Beckman Coulter, Vi-Cell XR) or manual cell-counting system
humidified cell culture incubator set at 37°C and 5% (vol/vol) CO2
orbital shaker suitable for use in a cell culture incubator (Benchmark Scientific, OrbiShaker CO2)
37°C water bath
biosafety cabinet
-20°C and -80°C freezers
light microscope
confocol microscope
flow cytometer
qRT-PCR thermocycler
plate reader capable of reading at 450 nm and 520 nm
pH meter
centrifuges for use with 50 mL conical tubes and 1.7 mL microcentrifuge tubes
pressure cooker for antigen retrieval (Electron Microscopy Sciences, Retriever 2100)
Consumables
serological pipettes (5 mL, 10 mL, and 25 mL; USA Scientific, 1075-0110, 1071-0810,
and 1072-5410)
2 mL aspirating pipette (Falcon, 1367516)
barrier pipet tips (P10, P20, P200, and P1000; Corning, 4135, 4136, 4139, and 4140)
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1.7 mL microcentrifuge tubes (BioExpress, C-3262-1)
50 mL conical tubes (USA Scientific, 1500-1211)
96-well tissue culture treated plates (Thermo Fisher Scientific, 167008)
24-well tissue culture treated plates (Falcon, 353226)
6-well tissue culture treated plates (Corning, 07-200-80)
T25 tissue culture treated flasks (TPP, 90026)
T75 tissue culture treated flasks (TPP, 90076)
T150 tissue culture treated flasks (TPP, 90151)
disposable sterile filter systems (50 mL, 500 mL, and 1000 mL; MilliporeSigma,
SE1M179M6; Corning, 431097 and 431098)
96-well qRT-PCR reaction plates and adhesive film (Applied Biosystems, 4346906 and
4311971)
transwell inserts for static GSIS (MilliporeSigma, PIXP01250)
reagent reservoirs (MIDSCI, P8010)
tubes for flow cytometry (Falcon, 352235)
tissue-loc histoscreen cassettes (Thermo Fisher Scientific, C-1000-BL)
micro coverslips (VWR, 48393-081)
glass slides (VWR, 48300-026)
Dynamic GSIS setup
Bio-Gel P-4 polyacrylamide beads (Bio-Rad, 150-4124)
high precision 8-channel dispenser pump (Ismatec, ISM931C)
0.015 ID inlet and outlet tubing (Ismatec, 070602-04-ND)
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0.04 ID connection tubing (BioRep Diabetes, Peri-TUB-040)
275- l cell chambers (BioRep Diabetes, Peri-Chamber)
dispensing nozzles (BioRep Diabetes, PERI-NOZZLE)
filter paper (BioRep Diabetes, PERI-FILTER)

6.3.4 Reagent Setup
Stem cell culture. Thaw the mTeSR1 5x supplement and mix it into the basal medium. Do not,
however, add Y-27632 until use during passaging. This media can be stored at 4°C for up to two
weeks, or aliquoted and stored at -20°C for up to 6 months.
For easier handling, the Matrigel used for coating plasticware should be aliquoted from the stock
bottle into microcentrifuge tubes. Before aliquoting, place pipette tips and tubes in a -20°C
freezer to get them cold, as warming concentrated Matrigel to room temperature will cause it to
solidify. Thaw the stock vial overnight at 4°C and keep on ice during aliquoting. Store the
aliquots at -80°C until use.

Base media. All stages of this differentiation protocol use custom media consisting of MCDB131
supplemented with the components detailed in Table 2. Note that BE3 is used for both stages 3
and 4. Make stock solutions of heparin at 10 mg/mL in PBS and ZnSO4 at 1 mM in sterile MilliQ water and store them at 4°C for up to 4 months. Antibiotics have been omitted from BE1-BE3,
but we have successfully generated SC- cells with P/S added during all stages, so it can be
added to early stages if needed. The remaining components can be added directly from the
purchased stock containers. For each media, mix all components together in the MCDB131
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bottle and warm in a 37°C water bath to dissolve the materials, particularly the BSA. Sterile
filter and store at 4°C for up to 2 months. Avoid extended light exposure when using all media.
CRITICAL: Do not add differentiation factors to these base media yet, as those
factors will be added each day before feeding cells.
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Table 6.2 Base media formulations
Media
BE1
stage 1

BE2
stage 2

BE3
stages 3 and 4

S5
stage 5

Enhanced
serum-free
media (ESFM)
stage 6

Reagent
MCDB131
Glucose
NaHCO3
BSA
GlutaMAX
MCDB131
Glucose
NaHCO3
BSA
GlutaMAX
Vitamin C
MCDB131
Glucose
NaHCO3
BSA
GlutaMAX
Vitamin C
ITS-X
MCDB131
Glucose
NaHCO3
BSA
GlutaMAX
Vitamin C
ITS-X
P/S
Heparin
(10 mg/mL stock)
MCDB131
Glucose
BSA
GlutaMAX
P/S
MEM nonessential
amino acids
Trace Elements A
Trace Elements B
ZnSO4
(1 mM stock)
Heparin
(10 mg/mL stock)
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Amount
500 mL
0.8 g
0.587 g
0.5 g
5 mL
500 mL
0.4 g
0.587 g
0.5 g
5 mL
22 mg
500 mL
0.22 g
0.877 g
10 g
5 mL
22 mg
2.5 mL
500 mL
1.8 g
0.877 g
10 g
5 mL
22 mg
2.5 mL
5 mL
500 µL
500 mL
0.23 g
10.5 g
5.2 mL
5.2 mL
5.2 mL
523 µL
523 µL
523 µL
523 µL

Differentiation factors. The differentiation factors for each stage are added fresh to the base
media immediately prior to every feed. In order to maintain optimum activity of these
differentiation factors, they should be aliquoted in microcentrifuge tubes to prevent no more than
2 freeze/thaw cycles for each aliquot. Factors reconstituted in a PBS solution containing 0.1%
BSA can be kept at 4°C for up to one week after a thaw, while factors in DMSO should always
be put back in the freezer after a thaw since they will already freeze at 4°C. Frozen factors can be
kept at -20°C in the short-term but should be kept at -80°C for extended storage up to a year.
Furthermore, avoid extended light exposure for all factors but particularly with retinoic acid.
To reconstitute factors, first create a sterile 0.1% (vol/vol) BSA solution by diluting a
7.5% BSA solution (MilliporeSigma, A8412) in PBS. Then, sterilely open each factor in a
biosafety cabinet and add the amount of either DMSO or 0.1% BSA solution to the lyophilized
powders as described in Table 3. Once reconstituted, aliquot into microcentrifuge tubes and store
in the freezer. Determine the appropriate aliquot size for each factor based on how much media
will be needed each feed for the chosen plate or flask, always adding a little more than needed to
avoid running out on the day of feeding. Note that bFGF is only needed for optimizing some cell
lines. !CAUTION: Take care when reconstituting factors to avoid creating dust from the
powders. See the MSDS of each factor for safety information.
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Table 6.3 Reconstituting differentiation factors

Factor

Factor
Amount
(mg)

Y-27632

50

CHIR99021
Activin A
KGF
RA
LDN193189
TPPB
SANT1
ALK5i II
T3
XXI

5
0.1
1
50
5
1
5
5
250
1

Latrunculin A

-

-

-

bFGF

1

molecular biology
grade water

10 mL

Solvent

Solvent
Amount

molecular biology
14.8 mL
grade water
DMSO
358 µL
0.1% BSA in PBS
1 mL
0.1% BSA in PBS
20 mL
DMSO
16.64 mL
DMSO
12.3 mL
DMSO
995 µL
DMSO
13.4 mL
DMSO
174 µL
DMSO
37.15 mL
DMSO
204 µL

Resulting Stock
Concentration

Aliquot
size for one
30 mL feed
(µL)

10 mM

33

30 mM
100 µg/mL
50 µg/mL
10 mM
1 mM
2 mM
1 mM
10 mM
10 mM
10 mM
Comes pre-mixed at
237 µM

3.5
33
33
6.6
6.6
3.5
8.3
3.5
3.5
3.5

100 µg/mL

130
3.5

KRB buffer. Properly making KRB buffer is critical to accurately assessing the glucose
responsiveness of SC- cells in a GSIS assay. First, make stock salt solutions by dissolving the
salts in Milli-Q water as detailed in Table 4. These stocks can be stored at room temperature and
may be used for several months.

Table 6.4 Stock salt solutions
Chemical

Concentration (M)

Amount (g)

NaCl
KCl
CaCl2
MgSO4
Na2HPO4
KH2PO4
NaHCO3

2.5
2
1
1
0.1
1
1

87.66
7.46
7.35
6.02
0.71
6.80
4.20
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Volume of
water (mL)
600
50
50
50
50
50
50

In contrast to the stock salt solutions, fresh KRB buffer should be made the day of performing
GSIS. Mix components as detailed in Table 5, adjust the pH to 7.4 with 1M NaOH, and sterile
filter before use.
Table 6.5 KRB buffer
Component
Milli-Q H2O
NaCl [2.5M]
KCL [2M]
CaCl2 [1M]
MgSO4 [1M]
Na2HPO4 [0.1M]
KH2PO4 [1M]
NaHCO3 [1M]
HEPES
BSA (Proliant)

Amount
458.1 mL
25.6 mL
1.25 mL
1.35 mL
0.6 mL
5 mL
0.6 mL
2.5 mL
5 mL
0.5 g

In addition to the base KRB buffer, make 50 mL of a 1 M glucose solution in Milli-Q water and
sterile filter. This glucose stock solution can be stored at 4ºC for several months. On the day of
the assay, use this stock 1 M glucose solution to make 2 mM (1:500 dilution in KRB) and 20
mM (1:50 dilution in KRB) glucose solutions. When performing GSIS in a 24-well plate, you
will need 2 mL of the 2 mM low glucose solution per sample and 1 mL of the 20 mM high
glucose solution per sample.

Immunocytochemistry (ICC) solution. Make a solution of 0.1% (vol/vol) Triton X and 5%
(vol/vol) donkey serum in PBS. This solution is used during immunostaining for ICC, flow
cytometry, and immunohistochemistry.

235

Acid-ethanol extraction solution. Make an acid-ethanol solution consisting of 1.5% (vol/vol) HCl
and 70% (vol/vol) ethanol in Milli-Q water. !CAUTION: Use a chemical fume hood and
appropriate PPE when handling concentrated HCl.

DNA content lysis buffer. For lysing cells for DNA quantification for the dynamic GSIS assay,
make a solution consisting of 10 mM Tris, 1 mM EDTA, and 0.2% (vol/vol) Triton X.

6.4 Differentiation Procedure
This SC- cell differentiation protocol takes approximately 5 weeks to complete, plus 1-2
weeks to expand the stem cells as well as assess the SC- cells at the end of the differentiation
(Figure 6.1). The cells need to be fed every day for a majority of the protocol, and there are no
pause points until the end of the differentiation when assessing SC- cell quality and function.
Thus if planning consecutive experiments with SC- cells generated with this protocol, we
recommend starting differentiations every week or so to eliminate lag time between experiments
by ensuring a continuous supply of SC- cells. Troubleshooting of earlier stages can be done on
shorter time scales, however, as issues with differentiation efficiency can often be checked with
flow cytometry, immunocytochemistry, and qRT-PCR at the end of particularly stages.
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Figure 6.1 Overview of the 6-stage SC- cell differentiation protocol.
HPSCs are first seeded onto Matrigel-coated plates. Over the next 5 weeks, these stem cells are
driven through intermediate cell types toward a cell fate by progressive stages of specific
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growth factor and small molecule combinations in serum-free media. This stepwise approach
attempts to recreate stages of embryonic development in order to achieve high differentiation
efficiency and SC- cell maturity. At the end of stages 1, 3, and 4, the current quality of the
differentiation can be assessed by flow cytometry (FC) and immunocytochemistry (ICC) of the
indicated markers. After two weeks into stage 6, the presence of SC- cells can be determined by
measuring marker expression with FC, ICC, and qRT-PCR. Furthermore, the functionality of
these cells can be assessed by a static glucose stimulated insulin secretion (GSIS) assay as well
as measuring both insulin content and the ratio of proinsulin/insulin content. These assays can be
completed on SC- cells still attached to the plate or after they have been aggregated into isletlike clusters during stage 6. Additional assays can be performed on these clusters, including a
dynamic GSIS assay to further profile their functional characteristics and transplantation into
diabetic mice to assess their in vivo performance.
6.4.1 Stage 0: Stem cell culture and seeding differentiations
TIMING ~8 days (1-2 h/d hands-on)
1. Prepare tissue culture-treated polystyrene (TCP) for cell culture by coating it with
Matrigel in DMEM for 1 hr at 37°C in the incubator. See the Matrigel product
information for the appropriate dilution as it is lot-dependent, though it is typically ~13
µL Matrigel per mL DMEM. After coating, aspirate the DMEM and replace it with
mTeSR1 supplemented with 10 µM Y-27632.
2. Thaw a vial of hPSCs. Mix well with 10 mL mTeSR1 supplemented with 10 µM Y27632 and centrifuge at 300g for 3 minutes at room temperature to pellet cells.
3. Aspirate the media, resuspend the cells in mTeSR1 supplemented with 10 µM Y-27632,
and seed a Matrigel-coated flask at a minimum cell density of 0.8 x 105 cells/cm2.
4. Keep cells in a 37°C incubator at 5% (vol/vol) CO2 for all cell culture. Feed them every
day with at least 0.2 mL /cm2 of mTeSR1 (without Y-27632) and increase this volume as
cells become more confluent (Figure 6.2A, 6.2F, S6.1A, S6.1K). Culture the cells until
approximately 90% confluency, which should take several days but will vary depending
on the growth rate of each cell line.
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5. Before passaging the hPSCs, prepare a new Matrigel-coated flask as described in Step 1
for continuing this propagation. Multiple and/or larger flasks can be used to further
expand the hPSCs and ensure adequate cell numbers for seeding differentiations. If ready
to start a new differentiation at this point, also prepare the desired number of
plates/flasks.
CRITICAL: We typically aim to generate enough cells to both start
differentiations and re-seed a propagation flask, as maintaining a propagation
flask minimizes lag time between starting new differentiations.
CRITICAL: As cells need time to recover after thawing from cryofrozen
storage, do not start differentiations directly from a thaw, instead allowing for 1-2
passages before seeding a differentiation. Confirm that the proliferation rate is
similar to the pre-frozen rate, and pluripotency markers such as OCT4 and
NANOG can be checked with immunostaining or flow cytometry.
!CAUTION: We have found that plates with smaller well sizes (24-well plates
and smaller) can sometimes experience issues with differentiation efficiency, as
some edge effects can arise. Therefore, we recommend starting with 6-well plates
or larger when first testing this protocol.
6. Passage the hPSCs by first aspirating the media and adding approximately 0.2 mL
TrypLE/cm2. Incubate for 10 minutes or less at 37°C.
7. Pipette up and down gently to disperse the cells, and perform a cell count.
CRITICAL: Successful hPSC culture relies on accurate and consistent cell
counts. While this can be done manually using a hemocytometer, we have found
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it helpful to use an automated cell counter to ensure consistent cell counts across
multiple users.
8. Centrifuge the cell suspension at 300g for 3 minutes at room temperature to pellet the
cells, aspirate the TrypLE, and resuspend the cells in mTeSR1 supplemented with 10 µM
Y-27632.
9. To continue a propagation flask, seed a Matrigel-coated flask at a cell density of at least
0.8 x 105 cells/cm2. To start differentiations, seed Matrigel-coated flasks/plates at a cell
density of between 0.32-0.74 x 106 cells/cm2, with cell density dependent on cell line.
CRITICAL: To avoid differences in proliferation rates and maintain a
consistent starting cell density for differentiation, we have found it best to seed
near confluency and start the differentiation the next day. Thus, a T-75
propagation flask will usually only be enough to start one T-75 differentiation.
Plate format should be determined by the specifics of each experiment. If the user
wants to perform characterization assays of the cells while still in planar culture
(such as flow cytometry during the differentiation or GSIS of planar stage 6 cells),
it is easiest to start the differentiation in either a 24-well or 6-well plate. If
characterization assays are to be performed after aggregation in stage 6, then
larger formats (6-well, T-75, or T-150) are easier to use.

!CAUTION: Single-cell passaging of stem cells over several weeks to months
can lead to karyotype abnormalities, and thus undifferentiated stem cells should
be checked frequently for proper karyotype if cultured for extended periods. To
avoid extended passaging, stem cells can be initially expanded and frozen down
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to create a cell bank, and each thawed vial can be used for only a few passages
when seeding differentiations. Alternatively, a clump passaging method, such as
those described in the manufacturer s manual for using mTeSR1, can be used to
reduce the risk of karyotype abnormalities.

Figure 6.2 Morphology of differentiating cells.
Representative brightfield images at each stage of the protocol for the HUES8 cell line. The
specific morphology at each stage can be indicative of the quality of the differentiation.
(A-E, K-O) Images at low magnification, scale bar = 500 µm. (F-J, P-T) Images at high
magnification, scale bar = 100 µm.
6.4.2 Stage 1: Definitive endoderm differentiation
TIMING 4 days (30-60 min/d hands-on)
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10. 24 hours after seeding the differentiation, cells should be a confluent monolayer (Figure
6.2B, 6.2G, S6.1B, S6.1L). Prepare stage 1 media by adding Activin A (final
concentration of 100 ng/mL; 1:1,000 dilution from stock aliquot) and CHIR99021 (final
concentration of 3 µM; 1:10,000 dilution from stock aliquot) to BE1 base media and
warm in a 37°C water bath. The amount of media needed for each feed throughout the
differentiation can be calculated from the Table 6, and Table 7 provides a convenient
summary of the full differentiation feeding schedule.
CRITICAL: The differentiation factors throughout the protocol need to be
added fresh each day before feeding to ensure maximum efficacy. Adhere to the 2
freeze/thaw limit for the factor aliquots.
Table 6.6 Differentiation media needed per feed
Plasticware
24-well
6-well
T25
T75
T150

Feeding
amount (mL)
0.6
2
5
15
30
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Table 6.7 SC- Cell Differentiation Sched le

Stage 0
Stage 1
Stage 2

Factor

Final
Concentrations

Dilution
from
Aliquots

Y-27632

10 µM

1:1,000

BE1

Activin A
CHIR99021
Activin A

100 ng/mL
3 uM
100 ng/mL

1:1,000
1:10,000
1:1,000

BE2

KGF

50 ng/mL

1:1,000

KGF
TPPB
SANT1
RA
LDN
KGF
TPPB
SANT1
RA
LDN
XXI
Alk5i
T3
SANT1
RA
Latrunculin
A
XXI
Alk5i
T3
SANT1
RA

50 ng/mL
0.2 µM
0.25 µM
2 µM
200 nM
50 ng/mL
0.2 µM
0.25 µM
0.1 µM
200 nM

1:1,000
1:10,000
1:4,000
1:5,000
1:5,000
1:1,000
1:10,000
1:4,000
1:100,000
1:5,000

1 µM
10 µM
1 µM
0.1 µM
0.25 µM
1 µM

1:10,000
1:10,000
1:10,000
1:4,000
1:100,000
1:237

1 µM
10 µM
1 µM
0.1 µM
0.25 µM

1:10,000
1:10,000
1:10,000
1:4,000
1:100,000

Day of
Differentiation

Base Media

1

mTeSR1

2

BE1

3-5
6-7

Stage 3

8-9

BE3

Stage 4

10-13

BE3

14

S5

Stage 5

15-20

S5

Stage 6

21-27

ESFM

-

-

-

Stage 6
After
aggregating
into clusters

28-35+

ESFM

-

-

-
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11. Wash cells once with PBS and add BE1 containing Activin A and CHIR99021.
12. After 24 hours, replace this media with BE1 containing only Activin A. Culture for an
additional 3 days with this media, replacing the media every day. Note that it is normal
for there to be some amount of cell death throughout stage 1, but the remaining cells
should still form a monolayer that completely covers the plate (Figure 6.2C, 6.2H, S6.1C,
S6.1M).
CRITICAL: The duration of exposure to CHIR99021 is important for
endoderm specification, so be sure to wait a full 24 hours before replacing the
Activin A/CHIR99021 media with the stage 1 media containing only Activin A.
CRITICAL: Efficient endoderm induction is crucial for the success of the rest
of the differentiation protocol. Thus, it can be beneficial to check the percentage
of FOXA2+/SOX17+ cells with flow cytometry (Figure 6.3A) or
immunocytochemistry (Figure 6.3D) to ensure expression in >90% of cells. While
we have empirically found these culture parameters and markers to work well,
there are many published variations for making definitive endoderm that could be
used. 8

15
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Figure 6.3 Quality control during differentiation.
To quantitatively assess differentiation status, flow cytometry can be used to look for key
markers. (A) At the end of stage 1 FOXA2+/ SOX17+ ( >90%) is evaluated with flow
cytometry. (B) At the end of stage 3 PDX1+ (>80%) is evaluated with flow cytometry. (C) At
the end of stage 4 PDX1+/NKX6-1+ (>40%) is evaluated with flow cytometry. (D-E) These
markers can also be quickly assessed qualitatively with ICC. Scale bars = 100 µm.
6.4.3 Stage 2: Primitive foregut generation
TIMING 2 days (30-60 min/d hands-on)
13. Prepare stage 2 media by adding KGF (final concentration of 50 ng/mL; 1:1,000 dilution
of stock aliquot) to BE2 base media and warm in a 37°C water bath.
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14. Aspirate stage 1 media and add BE2 supplemented with KGF. At the beginning of this
stage, cells should remain as a monolayer that completely covers the plate (Figure 6.2C,
6.2H, S6.1C, S6.1M), though there may be dead cells floating in the media as a result of
stage 1 endoderm induction.
15. Culture the cells for 2 days, replacing the media after the first 24 hours.
CRITICAL: We have not found a good marker that indicates whether cells at
the end of stage 2 will be competent to further differentiate into SC- cells. Thus,
any modulations in stage 2 must be assessed at later stages.
6.4.4. Stage 3: Generating pancreatic progenitor 1 cells
TIMING 2 days (30-60 min/d hands-on)
16. At the beginning of this stage, the cells often adopt a hill/valley morphology, with
some cells clustering together while others remaining in a monolayer (Figure 6.2D, 6.2I,
S6.1D, S6.1N). Prepare stage 3 media by adding KGF (final concentration of 50 ng/mL;
1:1,000 dilution of stock aliquot), TPPB (final concentration of 0.5 µM; 1:10,000 dilution
of stock aliquot), SANT1 (final concentration of 0.25 µM; 1:4,000 dilution of stock
aliquot), RA (final concentration of 2 µM; 1:5,000 dilution of stock aliquot), and
LDN193189 (final concentration of 200 nM; 1:5,000 dilution of stock aliquot) to BE3
base media and warm in a 37°C water bath.
17. Aspirate stage 2 media and add BE3 supplemented with the differentiation factors.
18. Culture the cells for 2 days, replacing the media after the first 24 hours.
CRITICAL: Stage 3 is designed to turn on the pancreatic transcription factor
PDX1. To determine the quality of the differentiation thus far, PDX1 expression
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can be measured quantitatively with flow cytometry (Figure 6.3B) or visually
with ICC. Differentations should achieve at least 80% PDX1+ cells.
?TROUBLESHOOTING
6.4.5 Stage 4: Generating pancreatic progenitor 2 cells
TIMING 4 days (30-60 min/d hands-on)
19. At the beginning of this stage, cells should be a confluent monolayer, although some cell
clustering may persist from the previous stage (Figure 6.2E, 6.2J, S6.1E, S6.1O). Prepare
stage 4 media by adding KGF (final concentration of 50 ng/mL; 1:1,000 dilution of stock
aliquot), TPPB (final concentration of 0.5 µM; 1:10,000 dilution of stock aliquot),
SANT1 (final concentration of 0.25 µM; 1:4,000 dilution of stock aliquot), RA (final
concentration of 0.1 µM; 1:100,000 dilution of stock aliquot), and LDN193189 (final
concentration of 200 nM; 1:5,000 dilution of stock aliquot) to BE3 base media and warm
in a 37°C water bath. Note that this is the same media used in stage 3 with the exception
of a significantly lower RA concentration.

20. Aspirate stage 3 media and add BE3 supplemented with stage 4 differentiation factors.
Culture the cells for 4 days, replacing the media every day.
CRITICAL: Stage 4 is designed to turn on the important

cell transcription

factor NKX6-1. Checking for the percentage of PDX1+/NKX6-1+ cells with flow
cytometry (Figure 6.3C) and ICC (Figure 6.3E) at this stage is our most routinely
used quality control check during this differentiation protocol. Differentiations
should have >40% PDX1+/NKX6-1+ cells at the end of stage 4.
?TROUBLESHOOTING
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6.4.6 Stage 5: Endocrine induction
TIMING 7 days (30-60 min/d hands-on)
21. At the beginning of this stage, the cells should continue to be in a monolayer, though
often some holes may appear in this monolayer (Figure 6.2K, 6.2P, S6.1F, S6.1P).
Prepare stage 5 media by adding SANT1 (final concentration of 0.25 µM; 1:4,000
dilution of stock aliquot), RA (final concentration of 0.1 µM; 1:100,000 dilution of stock
aliquot), XXI (final concentration of 1 µM; 1:10,000 dilution of stock aliquot), Alk5i II
(final concentration of 10 µM; 1:10,000 dilution of stock aliquot), and T3 (final
concentration of 1 µM; 1:10,000 dilution of stock aliquot) to S5 base media and warm in
a 37°C water bath.
CRITICAL: For the first 24 hrs only, add latrunculin A (final concentration of
1 µM; 1:237 dilution of stock aliquot) to this stage 5 media.
?TROUBLESHOOTING
22. Aspirate stage 4 media and add S5 media supplemented with the differentiation factors,
including latrunculin A.
23. After the first 24 hours, aspirate the media and replace it with S5 media without
latrunculin A. Note that because latrunculin A depolymerizes the cytoskeleton and thus
the ability of cells to pull against their substrate, the cells will look spherical after the first
24 hours of stage 5 (Figure 6.2L, 6.2Q, S6.1G, S6.1Q). The cells should begin to flatten
out again after removal of latrunculin A.
24. Continue to culture the cells with S5 media (without latrunculin A) for six more days.
Replace the media every day through day 4 of stage 5. Starting on day 5, cells for the
remainder of the protocol can be fed every other day instead of every day.
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CRITICAL: Stage 5 is designed to convert the pancreatic progenitor population
into endocrine. There can be up to 30% cell death during this stage, the extent of
which is often dependent upon the number of progenitors lacking PDX1 expression.
The cells tend to recover, however, and most of the plate should still be covered with
cells in a successful differentiation by the end of this stage (Figure 6.2M, 6.2R). The
degree of overall endocrine induction can be checked with flow cytometry by
quantifying the percentage of CHGA+ cells, which should be >80% at the end of
stage 5. Within this population, the percentage of specifically SC- cells can be
determined by those that co-express NKX6-1+/C-peptide+. Furthermore, qRT-PCR at
this point should reveal high expression of the hormones insulin, glucagon, and
somatostatin.

6.4.7 Stage 6: SC- cell mat ration
TIMING 14-30+ days (30-60 min/d hands-on)
25. At the beginning of this stage, there will often be some regions of the plate with bare
spots and others where cells are beginning to cluster together (Figure 6.2M, 6.2R, S6.1H,
S6.1R). Warm ESFM in a 37°C water bath. Note that there are no differentiation factors
that need to be added to this media.
26. Aspirate stage 5 media and replace with ESFM. Continue to replace the media every
other day. After a few days in ESFM, the cells often become larger and more rounded
(Figure 6.2N, 6.2S, S6.2I, S6.2S). They may also start to have a golden hue to them under
a brightfield microscope.
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CRITICAL: We have found that in vitro function peaks around 14 days into stage
6. The cells can remain functional for weeks in culture (Figure S6.2A), though their
function may deteriorate after extended periods of in vitro culture.
(A) Assessing cells in planar culture
(i) Planar culture can be continued by replacing the ESFM every other day through
day 14, at which point the standard set of assessments described in the next section
can be performed to evaluate the SC- cells.
(B) Aggregating endocrine cells into islet-like clusters
(i) Alternatively, the SC- cells can be aggregated into clusters (Figure 6.2O, 6.2T,
S6.1J, S6.1T) for use in assays which cannot be performed on TCP, such as
dynamic GSIS and transplantation into diabetic mice. On day 7 of stage 6,
aspirate the media and add approximately 0.2 mL TrypLE/cm2. Incubate for 10
minutes at 37°C.
(ii) Pipette up and down gently to disperse the cells, and perform a cell count.
(iii) Centrifuge the cell suspension at 300g for 3 minutes at room temperature to
pellet the cells, aspirate the TrypLE, and resuspend the cells in ESFM at a
concentration of 1 million cells/mL.
(iv) Pipette 5 mL of this cell solution into one well of a 6-well plate. Put this plate
on an orbital shaker at 100 RPM in the cell culture incubator at 37°C and 5%
CO2.
(v) Continue to feed the cells every other day with ESFM on the orbital shaker. Cells
will form clusters over the next several days, reaching a stable cluster size of
approximately 200-250 µm in diameter (Figure 6.2J, Supplemental Figure 6.3A).
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?TROUBLESHOOTING
(vi) After allowing the cells to form clusters and recover over the next week, the
islet-like clusters can be evaluated around day 14 of stage 6 by all the assessment
methods described in the next sections.
CRITICAL: Up to 50% of cells can be lost during aggregation depending on
the efficiency of the differentiation. Mostly endocrine cells seem to aggregate into
clusters with this method, and thus this simple aggregation step tends to purify the
endocrine population (Figure S6.3B) since any remaining progenitor and offtarget cell types are prone to dying during this procedure. As a result, we tend to
get better performance out of aggregated clusters when compared to cells left on
the plate. If functional performance is lacking during static GSIS assays
performed in planar culture, this aggregation may help to improve results (Figure
S6.3C). After aggregation, clusters should consist of >80% CHGA+ cells and
approximately 20-60% NKX6-1+/C-peptide+ cells as assessed by flow cytometry.
For any given cell line, the percentage of SC- cells generated after aggregation is
similar from different culture vessel sizes used for the differentiation (Figure
S6.3D).

6.5 Characterization Procedure
6.5.1 Static GSIS
TIMING 6 hours (4 hours for setup and sample collection, 2 hours to quantify insulin with
ELISA)
The SC- cells attain function typically between days 10-14 of stage 6, at which point
they can be assessed by a static glucose-stimulated insulin secretion assay. On the day of the
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assay, prepare fresh KRB buffer as well as the low (2 mM) and high (20 mM) glucose
solutions as described in Reagent Setup. The remainder of the procedure differs slightly
depending on whether it is performed on cells still attached to the plate or on aggregated
clusters.
(A) Static GSIS for cells attached to TCP
(i) Aspirate the media and wash each well 3x with KRB buffer.
(ii) Add the 2 mM glucose solution into each well and incubate for 1 hour at 37°C
and 5% CO2. For a 24-well plate, use 1 mL of the glucose solutions for all steps.
Scale accordingly for other well sizes.
CRITICAL: During all incubations, return the unused low and high glucose
solutions to the incubator with the caps loosened to maintain optimal
temperature and pH.
(iii) After one hour, aspirate the low glucose solution and wash once with KRB
buffer. Add fresh 2 mM low glucose to each well again and incubate for 1 hour.
(iv) After one hour, pipette the supernatants into a separate, adequately labeled
plate. The insulin within these samples that was secreted at low glucose will be
quantified later. The samples can either be placed in the fridge at 4°C if they are
to be quantified immediately following the assay, or at -80ºC for up to 3
months.
(v) Wash each well once with KRB buffer and replace with the 20 mM high
glucose solution. Incubate for 1 hour.
(vi) After one hour, pipette the supernatants into a separate, adequately labeled
plate. The insulin within these samples that was secreted at high glucose will be
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quantified later. The samples can either be placed in the fridge at 4°C if they are
to be quantified immediately following the assay, or at -80ºC for up to 3
months.
(vii)

Add TrypLE to each well and place in the incubator for 10 minutes.

(viii)

Pipette up and down to disperse the cells and perform cell counts on each

well.
PAUSE POINT The samples can be either quantified immediately or stored at
-80ºC for up to 3 months.
(B) Static GSIS for aggregated clusters
(i) Prepare two 24-well plates by pipetting 1 mL of 2 mM glucose into a well of
each plate for every sample to be run. Prepare a third 24-well plate by pipetting
1 mL of 20 mM glucose into one well for every sample to be run.
(ii) In a fourth 24-well plate, use forceps to place a transwell insert
(MilliporeSigma, PIXP01250) into a well for every sample to be run. Pipette 0.5
mL of KRB buffer into each transwell.
(iii) Collect ~15-30 SC- cell clusters with a P1000 and pipette them into one of the
transwell inserts. We recommend running at least three replicates per condition.
(iv) Add another 0.5 mL of KRB buffer into each transwell and allow the clusters to
settle.
(v) Use forceps to remove each transwell, being careful to do so slowly and angling
the transwell to allow wicking to drain the liquid. Place each transwell into
another well containing fresh KRB to further wash each sample.
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CRITICAL: During all steps that transfer the transwell inserts to another
well, care should be taken to ensure that almost all of the liquid has drained.
When performed correctly, this draining should only take about 5 seconds per
transwell.
(vi) Transfer each transwell into a well of one of the 24-well plates containing 2 mM
glucose. Incubate for 1 hour at 37°C and 5% CO2.
CRITICAL: During all incubations, also place the 24-well plates containing
the unused low and high glucose solutions in the incubator to maintain optimal
temperature and pH.
(vii)

After 1 hour, transfer each transwell into a well of the other 24-well plate

containing fresh 2 mM glucose and incubate for another hour. Discard the used
plate.
(viii)

After 1 hour, transfer each transwell into a well of the 24-well plate

containing fresh 20 mM glucose and incubate for another hour. Keep the used
plate, as the insulin within these samples that was secreted at low glucose will
be quantified later. The samples can either be placed in the fridge at 4°C if they
are to be quantified immediately following the assay, or at -80ºC for up to 3
months.
(ix) After 1 hour, transfer each transwell into a well of another 24-well plate
containing 1 mL of TrypLE and incubate for 10 minutes. Keep the used plate, as
the insulin within these samples that was secreted at high glucose will be
quantified later. The samples can either be placed in the fridge at 4°C if they are
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to be quantified immediately following the assay, or at -80ºC for up to 3
months.
(x) Pipette up and down to disperse the cells and perform cell counts on each well.
PAUSE POINT The supernatant samples can be either quantified
immediately or stored at -80ºC for up to 3 months.
27. After either procedure, quantify the total amount of insulin within each sample from both
the low and high glucose challenges on a human insulin ELISA according to the
manufacturer s instructions. Depending on the user s needs, a C-peptide ELISA can
alternatively be used to quantify insulin secretion. Here, we present insulin units in either
µIU (international units) or ng, where 1 µIU equals 0.0348 ng insulin. To normalize each
sample, divide this calculated insulin value by its respective cell count to calculate the
total insulin secreted per cell.
CRITICAL: Due to the high functionality of the SC- cells generated with this
protocol, we often have to dilute our samples in KRB (typically by 3-5x) in order to
avoid saturating the ELISA.
CRITICAL: In order to account for variations in differentiation efficiency between
cell lines, insulin secretion can also be normalized to the number of SC- cells rather
than the total cell number (Figure S6.2B). Multiply the cell count for each GSIS
sample by the percentage of C-peptide+/NKX6-1+ cells as assessed by flow cytometry
to get the total number of SC- cells per sample, and divide the insulin secreted in
each sample by its number of SC- cells.
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6.5.2 Intracellular flow cytometry
TIMING 2 days (2.5 h sample preparation and primary antibody staining on day 1, 3 h sample
preparation and staining secondary antibodies on day 2)
28. At the end of the desired stage, aspirate the media and add approximately 0.2 mL
TrypLE/cm2. For aggregated clusters at the end of stage 6, pipette the clusters into a
microcentrifuge tube with a P1000 and add 1 mL TrypLE. Incubate for 10 minutes at
37°C.
29. Pipette up and down gently to disperse the cells, transfer the solution to a
microcentrifuge tube, and centrifuge at 300g for 3 minutes at room temperature.
30. Aspirate the TrypLE and add 0.5 mL of 4% PFA solution for 30 minutes at 4ºC.
CRITICAL: To avoid cells sticking together, be sure to disperse the cell pellet
shortly after adding the 4% PFA by either pipetting up and down or vigorously
shaking the microcentrifuge tube.
!CAUTION: We advise using the 4% PFA in a chemical fume hood to avoid repeated
exposure.
31. Centrifuge at 1000g for 3 minutes at room temperature. Remove and appropriately
dispose of the PFA.
32. Resuspend in 1 mL PBS and mix well to disperse the cell pellet.
PAUSE POINT These fixed cells can be stored at 4°C for at least a month.
33. Centrifuge at 1000g for 3 minutes at room temperature.
34. Discard the PBS, add 0.5 mL of ICC solution (see Reagent Setup ), mix well, and
incubate for 45 minutes at 4°C.
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35. Prepare the primary antibodies by diluting them in ICC solution as described in Table 8.
Cells can be co-stained with multiple markers depending on the capabilities of the flow
cytometer and compatibility of the antibodies.
Table 6.8 Immunostaining antibodies
End of
Stage #
0
1
2
3
4
5

6

Primary Antibodies
(dilution, compatible secondary antibody)
OCT4 (1:300, anti-mouse alexa fluor 488)
NANOG (1:300, anti-goat alexa fluor 647)
SOX17 (1:300, anti-mouse alexa fluor 647)
FOXA2 (1:300, anti-rabbit alexa fluor 488)
PDX1 (1:300, anti-goat alexa fluor 647)
PDX1 (1:300, anti-goat alexa fluor 647)
NKX6-1 (1:100, anti-mouse alexa fluor 488)
C-peptide (1:300, anti-rat PE)
CHGA (1:1000, anti-rabbit alexa fluor 488)
NKX6-1(1:100, anti-mouse alexa fluor 488)
CHGA (1:1000, anti-rabbit alexa fluor 488)
C-peptide (1:300, anti-rat PE)
NKX6-1(1:100, anti-mouse alexa fluor 488)
GCG (1:300, anti-mouse alexa fluor 647)
SST (1:300, anti-rabbit alexa fluor 488)

36. Centrifuge the samples at 1000g for 3 minutes at room temperature.
37. Remove the ICC solution. Resuspend cells in 0.3 mL of the primary antibody solutions
and incubate overnight at 4°C.
38. Prepare the appropriate secondary antibodies by diluting them in ICC solution at a 1:300
dilution.
39. Centrifuge the samples at 1000g for 3 minutes at room temperature.
40. Remove the ICC solution containing the primary antibodies. Resuspend cells in 0.5 mL
ICC solution, mix well, and centrifuge the samples at 1000g for 3 minutes at room
temperature.
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41. Remove the ICC solution. Resuspend cells in 0.3 mL of the prepared secondary
antibodies, mix well, and incubate for 2 hours at 4°C.
42. Centrifuge the samples at 1000g for 3 minutes at room temperature. Remove the ICC
solution and resuspend cells in 0.3 mL ICC solution.
43. Pipette the stained cell solution through the strainer caps on polystyrene test tubes used
for flow cytometry, and run samples on a flow cytometer the same day. Record
approximately 50,000 cells for each sample.
CRITICAL: Because the markers measured during the differentiation protocol only
turn on after the start of differentiation, it is useful to include stem cells as a negative
biological control when running the samples on the flow cytometer (Figure 6.3A-C).
Perform this staining procedure on fixed stem cells in parallel with the other samples.
A stock of fixed stem cells can be kept at 4°C for at least one month for this purpose.
The results can be analyzed with an appropriate software package, such as FlowJo.
Cell debris and doublets can be gated out (Figure S6.4A), and then the negative stem
cell control can be used to gate the cell populations (Figure 6.3A-C). Human islets can
be used as a positive control for PDX1, NKX6-1, GCG, SST, C-peptide, and FOXA2.
The OVCAR-3 cell line can be used as a positive control for SOX17. A secondary
antibody only control can also be run (Figure 6.4B).
6.5.3 Immunocytochemistry
TIMING 2 days (2 h sample preparation and primary antibody staining on day 1, 3 h sample
preparation and staining secondary antibodies on day 2)
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Throughout the protocol, cells can be stained, fixed, and immunostained directly on the plate for
markers of various differentiation stages. At the desired timepoint, aspirate the media and wash
each well with PBS.
44. Aspirate the PBS and add enough 4% PFA to cover the cells. Incubate at room
temperature for 30 minutes.
45. Remove and properly dispose of the PFA.
46. Wash the wells once with PBS and add ICC solution (see Reagent Setup ) for 45
minutes at room temperature to block and permeabilize the cells.
47. Prepare the primary antibodies by diluting them in ICC solution as described in Table 8.
48. Remove the ICC solution, add the diluted primary antibodies, and incubate overnight at
4°C.
49. Prepare the appropriate secondary antibodies by diluting them in ICC solution at a 1:300
dilution.
50. Remove the primary antibodies, wash once with ICC solution, and add the secondary
antibodies. Incubate for 2 hours at room temperature, protecting samples from light.
51. Remove the secondary antibodies, wash once with ICC solution, and add the DAPI
nuclear stain. Incubate for 12 minutes at room temperature, protecting samples from
light.
52. Remove the DAPI nuclear stain, wash once with ICC solution, and then once with PBS.
Store samples in PBS at 4°C until they are imaged on a confocal or wide-field
fluorescence microscope. The images can be processed with an appropriate software
package, such as ImageJ. Examples of secondary antibody only controls are given in
Figure S5.
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6.5.4 Histology for stage 6 aggregated clusters
TIMING 2 days (6 h sample preparation and primary antibody staining on day 1, 3 h sample
preparation and secondary staining on day 2)
53. In order to immunostain stage 6 SC- cells after aggregation, the clusters must be
embedded in paraffin and sectioned into slides. To begin this procedure, pipette the
clusters into a microcentrifuge tube with a P1000. Allow the clusters to settle, remove the
media, and wash once with PBS.
54. Remove the PBS and add 0.5 mL of 4% PFA solution for 30 minutes at room
temperature.
55. Remove and properly dispose of the PFA.
56. Wash once with PBS, suspend clusters in 20 µL of warmed histogel, and allow the
histogel to solidfy for 30 minutes at 4°C.
57. Remove the samples from the microcentrifuge tube with a 200 µL pipette, place them in
a histoscreen cassette, and store it in 70% (vol/vol) ethanol.
58. Paraffin-embed samples and section onto glass slides using standard histological
techniques.
PAUSE POINT The sectioned samples can be stored for at least 1 year.
59. To remove the paraffin from the slides in preparation for immunostaining, fill 9
containers with 100 mL of the following liquids and transfer the slides between them for
the time indicated in Table 9.
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Table 6.9 De-paraffin histological sections
Solution
Histoclear
Histoclear
100% ethanol
100% ethanol
95% ethanol
95% ethanol
70% ethanol
70% ethanol

Submersion time (min)
5
5
2
2
2
2
2
2

60. Insert and remove glass slides from Milli-Q water until no ethanol remains.
61. Perform antigen retrieval by placing slides into a 0.05% (vol/vol) EDTA solution and run
in a pressure cooker for 2 hours.
62. Rinse glass slides carefully and slowly at least two times with Milli-Q water and once
with PBS.
63. Block histology samples for 30 minutes at room temperature by pipetting 300 µL of ICC
solution onto the slide and placing a coverslip on top.
64. Remove the coverslip and ICC solution. Apply primary antibodies diluted in ICC as
detailed in Table 8. Note, however, that we use different GCG and SST antibodies for
immunohistochemistry, and this GCG antibody can be diluted 1:2.
65. Place coverslips on the slides and incubate in a humidified box overnight at 4°C by
laying the slides on top of wet paper towels inside a slide box.
66. Remove the coverslips and wash the slides with PBS.
67. Remove the liquid and apply the appropriate secondary antibodies at a 1:300 dilution in
ICC solution.
68. Place coverslips on the slides and incubate in the humidified box for 2 hours at room
temperature.
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69. Remove the coverslips and wash slides in PBS for 5 minutes.
CRITICAL: Do not let samples dry out at this point.
70. Remove the liquid and use a P1000 pipette to place 2-3 drops of DAPI Fluoromount-G
solution to each slide.
71. Place a coverslip onto each slide and allow the solution to dry, protecting them from
light.
CRITICAL: Be careful to not introduce bubbles under the coverslip,
especially where samples are located on the slide.
72. Use a sealing solution, such as clear nail polish, to secure the coverslip. Store the samples
in a slide box at 4°C until they are imaged on a confocal or wide-field fluorescence
microscope.
6.5.5 qRT-PCR
TIMING 7 hours (1.5 h for RNA extraction, 2.5 h for reverse transcription, 3 h for plate setup
and PCR reaction)
73. To process planar cells for qRT-PCR directly on the plate during differentiation, aspirate
the media, add RLT lysis buffer into each well, incubate at room temperature for 5
minutes, pipette vigorously to disperse cells, and transfer to a microcentrifuge tube.
Alternatively, collect aggregated stage 6 clusters in a microcentrifuge tube, aspirate the
media, add RLT lysis buffer, incubate at room temperature for 5 minutes, and pipette
vigorously to disperse cells.
PAUSE POINT Lysed cells can be stored in RLT buffer at -20°C for several
months.
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74. Continue with the mRNA extraction, reverse transcription reaction, and PCR reaction
according to the manufacturer s instructions.
75. There are large changes in gene expression as cells progress through the various stages
that can be helpful to track the success of a differentiation. Table 10 details markers for
each stage with validated primers.
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Table 6.10 qRT-PCR primers for each stage
End
of
Stage
#
0
1
3
4

5

6

Marker

Forward Primer

Reverse Primer

OCT4
GGTTCTCGATACTGGTTCGC
GTGGAGGAAGCTGACAACAA
(POU5F1)
ATGGAGGAGGGAAGAGGAGA
GATTTGTGGGCCTGAAGAAA
NANOG
TACGTGTTCATGCCGTTCAT
CGACTGGAGCAGCTACTATGC
FOXA2
TCTGCCTCCTCCACGAA
CAGAATCCAGACCTGCACAA
SOX17
CGTCCGCTTGTTCTCCTC
CCTTTCCCATGGATGAAGTC
PDX1
CGTCCGCTTGTTCTCCTC
CCTTTCCCATGGATGAAGTC
PDX1
CCGAGTCCTGCTTCTTCTTG
ATTCGTTGGGGATGACAGAG
NKX6-1
TTAAACCCTCTTCAGAGCAAGC GATTTAGCACACTGATCACACGA
SOX9
CTTCGTCTTCCGAGGCTCT
CTATTCTTTTGCGCCGGTAG
NEUROG3
GGAGCTTGAGTCCTGAGGG
TCTACGACAGCAGCGACAAC
NKX2-2
ATCAGCCCACTCTCGCTGTA
GCCCCAGGGTTATGAGACTAT
NEUROD1
TGACCTCAACGATGCATTTC
CTGTCCTGGCTCTTCTGCTC
CHGA
CCGAGTCCTGCTTCTTCTTG
ATTCGTTGGGGATGACAGAG
NKX6-1
CAATGCCACGCTTCTGC
TTCTACACACCCAAGACCCG
INS
CAATGCCACGCTTCTGC
TTCTACACACCCAAGACCCG
INS
AGCTGCCTTGTACCAGCATT
TGCTCTCTCTTCACCTGCTCT
GCG
TGGGTTCAGACAGCAGCTC
CCCAGACTCCGTCAGTTTCT
SST
TGACCTCAACGATGCATTTC
CTGTCCTGGCTCTTCTGCTC
CHGA
ACATGTGGCAGTGTTGCATT
TCATTGTGCTCTCTGTTGCAT
IAPP
TCACGAAGTCGTTCTTGCTG
CATGCTTTGTTAGGGATGGG
ISL1
ATGCTGGACGACAGAGCC
CCTTCTTCAGGTCCTCCTCC
GCK
CATAGAGAACGTGGCAGCAA
ATGCCCGGAACTTTTTCTTT
MAFB
6.5.6 Insulin content and proinsulin/insulin ratio
TIMING 3 days (1 h on day 1, 10 min on day 2, 2 h on day 3 for each ELISA)
76. Around day 14 of stage 6, aspirate the media from cells still attached to the plate and
wash with PBS. For aggregated clusters, pipette the clusters into a microcentrifuge tube
with a P1000 and wash with PBS.
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77. For normalization of total insulin content, disperse either an equivalent but separate well
of planar cells or half of the aggregated clusters with TrypLE. Perform cell counts on
these samples.
CRITICAL: Cells should not be single-cell dispersed with TrypLE before adding
the acid-ethanol solution, as this can interfere with the assay. Thus, to obtain cell
counts for insulin content when cells are still attached to the plate, use a separate well
from the same differentiation. This approximation works well since cell numbers are
consistent across similar wells of the same differentiation. For aggregated clusters
within a microcentrifuge tube, gently pipette up and down to evenly suspend the
clusters, transfer half of the volume to a new microcentrifuge tube, and disperse these
cells for counting.
78. Remove the PBS from the washed cells and add 0.5 mL acid-ethanol (see Reagent
Setup ) per well of a 24-well plate or to clusters in a single microcentrifuge tube. For
cells still attached to the plate, pipette up and down vigorously to disperse the cells and
move to a microcentrifuge tube. Vortex the tubes vigorously and incubate overnight at
-20°C.
79. After 24 hours, vortex the microcentrifuge tubes vigorously and place them back at
-20°C.
80. After an additional 24 hours, vortex the microcentrifuge tubes vigorously and centrifuge
them at 2,100g for 15 minutes at room temperature.
81. Transfer the 0.5 mL supernatant to a new tube and neutralize it by adding 0.5 mL of 1M
TRIS.
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82. To determine insulin content, run this solution on a human insulin ELISA according to
the manufacturer s instructions. Normalize to cell counts to get the total insulin content
per cell.
CRITICAL: Due to the high levels of insulin within SC- cells generated with this
protocol, we often have to dilute our samples in KRB by 500x or more in order to
avoid saturating the insulin ELISA.
83. To determine the proinsulin/insulin ratio, run the same samples on a human proinsulin
ELISA according to the manufacturer s instructions. To get the proinsulin/insulin ratio,
simply divide the proinsulin ELISA values by those from the insulin ELISA from the
same sample.
CRITICAL: Due to the high levels of insulin and proinsulin within SC- cells
generated with this protocol, we often have to dilute our samples in KRB by 100x or
more in order to avoid saturating the proinsulin ELISA.
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6.5.7 Dynamic GSIS
TIMING 8 hours (5 h for setup and sample collection, 2 h to quantify insulin with ELISA, 1 h
to quantify DNA content)

Figure 6.4 Setup for the dynamic GSIS assay.
(A) Schematic of the chambers used to immobilize the SC- cell clusters as fluid flows across
the cells. (B-C) The SC- cell clusters are sandwiched between two layers of hydrated
polyacrylamide microbeads. (D) This chamber containing the SC- cell clusters is attached to a
perfusion pump and placed in a water bath at 37°C. 2 mM and 20 mM glucose solutions are
pumped through the chambers at a flow rate of 100 µL/min, and the effluent is collected in a 96well plate that is manually moved every 2 minutes. Up to 8 chambers can be run at once with the
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specified pump.
84. Prepare the perfusion setup by first connecting the 0.015 inch inlet and outlet tubing to
the 275- L cell chambers with 0.04 inch connection tubing (Figure 6.4A). Connect the
other end of the outlet tubing to a dispensing nozzle. Connect the inlet tubing to a high
precision 8-channel dispenser pump.
CRITICAL: Here, we describe a custom setup for performing a dynamic GSIS
assay in order to provide an accessible and cost-efficient system. Alternatively, this
dynamic GSIS procedure can also be adapted to work on the commercially available
Biorep Perfusion System (BioRep Diabetes, PERI5-FA-115), following the
manufacturer s instructions for operation.
85. Scoop approximately 5 mL of Bio-Gel beads into a 50 mL tube. To hydrate the beads,
add 40 mL of Milli-Q water and incubate at 75°C with gentle agitation for 90 minutes.
!CAUTION: Opening and handling of the dry beads should be done in a fume hood or
biosafety cabinet to avoid inhalation of the beads.
86. While the beads are hydrating, prepare 500 mL of KRB buffer as described in Table 5.
With this KRB buffer, prepare 150 mL of 2 mM glucose and 50 mL of 20 mM glucose.
Store these solutions in the 37°C water bath with their caps loose.
87. Place the inlet tubing into a 50 mL tube containing Milli-Q water. With the empty cell
chambers connected, turn on the perfusion pump at a flow rate of 200 µL/min for 15
minutes to purge air from the tubes and rinse the tubing of any residual salts.
88. After flushing the system, replace the Milli-Q water with KRB buffer and continue to
pump for 15 minutes to replace the Milli-Q water with KRB buffer in the lines and
chamber.
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89. Use a hole punch to cut out one piece of filter paper per chamber. Stop the pump and
unscrew the outlet cap from the chamber body. Using forceps, remove the orange gasket
in the outlet cap, place the filter paper into the outlet cap, replace the orange gasket, and
reattach the outlet cap to the chamber body (Figure 6.4A).
90. After the Bio-Gel beads have incubated for at least 90 minutes, wash them twice with
Milli-Q water and then twice with KRB buffer, resuspending the beads finally in KRB
buffer.
91. Unscrew the chamber body from the inlet cap and pipette approximately 200 µL of
settled beads into each chamber (Figure 6.4B). Allow beads to settle for 5 minutes.
92. Collect approximately 15 cell clusters per chamber and wash twice with KRB buffer.
Pipette these clusters into the chambers on top of the settled beads (Figure 6.4B). After
cells have settled, add an additional 200 µL of beads into the chamber (Figure 6.4C).
93. Turn the pump on at a flow rate of 100 µL/min and reattach the chamber to inlet cap.
Ensure that KRB buffer is coming out at the metal outlet nozzles and that there are no
leaks in the tubing. Once confirmed that there are no leaks, place the chambers in the
water bath (Figure 6.4D).
CRITICAL: Immediately check to ensure that beads and cells are not leaking into
the outlet tubing. If this occurs, stop the pump immediately and replace the filter
paper.
94. Move the inlet tubing from the KRB buffer into the 2 mM glucose KRB solution in the
water bath (Figure 6.4D). Run for 80 minutes, refilling the glucose solution periodically
to ensure that it does not run out. The flow-through may be discarded.

269

95. Arrange each metal outlet nozzle into a holder or rack so that they will drip easily into a
96-well plate (Figure 6.4D). Label two 96-well plates long-ways, corresponding to the 8
cell chambers.
96. After the 80 minute pre-incubation, move the metal outlet nozzles over the first 96-well
plate and start collecting the effluent. After 2 minutes, manually move the 96-well plate
to the next row and collect the effluent. Each well should collect 200 µL of sample.
Continue this procedure until the end of the experiment. We typically collect 4 time
points (8 minutes) at 2 mM glucose, 12 time points (24 minutes) at 20 mM glucose, and 8
time points (16 minutes) at 2 mM glucose. This is a total of 24 time points (48 minutes)
that will fit on two 96-well plates long-ways.
CRITICAL: Set a timer and be very exact when moving the plate every 2 minutes.
CRITICAL: In order to switch from one glucose concentration to another, stop the
pump, move the inlet tubing into the appropriate 50 mL tube, then start the pump. It is
important to do this as fast as possible and to minimize the introduction of bubbles.
97. At the end of the experiment, cover the 96-well collection plates with an adhesive cover
and place in the -80ºC freezer.
98. To collect the cells for DNA content quantification, unscrew the inlet and outlet caps and
place the chamber body in a microcentrifuge tube. Add 1 mL of the DNA content lysis
buffer (see Reagent Setup ) to the chamber body to flush the beads containing the cells
into the microcentrifuge tube. Vortex for 30 seconds every 10 minutes for a total of 30
minutes, keeping the tubes on ice. Store the samples at -80ºC until ready to quantify them
with the Quant-iTPicogreen dsDNA assay kit according to the manufacturer s
instructions.
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99. To clean the components, rinse the chamber body, outlet cap, and gaskets in a beaker of
Milli-Q water. Start pumping 50 mL Milli-Q water through the system and reattach the
chambers. Continue to run the pump for approximately 30 minutes, which will drain the
water and then pump air through the system to dry the tubing.
CRITICAL: It is important to thoroughly clean the components in order to avoid
residual salts from drying and clogging the tubing before the next use.
100.

Run each of the effluent samples on a human insulin ELISA according to the

manufacturer s instructions, yielding the amount of insulin secreted into 200 L every 2
minutes. Alternatively, two consecutive time points can be pooled and averaged
together thus giving a data point every 4 minutes instead of every 2 minutes

to reduce

the number of ELISA wells needed to complete the quantification. Normalize these
values to the DNA content for each sample.
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6.6 Timing
The differentiation of stem cells to SC- cells takes approximately 5 weeks to complete, plus 1-2
weeks for stem cell expansion before beginning differentiation and assessment of the SC- cells
at the end of the protocol. The amount of time spent each day on cell culture will depend on the
number of separate differentiations and plate configurations.
6.6.1 Production of SC- cells
Steps 1-9, Stem cell culture and seeding differentiations (Stage 0): 8 days (1-2 h/d hands-on)
Steps 10-12, Definitive endoderm differentiation (Stage 1): 4 days (30-60 min/d hands-on)
Steps 13-15, Primitive foregut generation (Stage 2): 2 days (30-60 min/d hands-on)
Steps 15-18, Generating pancreatic progenitor 1 cells (Stage 3): 2 days (30-60 min/d hands-on)
Steps 19-20, Generating pancreatic progenitor 2 cells (Stage 4). 4 days (30-60 min/d hands-on)
Steps 21-24, Endocrine induction (Stage 5): 7 days (30-60 min/d hands-on)
Steps 25-26, SC- cell maturation (Stage 6): 14-30+ days (30-60 min/d hands-on)
6.6.2 In vitro assays to assess SC- cell q alit and f nction
Steps 27-28, Static GSIS: 6 hours (4 hours for setup and sample collection, 2 hours to quantify
insulin with ELISA)
Steps 29-44, Intracellular flow cytometry: 2 days (2.5 h sample preparation and primary antibody
staining on day 1, 3 h sample preparation and staining secondary antibodies on day 2)
Steps 45-54, Immunostaining: 2 days (2.5 h sample preparation and primary antibody staining on
day 1, 3 h sample preparation and staining secondary antibodies on day 2)
Steps 55-74. Histology: 2 days (6 h sample preparation and primary antibody staining on day 1, 3
h sample preparation and secondary staining on day 2)
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Steps 75-77, qRT-PCR: 7 hours (1.5 h for RNA extraction, 2.5 h for reverse transcription, 3 h for
plate setup and PCR reaction)
Steps 78-85, Insulin content and proinsulin/insulin ratio, 3 days (1 h on day 1, 10 min on day 2, 2
h on day 3 for each ELISA)
Steps 86-102, Dynamic GSIS: 8 hours (5 h for setup and sample collection, 2 h to quantify
insulin with ELISA, 1 h to quantify DNA content)

6.7 Troubleshooting
The main assays that can be used to check differentiation efficiency during the protocol are flow
cytometry (quantitative) or immunocytochemistry imaging (qualitative) to ensure >90% of the
cells co-express SOX17 and FOXA2 at the end of stage 1, >80% of the cells express PDX1 at
the end of stage 3, and >40% of the cells co-express PDX1 and NKX6-1 at the end of stage 4
(Figure 6.1). Comparing gene expression between stages with qRT-PCR can also be useful for
determining if a particular gene has turned on, as expression levels of these genes will change
drastically between stages. Each stage depends upon efficient induction of the previous cell type,
and thus later stages will not produce the desired cells if the previous stage does not work
efficiently. Therefore, monitoring these genes throughout the protocol allows the user to pinpoint
where any issues are occurring. Cell morphology can also be an initial indicator of success, as
various cell lines look similar at each stage (Figure 6.2, S6.1), but users should ultimately rely on
marker expression to assess differentiation status. If any of these stages does not meet the
specified threshold for these markers, the differentiation should be discarded, since they will not
efficiently produce SC- cells. The first troubleshooting steps that should be attempted if any of
these thresholds are not met are to check the pluripotency of the starting stem cell population and
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adjust initial cell seeding density at the beginning of the protocol, as these parameters can have
strongest effect on the success of the differentiation. The culture parameters outlined in Table 11,
however, should allow a user to differentiate these specific cell lines, including the commonly
used HUES8 and H1 cell lines, as stated without any further optimization.
Unique cell lines will naturally have different competencies to differentiate into various
cell types, and thus it is not expected that cell lines from a wide variety of genetic backgrounds
will necessarily have the same differentiation efficiency. While we have had very good success
with differentiating new iPSC lines with this protocol, we recommend performing some initial
troubleshooting when adapting the protocol to a new cell line. First, we strongly recommend
optimizing the initial seeding density of stem cells prior to executing the entire differentiation
process. We suggest starting with 0.53 x 106 cells/cm2 (i.e., 5 x 106 cells in a well of 6 well
plate). Ensure that this seeding density creates a confluent monolayer of cells 24 hours after
seeding. If the culture is not confluent, increase seeding density by increments of 0.1 x 106
cells/cm2. If the stem cells are over-confluent, reduce cell seeding density in a similar manner,
though over-confluency is less of an issue. Typically, if cells are not confluent enough, they
begin to fall off the plate, further exacerbating the issue. Even if the cells remain on the plate, the
effects of improper seeding cell density on cell fate will become apparent by stage 4 as
determined by a low percentage of PDX1+ cells. We recommend testing for differentiation
performance by measuring PDX1+ yields at the end of stage 3 using flow cytometry. We expect
to see at least 80% PDX1 positivity for the differentiation to be successful. If low PDX1+ cell
yields persist after optimizing initial cell seeding density, additional steps that have worked on
certain cell lines include adding 10 ng/mL of bFGF throughout stage 1 of the differentiation or
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using the Stem Cell Technologies Definitive Endoderm kit (catalog #05110) in place of stage 1
media and factors.
After optimizing pancreatic progenitor generation, further troubleshooting is typically not
needed. However, there may be some cases where an extensive amount of cell death occurs
following latrunculin A treatment during stage 5. If so, we recommend lowering the latrunculin
A concentration to 0.75 or 0.5 M. Up to 30% cell death can occur during this stage, however,
and is dependent upon the efficiency of the differentiation. On the other hand, if there are large
areas of off-target cells that look different than the expected morphology (Figure 6.2H),
latrunculin A concentration may need to be increased to 1.5 or 2 M. If problems continue
during stage 5, feeding the cells everyday rather than every other day can help. See Table 11 for
the conditions used for the cell lines presented here. Table 12 details these and other
troubleshooting steps that help ensure successful differentiations.
Table 6.11 Cell line optimizations

Stem cell line

Initial stem cell
seeding density
(106 cells / cm2)

Add 10 ng/mL
bFGF in stage 1

HUES8
H1
1013-4FA
1016SeVA
AN1.1
1026-3FC
1031SeVA
T2D001A
WS4corr
WS4unedit

0.63
0.53
0.53
0.32
0.74
0.53
0.53
0.53
0.53
0.42

yes
yes
-
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SCT
Definitive
Endoderm kit
in stage 1
yes
yes
-

Latrunculin A
concentration
(µM)
1
1
1
1
1
1.5
1
0.5
1
1

Table 6.12 Troubleshooting poor quality differentiations
Step
12

Problem
Cells are falling off
the plate during stage
1

Possible reason
-cell density is too low

Solution
-increase initial stem
cell seeding density
-before beginning
stage 1, ensure
expression of stem
cell pluripotency
markers, such as
OCT4 and NANOG,
with flow cytometry
or
immuncytochemistry

12

Low percentage of
SOX17+/FOXA2+
cells (<90%) at the
end of stage 1

-cell density is not optimal
-variation of a particular cell
line

-use Accutase instead
of TrypLE for
passaging stem cells
-optimize initial stem
cell seeding density,
typically between
0.32-0.74 x 106
cells/cm2
-add 10 ng/mL bFGF
in stage 1
-replace stage 1 media
and factors with the
SCT DE kit

18

20

Low percentage of
PDX1+ cells (<80%)
at the end of stage 3

Low percentage of

-cell density is not optimal

-optimize initial stem
cell seeding density,
typically between
0.32-0.74 x 106
cells/cm2

-variation of a particular cell
line

-add 10 ng/mL bFGF
in stage 1

-poor quality of pancreatic

-replace stage 1 media
and factors with the
SCT DE kit
-optimize
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PDX1+/NKX6-1+
cells (<40%) at the
end of stage 4

21

21

26

High levels of cell
death during stage 5
endocrine induction
High levels of offtarget cell types after
stage 5 endocrine
induction

After aggregation in
stage 6, clusters are
either very large or do
not form at all

progenitor 1 cells

SOX17/FOXA2
induction in stage 1

-latrunculin A concentration
is too high for this particular
cell line

-optimize PDX1
induction in stage 3
-decrease latrunculin
A concentration down
to 0.75 or 0.5 µM

-latrunculin A concentration
is too low for this particular
cell line

-increase latrunculin
A concentration up to
1.5 or 2 µM
-avoid strong
mechanical agitation
by gently pipetting up
and down to disperse
cells after incubating
in TrypLE

-user too harsh on cells when
dispersing, causing cell death

-increase incubation
time in TrypLE so the
cells detach from the
plate more easily
-use Accutase instead
of TrypLE

26

1-26

Cells are not glucose
responsive while
remaining on the plate

Many stages of the
differentiation are not
working

-presence of too many offtarget cell types

-perform aggregation
procedure

-improper handling of the
differentiation factors

-do not freeze/thaw
the factors more than
twice

-substituted factors are not
working as well

-use the exact
products from the
specified vendors
listed in this protocol

-edge effects of small well
sizes (24-well plates and
smaller) are negatively
-use a 6-well plate or
influencing the differentiation
larger

277

6.8 Anticipated Results
SC- cells generated with this protocol should exhibit several key characteristics,
including glucose responsiveness in both static and dynamic GSIS assays as well as high
expression of endocrine gene and protein markers, all of which can be assessed by the in vitro
assays detailed here. While the extent of this functionality will depend on the particular cell line
and its disease state, this protocol is very robust in generating SC- cells from a variety of cell
lines. These stem cell lines can be derived from a wide range of genetic backgrounds, including
iPS lines of patients with T1D, T2D, and monogeneic forms of diabetes such as MODY and
Wolfram Syndrome. Studying

cells derived from these disease states can be potentially very

useful in investigating diabetic pathogenesis and testing new treatment options.
Here, we provide representative data from in vitro assessment assays of SC- cells
generated from 10 different human stem cell lines after aggregation into clusters. All data
presented here have been freshly generated and not published previously. On average, this
protocol generates approximately the same number of endocrine cells as the number of starting
stem cells, though this yield will vary depending on the differentiation efficiency of a particular
cell line. In other words, one well of a 6-well plate that is seeded with 5 million stem cells in
Stage 0 will typically yield 5 million endocrine cells after aggregation into clusters. Around 2060% of these will be SC- cells (Figure 6.5A). This protocol was originally developed and
optimized with the HUES8 cell line, and therefore it can provide a good benchmark for
comparing SC- cells generated from new lines.
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Figure 6.5 SC- cells differentiated from a ide range of cell lines.
(A) SC- cells, indicated by the co-expression of NKX6-1 and C-peptide as assessed by flow
cytometry, can be robustly differentiated from a variety of cell lines with this protocol (n = 6 for
HUES8, 1013-4FA, and 1016SeVA; n = 4 for human islets, H1, AN1.1, 1031SeVA, and
WS4corr; n = 3 for 1026-3FC and WS4unedit; n = 2 for T2D001A). (B) While all these SC- cells
secrete insulin, their glucose responsiveness in a static GSIS assay is dependent upon their
genetic background and disease state (n = 7 for WS4corr and WS4unedit; n = 5 for HUES8; n = 4
for donor #1, H1, 1013-4FA, 1016SeVA, AN1.1, and 1031SeVA; n = 3 for donor #2, donor #3,
1026-3FC, and T2D001A). A paired, two-way t-test was performed between low and high
glucose for each cell line. (C) Representative brightfield images of human islets and the SCcells derived from each cell line after stage 6 aggregation into islet-like clusters. All data
presented in this figure are from stage 6 cells after aggregation into clusters. All data are
represented as the mean, and all error bars represent SEM. Individual data points are shown for
all bar graphs, where n = number of separate wells from one or more independent
differentiations. n.s. = not significant; * = P < 0.05, ** = P < 0.01, *** = P < 0.001.
All lines presented here secrete insulin in a static GSIS assay, though the degree of
functionality is dependent on the specific cell line and its disease state (Figure 6.5B). For
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example, an iPSC line with a pathogenic variant in the WFS1 gene (WS4unedit) generates SCcells that are not glucose-responsive, but CRISPR-correcting this variant (WS4corr) allows these
stem cells to produce highly functional SC- cells (Figure 6.5B).39 The best functioning lines can
even approach the insulin secretion levels observed in human islets (Figure 6.5B), and SC- cells
from all lines are able to be aggregated into islet-like clusters (Figure 6.5C). These clusters
contain more than 80% CHGA+ endocrine cells, with a majority being

cells in addition to

small numbers of glucagon (GCG) and somatostatin (SST) positive cells (Figure 6.5A-B). The
ratio of these endocrine cell types is similar across cell lines, but the number of alpha and delta
cells present in these clusters are lower than in a human islet (Figure 6.6B). These islet-like
clusters also exhibit the first and second phase dynamic insulin secretion kinetics that is observed
in primary human islets, though the magnitude of dynamic response is often lower (Figure 6.6C).
Furthermore, these SC- cells have high levels of insulin content (Figure 6.6D) and a low ratio
(<0.1) of proinsulin/insulin content (Figure 6.6E), indicating proper insulin processing. Gene
expression for many endocrine genes is close to that of human islets across cell lines (Figure
6.6F). In contrast to stem cells, they do not express high levels of disallowed genes such as
LDHA. One notable difference from primary human islets that we consistently observe is that
both CHGA and NEUROG3 are much higher in freshly generated SC- cells. Furthermore,
while MAFB is expressed similarly in SC- cells, MAFA is much lower than in human islets.
However, we have recently demonstrated that the transcriptional profile of SC- cells becomes
much more similar to native human islets after long-term transplantation into mice,
demonstrating that in vitro generated SC- cells have the potential for further maturation.47
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Figure 6.6 In-depth characterization of SC- cells.
(A) Immunostaining of histological sections of SC- cell clusters demonstrates that a majority of
cells are co-positive for C-peptide and NKX6-1, while there are also a few glucagon (GCG) and
somatostatin (SST) positive cells. (B) This ratio of C-peptide, GCG, and SST is confirmed
quantitatively by flow cytometry (n = 4). (C) SC- cell clusters demonstrate both first and
second phase insulin secretion in a dynamic GSIS assay (n = 4). (D-E) SC- cells generated with
this protocol have high insulin content and a favorable proinsulin/insulin content ratio (< 0.1) (n
= 4 for HUES8 and 1026-3FC; n = 3 for WS4corr and human islets). (F) They also express similar
levels of a number of islet genes compared with primary human islets, though some gene
expression differences persist (n = 5 for human islets and 1026-3FC; n = 4 for 1031SeVA; n = 3
for stem cells and HUES8). For the assays shown here, data is given for HUES8 and 2 iPSC lines
compared with primary human islets. The original protocol was developed with the HUES8 cell
line, and thus it can serve as a good baseline to compare SC- cells generated from new cell
281

lines. All data presented in this figure are from stage 6 cells after aggregation into clusters. All
data are represented as the mean, and all error bars represent SEM. Individual data points are
shown for all bar graphs, where n = number of separate wells from one or more independent
differentiations.
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6.10 Supplemental Figures

Figure S6.1 Additional cell morphology.
(A-J) Cell morphology shown at each stage for the AN1.1 cell line. (K-T) Cell morphology
shown at each stage for the WS4corr cell line.
Scale bars = 500 m.
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Figure S6.2 Additional functional assessment.
(A) Static GSIS data of aggregated SC- cell clusters on the indicated day of stage 6
demonstrating that the cells remain functional for weeks in vitro. (B) Static GSIS data from
Figure 5b that has been normalized to the number of SC- cells rather than total number of cells,
which was calculated from the percentage of C-peptide+/NKX6-1+ cells shown in Figure 6.5A.
All data are represented as the mean, and all error bars represent SEM. Individual data points are
shown for all bar graphs, where n = number of separate wells from one or more independent
differentiations.
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Figure S6.3 Analysis of stage 6 cells.
(A) Images of cells before aggregation (stage 6, day 7) and on days after aggregation (stage 6,
day 8-14), demonstrating formation of the clusters. (B) Flow cytometry of cells before and after
aggregation, showing enrichment of endocrine (CHGA+) and SC- cells (C-peptide+/NKX61+). (C) If SC- cells are not glucose-responsive while remaining plated, the aggregation step
can improve their function, measured here in a static GSIS assay. (D) Flow cytometry data
demonstrating that the percentage of SC- cells is similar in aggregated clusters that were
generated from different culture plate sizes. All data are represented as the mean, and all error
bars represent SEM. Individual data points are shown for all bar graphs, where n = number of
separate wells from one or more independent differentiations.
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Figure S6.4 Flow cytometry analysis details.
(A) An example gating scheme that removes debris and doublets when analyzing flow cytometry
data. (B) Flow cytometry plots demonstrating negative staining of stage 6 cells when omitting
primary antibodies and only using the indicated secondary antibodies.
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Figure S6.5 Negative staining for fluorescence images.
Fluorescence images demonstrating negative staining of stage 6 cells when omitting primary
antibodies and only using the indicated secondary antibodies.
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